#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Higher Social Rejection Sensitivity in Opioid-Dependent Patients Is Related to Smaller Insula Gray Matter Volume: A Voxel-Based Morphometric Study
#Text=Abstract
#Text=Opioid-dependent patients are highly sensitized to negative social feedback, and increased social rejection sensitivity was linked to adverse treatment outcome, but its neurobiological underpinnings have not been understood yet.
1-1	0-6	Higher	_	
1-2	7-13	Social	_	
1-3	14-23	Rejection	_	
1-4	24-35	Sensitivity	_	
1-5	36-38	in	_	
1-6	39-55	Opioid-Dependent	_	
1-7	56-64	Patients	_	
1-8	65-67	Is	_	
1-9	68-75	Related	_	
1-10	76-78	to	_	
1-11	79-86	Smaller	_	
1-12	87-93	Insula	_	
1-13	94-98	Gray	_	
1-14	99-105	Matter	_	
1-15	106-112	Volume	_	
1-16	112-113	:	_	
1-17	114-115	A	_	
1-18	116-127	Voxel-Based	_	
1-19	128-140	Morphometric	_	
1-20	141-146	Study	_	
1-21	147-155	Abstract	_	
1-22	156-172	Opioid-dependent	_	
1-23	173-181	patients	_	
1-24	182-185	are	_	
1-25	186-192	highly	_	
1-26	193-203	sensitized	_	
1-27	204-206	to	_	
1-28	207-215	negative	_	
1-29	216-222	social	_	
1-30	223-231	feedback	_	
1-31	231-232	,	_	
1-32	233-236	and	_	
1-33	237-246	increased	_	
1-34	247-253	social	_	
1-35	254-263	rejection	_	
1-36	264-275	sensitivity	_	
1-37	276-279	was	_	
1-38	280-286	linked	_	
1-39	287-289	to	_	
1-40	290-297	adverse	_	
1-41	298-307	treatment	_	
1-42	308-315	outcome	_	
1-43	315-316	,	_	
1-44	317-320	but	_	
1-45	321-324	its	_	
1-46	325-340	neurobiological	_	
1-47	341-354	underpinnings	_	
1-48	355-359	have	_	
1-49	360-363	not	_	
1-50	364-368	been	_	
1-51	369-379	understood	_	
1-52	380-383	yet	_	
1-53	383-384	.	_	

#Text=The present study investigated gray matter (GM) volume differences between 19 opioid maintenance treatment (OMT) patients and 20 healthy controls using magnetic resonance imaging and voxel-based morphometry.
2-1	385-388	The	_	
2-2	389-396	present	_	
2-3	397-402	study	_	
2-4	403-415	investigated	_	
2-5	416-420	gray	_	
2-6	421-427	matter	_	
2-7	428-429	(	_	
2-8	429-431	GM	_	
2-9	431-432	)	_	
2-10	433-439	volume	_	
2-11	440-451	differences	_	
2-12	452-459	between	_	
2-13	460-462	19	_	
2-14	463-469	opioid	_	
2-15	470-481	maintenance	_	
2-16	482-491	treatment	_	
2-17	492-493	(	_	
2-18	493-496	OMT	_	
2-19	496-497	)	_	
2-20	498-506	patients	_	
2-21	507-510	and	_	
2-22	511-513	20	_	
2-23	514-521	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[1]	
2-24	522-530	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[1]	
2-25	531-536	using	_	
2-26	537-545	magnetic	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[2]	
2-27	546-555	resonance	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[2]	
2-28	556-563	imaging	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[2]	
2-29	564-567	and	_	
2-30	568-579	voxel-based	_	
2-31	580-591	morphometry	_	
2-32	591-592	.	_	

#Text=Associations of GM volumes with subjective feelings of exclusion and inclusion during a social ostracism (Cyberball) paradigm, with rejection sensitivity, social interaction anxiety and social phobia were explored.
3-1	593-605	Associations	_	
3-2	606-608	of	_	
3-3	609-611	GM	_	
3-4	612-619	volumes	_	
3-5	620-624	with	_	
3-6	625-635	subjective	_	
3-7	636-644	feelings	_	
3-8	645-647	of	_	
3-9	648-657	exclusion	_	
3-10	658-661	and	_	
3-11	662-671	inclusion	_	
3-12	672-678	during	_	
3-13	679-680	a	_	
3-14	681-687	social	_	
3-15	688-697	ostracism	_	
3-16	698-699	(	_	
3-17	699-708	Cyberball	_	
3-18	708-709	)	_	
3-19	710-718	paradigm	_	
3-20	718-719	,	_	
3-21	720-724	with	_	
3-22	725-734	rejection	_	
3-23	735-746	sensitivity	_	
3-24	746-747	,	_	
3-25	748-754	social	_	
3-26	755-766	interaction	_	
3-27	767-774	anxiety	_	
3-28	775-778	and	_	
3-29	779-785	social	_	
3-30	786-792	phobia	_	
3-31	793-797	were	_	
3-32	798-806	explored	_	
3-33	806-807	.	_	

#Text=OMT patients displayed smaller GM volume in the bilateral insula and inferior frontal gyri.
4-1	808-811	OMT	_	
4-2	812-820	patients	_	
4-3	821-830	displayed	_	
4-4	831-838	smaller	_	
4-5	839-841	GM	_	
4-6	842-848	volume	_	
4-7	849-851	in	_	
4-8	852-855	the	_	
4-9	856-865	bilateral	_	
4-10	866-872	insula	_	
4-11	873-876	and	_	
4-12	877-885	inferior	_	
4-13	886-893	frontal	_	
4-14	894-898	gyri	_	
4-15	898-899	.	_	

#Text=Psychometric and task data showed that patients reported significantly higher rejection sensitivity, social anxiety and social phobia scores and felt more excluded and less included during the social ostracism paradigm.
5-1	900-912	Psychometric	_	
5-2	913-916	and	_	
5-3	917-921	task	_	
5-4	922-926	data	_	
5-5	927-933	showed	_	
5-6	934-938	that	_	
5-7	939-947	patients	_	
5-8	948-956	reported	_	
5-9	957-970	significantly	_	
5-10	971-977	higher	_	
5-11	978-987	rejection	_	
5-12	988-999	sensitivity	_	
5-13	999-1000	,	_	
5-14	1001-1007	social	_	
5-15	1008-1015	anxiety	_	
5-16	1016-1019	and	_	
5-17	1020-1026	social	_	
5-18	1027-1033	phobia	_	
5-19	1034-1040	scores	_	
5-20	1041-1044	and	_	
5-21	1045-1049	felt	_	
5-22	1050-1054	more	_	
5-23	1055-1063	excluded	_	
5-24	1064-1067	and	_	
5-25	1068-1072	less	_	
5-26	1073-1081	included	_	
5-27	1082-1088	during	_	
5-28	1089-1092	the	_	
5-29	1093-1099	social	_	
5-30	1100-1109	ostracism	_	
5-31	1110-1118	paradigm	_	
5-32	1118-1119	.	_	

#Text=Smaller GM volume in the insula was associated with higher subjective exclusion, lower subjective inclusion and higher rejection sensitivity, social anxiety and social phobia scores.
6-1	1120-1127	Smaller	_	
6-2	1128-1130	GM	_	
6-3	1131-1137	volume	_	
6-4	1138-1140	in	_	
6-5	1141-1144	the	_	
6-6	1145-1151	insula	_	
6-7	1152-1155	was	_	
6-8	1156-1166	associated	_	
6-9	1167-1171	with	_	
6-10	1172-1178	higher	_	
6-11	1179-1189	subjective	_	
6-12	1190-1199	exclusion	_	
6-13	1199-1200	,	_	
6-14	1201-1206	lower	_	
6-15	1207-1217	subjective	_	
6-16	1218-1227	inclusion	_	
6-17	1228-1231	and	_	
6-18	1232-1238	higher	_	
6-19	1239-1248	rejection	_	
6-20	1249-1260	sensitivity	_	
6-21	1260-1261	,	_	
6-22	1262-1268	social	_	
6-23	1269-1276	anxiety	_	
6-24	1277-1280	and	_	
6-25	1281-1287	social	_	
6-26	1288-1294	phobia	_	
6-27	1295-1301	scores	_	
6-28	1301-1302	.	_	

#Text=Findings indicate that structural deficits in emotion- and anxiety-processing brain regions in OMT patients are associated with increased social rejection sensitivity.
7-1	1303-1311	Findings	_	
7-2	1312-1320	indicate	_	
7-3	1321-1325	that	_	
7-4	1326-1336	structural	_	
7-5	1337-1345	deficits	_	
7-6	1346-1348	in	_	
7-7	1349-1356	emotion	_	
7-8	1356-1357	-	_	
7-9	1358-1361	and	_	
7-10	1362-1380	anxiety-processing	_	
7-11	1381-1386	brain	_	
7-12	1387-1394	regions	_	
7-13	1395-1397	in	_	
7-14	1398-1401	OMT	_	
7-15	1402-1410	patients	_	
7-16	1411-1414	are	_	
7-17	1415-1425	associated	_	
7-18	1426-1430	with	_	
7-19	1431-1440	increased	_	
7-20	1441-1447	social	_	
7-21	1448-1457	rejection	_	
7-22	1458-1469	sensitivity	_	
7-23	1469-1470	.	_	

#Text=As social rejection is a potential trigger for relapse, patients might benefit from therapeutic strategies that promote social integration.
8-1	1471-1473	As	_	
8-2	1474-1480	social	_	
8-3	1481-1490	rejection	_	
8-4	1491-1493	is	_	
8-5	1494-1495	a	_	
8-6	1496-1505	potential	_	
8-7	1506-1513	trigger	_	
8-8	1514-1517	for	_	
8-9	1518-1525	relapse	_	
8-10	1525-1526	,	_	
8-11	1527-1535	patients	_	
8-12	1536-1541	might	_	
8-13	1542-1549	benefit	_	
8-14	1550-1554	from	_	
8-15	1555-1566	therapeutic	_	
8-16	1567-1577	strategies	_	
8-17	1578-1582	that	_	
8-18	1583-1590	promote	_	
8-19	1591-1597	social	_	
8-20	1598-1609	integration	_	
8-21	1609-1610	.	_	

#Text=Introduction
#Text=Opioid dependence is a chronic disease that is associated with social and physical impairments.
9-1	1611-1623	Introduction	_	
9-2	1624-1630	Opioid	_	
9-3	1631-1641	dependence	_	
9-4	1642-1644	is	_	
9-5	1645-1646	a	_	
9-6	1647-1654	chronic	_	
9-7	1655-1662	disease	_	
9-8	1663-1667	that	_	
9-9	1668-1670	is	_	
9-10	1671-1681	associated	_	
9-11	1682-1686	with	_	
9-12	1687-1693	social	_	
9-13	1694-1697	and	_	
9-14	1698-1706	physical	_	
9-15	1707-1718	impairments	_	
9-16	1718-1719	.	_	

#Text=Aside from cognitive dysfunction, opioid dependence is associated with changes in emotion processing and higher rates of depressive symptoms.
10-1	1720-1725	Aside	_	
10-2	1726-1730	from	_	
10-3	1731-1740	cognitive	_	
10-4	1741-1752	dysfunction	_	
10-5	1752-1753	,	_	
10-6	1754-1760	opioid	_	
10-7	1761-1771	dependence	_	
10-8	1772-1774	is	_	
10-9	1775-1785	associated	_	
10-10	1786-1790	with	_	
10-11	1791-1798	changes	_	
10-12	1799-1801	in	_	
10-13	1802-1809	emotion	_	
10-14	1810-1820	processing	_	
10-15	1821-1824	and	_	
10-16	1825-1831	higher	_	
10-17	1832-1837	rates	_	
10-18	1838-1840	of	_	
10-19	1841-1851	depressive	_	
10-20	1852-1860	symptoms	_	
10-21	1860-1861	.	_	

#Text=The underpinnings of those alterations are not fully understood, but studies indicate that, in part, constant negative social feedback might shape emotionality in patients toward a negative affective state and a higher rejection sensitivity.
11-1	1862-1865	The	_	
11-2	1866-1879	underpinnings	_	
11-3	1880-1882	of	_	
11-4	1883-1888	those	_	
11-5	1889-1900	alterations	_	
11-6	1901-1904	are	_	
11-7	1905-1908	not	_	
11-8	1909-1914	fully	_	
11-9	1915-1925	understood	_	
11-10	1925-1926	,	_	
11-11	1927-1930	but	_	
11-12	1931-1938	studies	_	
11-13	1939-1947	indicate	_	
11-14	1948-1952	that	_	
11-15	1952-1953	,	_	
11-16	1954-1956	in	_	
11-17	1957-1961	part	_	
11-18	1961-1962	,	_	
11-19	1963-1971	constant	_	
11-20	1972-1980	negative	_	
11-21	1981-1987	social	_	
11-22	1988-1996	feedback	_	
11-23	1997-2002	might	_	
11-24	2003-2008	shape	_	
11-25	2009-2021	emotionality	_	
11-26	2022-2024	in	_	
11-27	2025-2033	patients	_	
11-28	2034-2040	toward	_	
11-29	2041-2042	a	_	
11-30	2043-2051	negative	_	
11-31	2052-2061	affective	_	
11-32	2062-2067	state	_	
11-33	2068-2071	and	_	
11-34	2072-2073	a	_	
11-35	2074-2080	higher	_	
11-36	2081-2090	rejection	_	
11-37	2091-2102	sensitivity	_	
11-38	2102-2103	.	_	

#Text=Studies have shown that peer rejection contributes to latter social rejection sensitivity and increased social anxiety and withdrawal.
12-1	2104-2111	Studies	_	
12-2	2112-2116	have	_	
12-3	2117-2122	shown	_	
12-4	2123-2127	that	_	
12-5	2128-2132	peer	_	
12-6	2133-2142	rejection	_	
12-7	2143-2154	contributes	_	
12-8	2155-2157	to	_	
12-9	2158-2164	latter	_	
12-10	2165-2171	social	_	
12-11	2172-2181	rejection	_	
12-12	2182-2193	sensitivity	_	
12-13	2194-2197	and	_	
12-14	2198-2207	increased	_	
12-15	2208-2214	social	_	
12-16	2215-2222	anxiety	_	
12-17	2223-2226	and	_	
12-18	2227-2237	withdrawal	_	
12-19	2237-2238	.	_	

#Text=Further studies confirmed the association between social rejection sensitivity and social anxiety.
13-1	2239-2246	Further	_	
13-2	2247-2254	studies	_	
13-3	2255-2264	confirmed	_	
13-4	2265-2268	the	_	
13-5	2269-2280	association	_	
13-6	2281-2288	between	_	
13-7	2289-2295	social	_	
13-8	2296-2305	rejection	_	
13-9	2306-2317	sensitivity	_	
13-10	2318-2321	and	_	
13-11	2322-2328	social	_	
13-12	2329-2336	anxiety	_	
13-13	2336-2337	.	_	

#Text=Importantly, negative social interaction and poor social support are associated with negative treatment outcome in opioid-dependent patients.
14-1	2338-2349	Importantly	_	
14-2	2349-2350	,	_	
14-3	2351-2359	negative	_	
14-4	2360-2366	social	_	
14-5	2367-2378	interaction	_	
14-6	2379-2382	and	_	
14-7	2383-2387	poor	_	
14-8	2388-2394	social	_	
14-9	2395-2402	support	_	
14-10	2403-2406	are	_	
14-11	2407-2417	associated	_	
14-12	2418-2422	with	_	
14-13	2423-2431	negative	_	
14-14	2432-2441	treatment	_	
14-15	2442-2449	outcome	_	
14-16	2450-2452	in	_	
14-17	2453-2469	opioid-dependent	_	
14-18	2470-2478	patients	_	
14-19	2478-2479	.	_	

#Text=Attention has been drawn to the relevance of social context in addictive disorders with the insula being implicated as a key hub processing social inclusion and exclusion and drug craving.
15-1	2480-2489	Attention	_	
15-2	2490-2493	has	_	
15-3	2494-2498	been	_	
15-4	2499-2504	drawn	_	
15-5	2505-2507	to	_	
15-6	2508-2511	the	_	
15-7	2512-2521	relevance	_	
15-8	2522-2524	of	_	
15-9	2525-2531	social	_	
15-10	2532-2539	context	_	
15-11	2540-2542	in	_	
15-12	2543-2552	addictive	_	
15-13	2553-2562	disorders	_	
15-14	2563-2567	with	_	
15-15	2568-2571	the	_	
15-16	2572-2578	insula	_	
15-17	2579-2584	being	_	
15-18	2585-2595	implicated	_	
15-19	2596-2598	as	_	
15-20	2599-2600	a	_	
15-21	2601-2604	key	_	
15-22	2605-2608	hub	_	
15-23	2609-2619	processing	_	
15-24	2620-2626	social	_	
15-25	2627-2636	inclusion	_	
15-26	2637-2640	and	_	
15-27	2641-2650	exclusion	_	
15-28	2651-2654	and	_	
15-29	2655-2659	drug	_	
15-30	2660-2667	craving	_	
15-31	2667-2668	.	_	

#Text=Neuroimaging studies have identified structural deficits in patients on opioid maintenance therapy (OMT) in the insula and other areas associated with cognitive performance, emotion processing and social perception: Previous anatomical studies reported smaller gray matter (GM) volume in opioid-dependent patients in the bilateral insular gyrus; areas of the frontal lobe, such as the bilateral prefrontal cortex, inferior frontal cortex, and supplementary motor cortex; areas of the temporal lobe and thalamus; and right cerebellum.
16-1	2669-2681	Neuroimaging	_	
16-2	2682-2689	studies	_	
16-3	2690-2694	have	_	
16-4	2695-2705	identified	_	
16-5	2706-2716	structural	_	
16-6	2717-2725	deficits	_	
16-7	2726-2728	in	_	
16-8	2729-2737	patients	_	
16-9	2738-2740	on	_	
16-10	2741-2747	opioid	_	
16-11	2748-2759	maintenance	_	
16-12	2760-2767	therapy	_	
16-13	2768-2769	(	_	
16-14	2769-2772	OMT	_	
16-15	2772-2773	)	_	
16-16	2774-2776	in	_	
16-17	2777-2780	the	_	
16-18	2781-2787	insula	_	
16-19	2788-2791	and	_	
16-20	2792-2797	other	_	
16-21	2798-2803	areas	_	
16-22	2804-2814	associated	_	
16-23	2815-2819	with	_	
16-24	2820-2829	cognitive	_	
16-25	2830-2841	performance	_	
16-26	2841-2842	,	_	
16-27	2843-2850	emotion	_	
16-28	2851-2861	processing	_	
16-29	2862-2865	and	_	
16-30	2866-2872	social	_	
16-31	2873-2883	perception	_	
16-32	2883-2884	:	_	
16-33	2885-2893	Previous	_	
16-34	2894-2904	anatomical	_	
16-35	2905-2912	studies	_	
16-36	2913-2921	reported	_	
16-37	2922-2929	smaller	_	
16-38	2930-2934	gray	_	
16-39	2935-2941	matter	_	
16-40	2942-2943	(	_	
16-41	2943-2945	GM	_	
16-42	2945-2946	)	_	
16-43	2947-2953	volume	_	
16-44	2954-2956	in	_	
16-45	2957-2973	opioid-dependent	_	
16-46	2974-2982	patients	_	
16-47	2983-2985	in	_	
16-48	2986-2989	the	_	
16-49	2990-2999	bilateral	_	
16-50	3000-3007	insular	_	
16-51	3008-3013	gyrus	_	
16-52	3013-3014	;	_	
16-53	3015-3020	areas	_	
16-54	3021-3023	of	_	
16-55	3024-3027	the	_	
16-56	3028-3035	frontal	_	
16-57	3036-3040	lobe	_	
16-58	3040-3041	,	_	
16-59	3042-3046	such	_	
16-60	3047-3049	as	_	
16-61	3050-3053	the	_	
16-62	3054-3063	bilateral	_	
16-63	3064-3074	prefrontal	_	
16-64	3075-3081	cortex	_	
16-65	3081-3082	,	_	
16-66	3083-3091	inferior	_	
16-67	3092-3099	frontal	_	
16-68	3100-3106	cortex	_	
16-69	3106-3107	,	_	
16-70	3108-3111	and	_	
16-71	3112-3125	supplementary	_	
16-72	3126-3131	motor	_	
16-73	3132-3138	cortex	_	
16-74	3138-3139	;	_	
16-75	3140-3145	areas	_	
16-76	3146-3148	of	_	
16-77	3149-3152	the	_	
16-78	3153-3161	temporal	_	
16-79	3162-3166	lobe	_	
16-80	3167-3170	and	_	
16-81	3171-3179	thalamus	_	
16-82	3179-3180	;	_	
16-83	3181-3184	and	_	
16-84	3185-3190	right	_	
16-85	3191-3201	cerebellum	_	
16-86	3201-3202	.	_	

#Text=It was hypothesized that these structural abnormalities result in behavioral and neuropsychological impairments.
17-1	3203-3205	It	_	
17-2	3206-3209	was	_	
17-3	3210-3222	hypothesized	_	
17-4	3223-3227	that	_	
17-5	3228-3233	these	_	
17-6	3234-3244	structural	_	
17-7	3245-3258	abnormalities	_	
17-8	3259-3265	result	_	
17-9	3266-3268	in	_	
17-10	3269-3279	behavioral	_	
17-11	3280-3283	and	_	
17-12	3284-3302	neuropsychological	_	
17-13	3303-3314	impairments	_	
17-14	3314-3315	.	_	

#Text=However, there is still little evidence on the association between structural changes and behavioral correlates.
18-1	3316-3323	However	_	
18-2	3323-3324	,	_	
18-3	3325-3330	there	_	
18-4	3331-3333	is	_	
18-5	3334-3339	still	_	
18-6	3340-3346	little	_	
18-7	3347-3355	evidence	_	
18-8	3356-3358	on	_	
18-9	3359-3362	the	_	
18-10	3363-3374	association	_	
18-11	3375-3382	between	_	
18-12	3383-3393	structural	_	
18-13	3394-3401	changes	_	
18-14	3402-3405	and	_	
18-15	3406-3416	behavioral	_	
18-16	3417-3427	correlates	_	
18-17	3427-3428	.	_	

#Text=The study by) investigated associations between GM volume changes and cognitive performance, as well as depressive symptoms and anxiety: While OMT patients showed little to no impairments with regard to memory performance, executive function and visual construction skills, significantly higher depression and anxiety scores were found that showed significant associations to smaller volume in the prefrontal cortex, cingulate, cerebellum and insula.
19-1	3429-3432	The	_	
19-2	3433-3438	study	_	
19-3	3439-3441	by	_	
19-4	3441-3442	)	_	
19-5	3443-3455	investigated	_	
19-6	3456-3468	associations	_	
19-7	3469-3476	between	_	
19-8	3477-3479	GM	_	
19-9	3480-3486	volume	_	
19-10	3487-3494	changes	_	
19-11	3495-3498	and	_	
19-12	3499-3508	cognitive	_	
19-13	3509-3520	performance	_	
19-14	3520-3521	,	_	
19-15	3522-3524	as	_	
19-16	3525-3529	well	_	
19-17	3530-3532	as	_	
19-18	3533-3543	depressive	_	
19-19	3544-3552	symptoms	_	
19-20	3553-3556	and	_	
19-21	3557-3564	anxiety	_	
19-22	3564-3565	:	_	
19-23	3566-3571	While	_	
19-24	3572-3575	OMT	_	
19-25	3576-3584	patients	_	
19-26	3585-3591	showed	_	
19-27	3592-3598	little	_	
19-28	3599-3601	to	_	
19-29	3602-3604	no	_	
19-30	3605-3616	impairments	_	
19-31	3617-3621	with	_	
19-32	3622-3628	regard	_	
19-33	3629-3631	to	_	
19-34	3632-3638	memory	_	
19-35	3639-3650	performance	_	
19-36	3650-3651	,	_	
19-37	3652-3661	executive	_	
19-38	3662-3670	function	_	
19-39	3671-3674	and	_	
19-40	3675-3681	visual	_	
19-41	3682-3694	construction	_	
19-42	3695-3701	skills	_	
19-43	3701-3702	,	_	
19-44	3703-3716	significantly	_	
19-45	3717-3723	higher	_	
19-46	3724-3734	depression	_	
19-47	3735-3738	and	_	
19-48	3739-3746	anxiety	_	
19-49	3747-3753	scores	_	
19-50	3754-3758	were	_	
19-51	3759-3764	found	_	
19-52	3765-3769	that	_	
19-53	3770-3776	showed	_	
19-54	3777-3788	significant	_	
19-55	3789-3801	associations	_	
19-56	3802-3804	to	_	
19-57	3805-3812	smaller	_	
19-58	3813-3819	volume	_	
19-59	3820-3822	in	_	
19-60	3823-3826	the	_	
19-61	3827-3837	prefrontal	_	
19-62	3838-3844	cortex	_	
19-63	3844-3845	,	_	
19-64	3846-3855	cingulate	_	
19-65	3855-3856	,	_	
19-66	3857-3867	cerebellum	_	
19-67	3868-3871	and	_	
19-68	3872-3878	insula	_	
19-69	3878-3879	.	_	

#Text=It has been suggested that heroin-induced changes in regional cerebral blood flow with a resulting reduced perfusion of brain regions, in addition to an altered brain metabolism, might be the underlying cause for structural abnormalities in opioid-dependent patients.
20-1	3880-3882	It	_	
20-2	3883-3886	has	_	
20-3	3887-3891	been	_	
20-4	3892-3901	suggested	_	
20-5	3902-3906	that	_	
20-6	3907-3921	heroin-induced	_	
20-7	3922-3929	changes	_	
20-8	3930-3932	in	_	
20-9	3933-3941	regional	_	
20-10	3942-3950	cerebral	_	
20-11	3951-3956	blood	_	
20-12	3957-3961	flow	_	
20-13	3962-3966	with	_	
20-14	3967-3968	a	_	
20-15	3969-3978	resulting	_	
20-16	3979-3986	reduced	_	
20-17	3987-3996	perfusion	_	
20-18	3997-3999	of	_	
20-19	4000-4005	brain	_	
20-20	4006-4013	regions	_	
20-21	4013-4014	,	_	
20-22	4015-4017	in	_	
20-23	4018-4026	addition	_	
20-24	4027-4029	to	_	
20-25	4030-4032	an	_	
20-26	4033-4040	altered	_	
20-27	4041-4046	brain	_	
20-28	4047-4057	metabolism	_	
20-29	4057-4058	,	_	
20-30	4059-4064	might	_	
20-31	4065-4067	be	_	
20-32	4068-4071	the	_	
20-33	4072-4082	underlying	_	
20-34	4083-4088	cause	_	
20-35	4089-4092	for	_	
20-36	4093-4103	structural	_	
20-37	4104-4117	abnormalities	_	
20-38	4118-4120	in	_	
20-39	4121-4137	opioid-dependent	_	
20-40	4138-4146	patients	_	
20-41	4146-4147	.	_	

#Text=In addition, the duration of heroin use has been suggested to be a critical factor for the extent of brain damage.
21-1	4148-4150	In	_	
21-2	4151-4159	addition	_	
21-3	4159-4160	,	_	
21-4	4161-4164	the	_	
21-5	4165-4173	duration	_	
21-6	4174-4176	of	_	
21-7	4177-4183	heroin	_	
21-8	4184-4187	use	_	
21-9	4188-4191	has	_	
21-10	4192-4196	been	_	
21-11	4197-4206	suggested	_	
21-12	4207-4209	to	_	
21-13	4210-4212	be	_	
21-14	4213-4214	a	_	
21-15	4215-4223	critical	_	
21-16	4224-4230	factor	_	
21-17	4231-4234	for	_	
21-18	4235-4238	the	_	
21-19	4239-4245	extent	_	
21-20	4246-4248	of	_	
21-21	4249-4254	brain	_	
21-22	4255-4261	damage	_	
21-23	4261-4262	.	_	

#Text=However, the impact of structural abnormalities on social perception remains to be elucidated.
22-1	4263-4270	However	_	
22-2	4270-4271	,	_	
22-3	4272-4275	the	_	
22-4	4276-4282	impact	_	
22-5	4283-4285	of	_	
22-6	4286-4296	structural	_	
22-7	4297-4310	abnormalities	_	
22-8	4311-4313	on	_	
22-9	4314-4320	social	_	
22-10	4321-4331	perception	_	
22-11	4332-4339	remains	_	
22-12	4340-4342	to	_	
22-13	4343-4345	be	_	
22-14	4346-4356	elucidated	_	
22-15	4356-4357	.	_	

#Text=The present analyses were performed on a dataset that was collected within the framework of a larger study that used psychometric assessment tools, an funtional magnetic resonance imaging (fMRI) social ostracism Cyberball task and structural MRI to investigate functional and structural brain correlates of social interaction and social rejection.
23-1	4358-4361	The	_	
23-2	4362-4369	present	_	
23-3	4370-4378	analyses	_	
23-4	4379-4383	were	_	
23-5	4384-4393	performed	_	
23-6	4394-4396	on	_	
23-7	4397-4398	a	_	
23-8	4399-4406	dataset	_	
23-9	4407-4411	that	_	
23-10	4412-4415	was	_	
23-11	4416-4425	collected	_	
23-12	4426-4432	within	_	
23-13	4433-4436	the	_	
23-14	4437-4446	framework	_	
23-15	4447-4449	of	_	
23-16	4450-4451	a	_	
23-17	4452-4458	larger	_	
23-18	4459-4464	study	_	
23-19	4465-4469	that	_	
23-20	4470-4474	used	_	
23-21	4475-4487	psychometric	_	
23-22	4488-4498	assessment	_	
23-23	4499-4504	tools	_	
23-24	4504-4505	,	_	
23-25	4506-4508	an	_	
23-26	4509-4518	funtional	_	
23-27	4519-4527	magnetic	_	
23-28	4528-4537	resonance	_	
23-29	4538-4545	imaging	_	
23-30	4546-4547	(	_	
23-31	4547-4551	fMRI	_	
23-32	4551-4552	)	_	
23-33	4553-4559	social	_	
23-34	4560-4569	ostracism	_	
23-35	4570-4579	Cyberball	_	
23-36	4580-4584	task	_	
23-37	4585-4588	and	_	
23-38	4589-4599	structural	_	
23-39	4600-4603	MRI	_	
23-40	4604-4606	to	_	
23-41	4607-4618	investigate	_	
23-42	4619-4629	functional	_	
23-43	4630-4633	and	_	
23-44	4634-4644	structural	_	
23-45	4645-4650	brain	_	
23-46	4651-4661	correlates	_	
23-47	4662-4664	of	_	
23-48	4665-4671	social	_	
23-49	4672-4683	interaction	_	
23-50	4684-4687	and	_	
23-51	4688-4694	social	_	
23-52	4695-4704	rejection	_	
23-53	4704-4705	.	_	

#Text=The results of the social rejection functional correlates are reported in detail elsewhere.
24-1	4706-4709	The	_	
24-2	4710-4717	results	_	
24-3	4718-4720	of	_	
24-4	4721-4724	the	_	
24-5	4725-4731	social	_	
24-6	4732-4741	rejection	_	
24-7	4742-4752	functional	_	
24-8	4753-4763	correlates	_	
24-9	4764-4767	are	_	
24-10	4768-4776	reported	_	
24-11	4777-4779	in	_	
24-12	4780-4786	detail	_	
24-13	4787-4796	elsewhere	_	
24-14	4796-4797	.	_	

#Text=In short, results showed that patients on OMT felt less included and more excluded during fMRI Cyberball inclusion and control conditions and equally excluded during the social exclusion Cyberball condition.
25-1	4798-4800	In	_	
25-2	4801-4806	short	_	
25-3	4806-4807	,	_	
25-4	4808-4815	results	_	
25-5	4816-4822	showed	_	
25-6	4823-4827	that	_	
25-7	4828-4836	patients	_	
25-8	4837-4839	on	_	
25-9	4840-4843	OMT	_	
25-10	4844-4848	felt	_	
25-11	4849-4853	less	_	
25-12	4854-4862	included	_	
25-13	4863-4866	and	_	
25-14	4867-4871	more	_	
25-15	4872-4880	excluded	_	
25-16	4881-4887	during	_	
25-17	4888-4892	fMRI	_	
25-18	4893-4902	Cyberball	_	
25-19	4903-4912	inclusion	_	
25-20	4913-4916	and	_	
25-21	4917-4924	control	_	
25-22	4925-4935	conditions	_	
25-23	4936-4939	and	_	
25-24	4940-4947	equally	_	
25-25	4948-4956	excluded	_	
25-26	4957-4963	during	_	
25-27	4964-4967	the	_	
25-28	4968-4974	social	_	
25-29	4975-4984	exclusion	_	
25-30	4985-4994	Cyberball	_	
25-31	4995-5004	condition	_	
25-32	5004-5005	.	_	

#Text=Furthermore, patients showed reduced pain sensitivity, but subjective pain was higher after social exclusion compared to social inclusion trials.
26-1	5006-5017	Furthermore	_	
26-2	5017-5018	,	_	
26-3	5019-5027	patients	_	
26-4	5028-5034	showed	_	
26-5	5035-5042	reduced	_	
26-6	5043-5047	pain	_	
26-7	5048-5059	sensitivity	_	
26-8	5059-5060	,	_	
26-9	5061-5064	but	_	
26-10	5065-5075	subjective	_	
26-11	5076-5080	pain	_	
26-12	5081-5084	was	_	
26-13	5085-5091	higher	_	
26-14	5092-5097	after	_	
26-15	5098-5104	social	_	
26-16	5105-5114	exclusion	_	
26-17	5115-5123	compared	_	
26-18	5124-5126	to	_	
26-19	5127-5133	social	_	
26-20	5134-5143	inclusion	_	
26-21	5144-5150	trials	_	
26-22	5150-5151	.	_	

#Text=When contrasting social exclusion and inclusion trials, healthy participants displayed significant activation in brain areas related to social feedback and emotion processing, whereas OMT patients showed no difference across conditions probably due to direct pharmacological inhibitory effects of the opioids.
27-1	5152-5156	When	_	
27-2	5157-5168	contrasting	_	
27-3	5169-5175	social	_	
27-4	5176-5185	exclusion	_	
27-5	5186-5189	and	_	
27-6	5190-5199	inclusion	_	
27-7	5200-5206	trials	_	
27-8	5206-5207	,	_	
27-9	5208-5215	healthy	_	
27-10	5216-5228	participants	_	
27-11	5229-5238	displayed	_	
27-12	5239-5250	significant	_	
27-13	5251-5261	activation	_	
27-14	5262-5264	in	_	
27-15	5265-5270	brain	_	
27-16	5271-5276	areas	_	
27-17	5277-5284	related	_	
27-18	5285-5287	to	_	
27-19	5288-5294	social	_	
27-20	5295-5303	feedback	_	
27-21	5304-5307	and	_	
27-22	5308-5315	emotion	_	
27-23	5316-5326	processing	_	
27-24	5326-5327	,	_	
27-25	5328-5335	whereas	_	
27-26	5336-5339	OMT	_	
27-27	5340-5348	patients	_	
27-28	5349-5355	showed	_	
27-29	5356-5358	no	_	
27-30	5359-5369	difference	_	
27-31	5370-5376	across	_	
27-32	5377-5387	conditions	_	
27-33	5388-5396	probably	_	
27-34	5397-5400	due	_	
27-35	5401-5403	to	_	
27-36	5404-5410	direct	_	
27-37	5411-5426	pharmacological	_	
27-38	5427-5437	inhibitory	_	
27-39	5438-5445	effects	_	
27-40	5446-5448	of	_	
27-41	5449-5452	the	_	
27-42	5453-5460	opioids	_	
27-43	5460-5461	.	_	

#Text=Incremental to the previous publication, here we report data on the structural correlates of social anxiety and social rejection sensitivity.
28-1	5462-5473	Incremental	_	
28-2	5474-5476	to	_	
28-3	5477-5480	the	_	
28-4	5481-5489	previous	_	
28-5	5490-5501	publication	_	
28-6	5501-5502	,	_	
28-7	5503-5507	here	_	
28-8	5508-5510	we	_	
28-9	5511-5517	report	_	
28-10	5518-5522	data	_	
28-11	5523-5525	on	_	
28-12	5526-5529	the	_	
28-13	5530-5540	structural	_	
28-14	5541-5551	correlates	_	
28-15	5552-5554	of	_	
28-16	5555-5561	social	_	
28-17	5562-5569	anxiety	_	
28-18	5570-5573	and	_	
28-19	5574-5580	social	_	
28-20	5581-5590	rejection	_	
28-21	5591-5602	sensitivity	_	
28-22	5602-5603	.	_	

#Text=We investigated differences in GM volume between opioid-dependent patients and controls and their associations with social rejection sensitivity, social interaction anxiety and social phobia using structural MRI and voxel-based morphometry (VBM).
29-1	5604-5606	We	_	
29-2	5607-5619	investigated	_	
29-3	5620-5631	differences	_	
29-4	5632-5634	in	_	
29-5	5635-5637	GM	_	
29-6	5638-5644	volume	_	
29-7	5645-5652	between	_	
29-8	5653-5669	opioid-dependent	_	
29-9	5670-5678	patients	_	
29-10	5679-5682	and	_	
29-11	5683-5691	controls	_	
29-12	5692-5695	and	_	
29-13	5696-5701	their	_	
29-14	5702-5714	associations	_	
29-15	5715-5719	with	_	
29-16	5720-5726	social	_	
29-17	5727-5736	rejection	_	
29-18	5737-5748	sensitivity	_	
29-19	5748-5749	,	_	
29-20	5750-5756	social	_	
29-21	5757-5768	interaction	_	
29-22	5769-5776	anxiety	_	
29-23	5777-5780	and	_	
29-24	5781-5787	social	_	
29-25	5788-5794	phobia	_	
29-26	5795-5800	using	_	
29-27	5801-5811	structural	_	
29-28	5812-5815	MRI	_	
29-29	5816-5819	and	_	
29-30	5820-5831	voxel-based	_	
29-31	5832-5843	morphometry	_	
29-32	5844-5845	(	_	
29-33	5845-5848	VBM	_	
29-34	5848-5849	)	_	
29-35	5849-5850	.	_	

#Text=Hypotheses
#Text=Firstly, based on previous findings, we hypothesized that OMT patients would show smaller GM volume in frontal cortical and subcortical areas, including the insula cortex.
30-1	5851-5861	Hypotheses	_	
30-2	5862-5869	Firstly	_	
30-3	5869-5870	,	_	
30-4	5871-5876	based	_	
30-5	5877-5879	on	_	
30-6	5880-5888	previous	_	
30-7	5889-5897	findings	_	
30-8	5897-5898	,	_	
30-9	5899-5901	we	_	
30-10	5902-5914	hypothesized	_	
30-11	5915-5919	that	_	
30-12	5920-5923	OMT	_	
30-13	5924-5932	patients	_	
30-14	5933-5938	would	_	
30-15	5939-5943	show	_	
30-16	5944-5951	smaller	_	
30-17	5952-5954	GM	_	
30-18	5955-5961	volume	_	
30-19	5962-5964	in	_	
30-20	5965-5972	frontal	_	
30-21	5973-5981	cortical	_	
30-22	5982-5985	and	_	
30-23	5986-5997	subcortical	_	
30-24	5998-6003	areas	_	
30-25	6003-6004	,	_	
30-26	6005-6014	including	_	
30-27	6015-6018	the	_	
30-28	6019-6025	insula	_	
30-29	6026-6032	cortex	_	
30-30	6032-6033	.	_	

#Text=Secondly, we hypothesized that patients on OMT show higher dispositional social rejection sensitivity, social phobia symptoms and social anxiety symptoms, when measured using established psychometric scales.
31-1	6034-6042	Secondly	_	
31-2	6042-6043	,	_	
31-3	6044-6046	we	_	
31-4	6047-6059	hypothesized	_	
31-5	6060-6064	that	_	
31-6	6065-6073	patients	_	
31-7	6074-6076	on	_	
31-8	6077-6080	OMT	_	
31-9	6081-6085	show	_	
31-10	6086-6092	higher	_	
31-11	6093-6106	dispositional	_	
31-12	6107-6113	social	_	
31-13	6114-6123	rejection	_	
31-14	6124-6135	sensitivity	_	
31-15	6135-6136	,	_	
31-16	6137-6143	social	_	
31-17	6144-6150	phobia	_	
31-18	6151-6159	symptoms	_	
31-19	6160-6163	and	_	
31-20	6164-6170	social	_	
31-21	6171-6178	anxiety	_	
31-22	6179-6187	symptoms	_	
31-23	6187-6188	,	_	
31-24	6189-6193	when	_	
31-25	6194-6202	measured	_	
31-26	6203-6208	using	_	
31-27	6209-6220	established	_	
31-28	6221-6233	psychometric	_	
31-29	6234-6240	scales	_	
31-30	6240-6241	.	_	

#Text=Thirdly, based on previous findings that demonstrated negative associations between GM volume in the limbic system, specifically the insula, and symptoms of social anxiety and depression, we hypothesize that GM volume in the limbic system correlates negatively with social rejection sensitivity, social phobia and social anxiety scores.
32-1	6242-6249	Thirdly	_	
32-2	6249-6250	,	_	
32-3	6251-6256	based	_	
32-4	6257-6259	on	_	
32-5	6260-6268	previous	_	
32-6	6269-6277	findings	_	
32-7	6278-6282	that	_	
32-8	6283-6295	demonstrated	_	
32-9	6296-6304	negative	_	
32-10	6305-6317	associations	_	
32-11	6318-6325	between	_	
32-12	6326-6328	GM	_	
32-13	6329-6335	volume	_	
32-14	6336-6338	in	_	
32-15	6339-6342	the	_	
32-16	6343-6349	limbic	_	
32-17	6350-6356	system	_	
32-18	6356-6357	,	_	
32-19	6358-6370	specifically	_	
32-20	6371-6374	the	_	
32-21	6375-6381	insula	_	
32-22	6381-6382	,	_	
32-23	6383-6386	and	_	
32-24	6387-6395	symptoms	_	
32-25	6396-6398	of	_	
32-26	6399-6405	social	_	
32-27	6406-6413	anxiety	_	
32-28	6414-6417	and	_	
32-29	6418-6428	depression	_	
32-30	6428-6429	,	_	
32-31	6430-6432	we	_	
32-32	6433-6444	hypothesize	_	
32-33	6445-6449	that	_	
32-34	6450-6452	GM	_	
32-35	6453-6459	volume	_	
32-36	6460-6462	in	_	
32-37	6463-6466	the	_	
32-38	6467-6473	limbic	_	
32-39	6474-6480	system	_	
32-40	6481-6491	correlates	_	
32-41	6492-6502	negatively	_	
32-42	6503-6507	with	_	
32-43	6508-6514	social	_	
32-44	6515-6524	rejection	_	
32-45	6525-6536	sensitivity	_	
32-46	6536-6537	,	_	
32-47	6538-6544	social	_	
32-48	6545-6551	phobia	_	
32-49	6552-6555	and	_	
32-50	6556-6562	social	_	
32-51	6563-6570	anxiety	_	
32-52	6571-6577	scores	_	
32-53	6577-6578	.	_	

#Text=Materials and methods
#Text=Participants
#Text=Opioid-dependent patients were recruited in an outpatient opioid maintenance program of the Central Institute of Mental Health in Mannheim, Germany.
33-1	6579-6588	Materials	http://www.case.edu/ProvCaRe/provcare#StudyMethod[3]	
33-2	6589-6592	and	http://www.case.edu/ProvCaRe/provcare#StudyMethod[3]	
33-3	6593-6600	methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod[3]	
33-4	6601-6613	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
33-5	6614-6630	Opioid-dependent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[5]	
33-6	6631-6639	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
33-7	6640-6644	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
33-8	6645-6654	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
33-9	6655-6657	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
33-10	6658-6660	an	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
33-11	6661-6671	outpatient	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
33-12	6672-6678	opioid	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
33-13	6679-6690	maintenance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
33-14	6691-6698	program	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
33-15	6699-6701	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
33-16	6702-6705	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
33-17	6706-6713	Central	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
33-18	6714-6723	Institute	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
33-19	6724-6726	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
33-20	6727-6733	Mental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
33-21	6734-6740	Health	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
33-22	6741-6743	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
33-23	6744-6752	Mannheim	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
33-24	6752-6753	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
33-25	6754-6761	Germany	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
33-26	6761-6762	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	

#Text=The healthy control group consisted of volunteers that were recruited from newspaper and clinic homepage advertisement.
34-1	6763-6766	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
34-2	6767-6774	healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[7]	
34-3	6775-6782	control	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[7]	
34-4	6783-6788	group	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
34-5	6789-6798	consisted	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
34-6	6799-6801	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
34-7	6802-6812	volunteers	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
34-8	6813-6817	that	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
34-9	6818-6822	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
34-10	6823-6832	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
34-11	6833-6837	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
34-12	6838-6847	newspaper	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
34-13	6848-6851	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
34-14	6852-6858	clinic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
34-15	6859-6867	homepage	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
34-16	6868-6881	advertisement	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
34-17	6881-6882	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	

#Text=The study was approved by the local ethics committee of the University of Heidelberg and performed in accordance with the Declaration of Helsinki, and informed written consent was obtained.
35-1	6883-6886	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
35-2	6887-6892	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
35-3	6893-6896	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
35-4	6897-6905	approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
35-5	6906-6908	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
35-6	6909-6912	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
35-7	6913-6918	local	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
35-8	6919-6925	ethics	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
35-9	6926-6935	committee	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
35-10	6936-6938	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
35-11	6939-6942	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
35-12	6943-6953	University	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
35-13	6954-6956	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
35-14	6957-6967	Heidelberg	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
35-15	6968-6971	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
35-16	6972-6981	performed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
35-17	6982-6984	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
35-18	6985-6995	accordance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
35-19	6996-7000	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
35-20	7001-7004	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
35-21	7005-7016	Declaration	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
35-22	7017-7019	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
35-23	7020-7028	Helsinki	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
35-24	7028-7029	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
35-25	7030-7033	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
35-26	7034-7042	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
35-27	7043-7050	written	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
35-28	7051-7058	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
35-29	7059-7062	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
35-30	7063-7071	obtained	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
35-31	7071-7072	.	_	

#Text=All participants were required to be aged between 18 and 65 years.
36-1	7073-7076	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
36-2	7077-7089	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
36-3	7090-7094	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
36-4	7095-7103	required	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
36-5	7104-7106	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
36-6	7107-7109	be	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
36-7	7110-7114	aged	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
36-8	7115-7122	between	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
36-9	7123-7125	18	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
36-10	7126-7129	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
36-11	7130-7132	65	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
36-12	7132-7133	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
36-13	7133-7138	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
36-14	7138-7139	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	

#Text=Opioid-dependent patients had to meet the diagnosis of opioid dependence according to the ICD10.
37-1	7140-7156	Opioid-dependent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]|http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[11]	
37-2	7157-7165	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
37-3	7166-7169	had	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
37-4	7170-7172	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
37-5	7173-7177	meet	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
37-6	7178-7181	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
37-7	7182-7191	diagnosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
37-8	7192-7194	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
37-9	7195-7201	opioid	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
37-10	7202-7212	dependence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
37-11	7213-7222	according	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
37-12	7223-7225	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
37-13	7226-7229	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
37-14	7230-7235	ICD10	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
37-15	7235-7236	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	

#Text=Healthy participants were included only if no indication of substance abuse disorder or another mental illness was found during an interview with an experienced clinical psychiatrist.
38-1	7237-7244	Healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
38-2	7245-7257	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
38-3	7258-7262	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
38-4	7263-7271	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
38-5	7272-7276	only	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
38-6	7277-7279	if	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
38-7	7280-7282	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
38-8	7283-7293	indication	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
38-9	7294-7296	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
38-10	7297-7306	substance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
38-11	7307-7312	abuse	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
38-12	7313-7321	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
38-13	7322-7324	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
38-14	7325-7332	another	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
38-15	7333-7339	mental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
38-16	7340-7347	illness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
38-17	7348-7351	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
38-18	7352-7357	found	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
38-19	7358-7364	during	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
38-20	7365-7367	an	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
38-21	7368-7377	interview	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
38-22	7378-7382	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
38-23	7383-7385	an	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
38-24	7386-7397	experienced	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
38-25	7398-7406	clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
38-26	7407-7419	psychiatrist	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
38-27	7419-7420	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	

#Text=Exclusion criteria for both groups were: (i) substance use disorder other than nicotine (only for healthy controls), (ii) pregnancy, (iii) severe internal or neurological condition and (iv) contraindications for MRI scanning (e.g. tattoos, metal implants, pregnancy, pacemakers).
39-1	7421-7430	Exclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-2	7431-7439	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-3	7440-7443	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-4	7444-7448	both	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-5	7449-7455	groups	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-6	7456-7460	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-7	7460-7461	:	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-8	7462-7463	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-9	7463-7464	i	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-10	7464-7465	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-11	7466-7475	substance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-12	7476-7479	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-13	7480-7488	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-14	7489-7494	other	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-15	7495-7499	than	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-16	7500-7508	nicotine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-17	7509-7510	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-18	7510-7514	only	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-19	7515-7518	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-20	7519-7526	healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-21	7527-7535	controls	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-22	7535-7536	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-23	7536-7537	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-24	7538-7539	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-25	7539-7541	ii	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-26	7541-7542	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-27	7543-7552	pregnancy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-28	7552-7553	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-29	7554-7555	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-30	7555-7558	iii	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-31	7558-7559	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-32	7560-7566	severe	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-33	7567-7575	internal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-34	7576-7578	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-35	7579-7591	neurological	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-36	7592-7601	condition	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-37	7602-7605	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-38	7606-7607	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-39	7607-7609	iv	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-40	7609-7610	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-41	7611-7628	contraindications	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-42	7629-7632	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-43	7633-7636	MRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[14]	
39-44	7637-7645	scanning	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-45	7646-7647	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-46	7647-7650	e.g	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-47	7650-7651	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-48	7652-7659	tattoos	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-49	7659-7660	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-50	7661-7666	metal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-51	7667-7675	implants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-52	7675-7676	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-53	7677-7686	pregnancy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-54	7686-7687	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-55	7688-7698	pacemakers	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-56	7698-7699	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
39-57	7699-7700	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	

#Text=A total of 25 patients and 22 healthy controls were included in the current study. 19 patients (18 males and 1 female) and 20 controls (18 males and 2 females) provided complete VBM datasets of sufficient quality.
40-1	7701-7702	A	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
40-2	7703-7708	total	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
40-3	7709-7711	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
40-4	7712-7714	25	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
40-5	7715-7723	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
40-6	7724-7727	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
40-7	7728-7730	22	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
40-8	7731-7738	healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[16]	
40-9	7739-7747	controls	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[16]	
40-10	7748-7752	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
40-11	7753-7761	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
40-12	7762-7764	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
40-13	7765-7768	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
40-14	7769-7776	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
40-15	7777-7782	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
40-16	7782-7783	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
40-17	7784-7786	19	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
40-18	7787-7795	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
40-19	7796-7797	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
40-20	7797-7799	18	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
40-21	7800-7805	males	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
40-22	7806-7809	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
40-23	7810-7811	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
40-24	7812-7818	female	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
40-25	7818-7819	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
40-26	7820-7823	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
40-27	7824-7826	20	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
40-28	7827-7835	controls	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
40-29	7836-7837	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
40-30	7837-7839	18	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
40-31	7840-7845	males	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
40-32	7846-7849	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
40-33	7850-7851	2	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
40-34	7852-7859	females	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
40-35	7859-7860	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
40-36	7861-7869	provided	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
40-37	7870-7878	complete	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
40-38	7879-7882	VBM	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
40-39	7883-7891	datasets	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
40-40	7892-7894	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
40-41	7895-7905	sufficient	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
40-42	7906-7913	quality	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
40-43	7913-7914	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	

#Text=Patients did not undergo a formal screening for comorbid psychiatric disorders prior to being included in the current study; however, all patients were interviewed by two independent professional psychiatrists at the institute, in order to rule out relevant comorbid psychiatric diseases.
41-1	7915-7923	Patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
41-2	7924-7927	did	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
41-3	7928-7931	not	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
41-4	7932-7939	undergo	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
41-5	7940-7941	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
41-6	7942-7948	formal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
41-7	7949-7958	screening	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
41-8	7959-7962	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
41-9	7963-7971	comorbid	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
41-10	7972-7983	psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
41-11	7984-7993	disorders	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
41-12	7994-7999	prior	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
41-13	8000-8002	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
41-14	8003-8008	being	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
41-15	8009-8017	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
41-16	8018-8020	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
41-17	8021-8024	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
41-18	8025-8032	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
41-19	8033-8038	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
41-20	8038-8039	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
41-21	8040-8047	however	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
41-22	8047-8048	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
41-23	8049-8052	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
41-24	8053-8061	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
41-25	8062-8066	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
41-26	8067-8078	interviewed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
41-27	8079-8081	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
41-28	8082-8085	two	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
41-29	8086-8097	independent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
41-30	8098-8110	professional	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
41-31	8111-8124	psychiatrists	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
41-32	8125-8127	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
41-33	8128-8131	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
41-34	8132-8141	institute	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
41-35	8141-8142	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
41-36	8143-8145	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
41-37	8146-8151	order	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
41-38	8152-8154	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
41-39	8155-8159	rule	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
41-40	8160-8163	out	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
41-41	8164-8172	relevant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
41-42	8173-8181	comorbid	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
41-43	8182-8193	psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
41-44	8194-8202	diseases	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
41-45	8202-8203	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	

#Text=In addition, patients were treated at the department’s opioid maintenance unit for several years with regular appointments with a specialized psychiatrist once a week and no clinical evidence for a comorbid psychiatric disorder.
42-1	8204-8206	In	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-2	8207-8215	addition	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-3	8215-8216	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-4	8217-8225	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-5	8226-8230	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-6	8231-8238	treated	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-7	8239-8241	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-8	8242-8245	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-9	8246-8256	department	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-10	8256-8257	’	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-11	8257-8258	s	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-12	8259-8265	opioid	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-13	8266-8277	maintenance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-14	8278-8282	unit	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-15	8283-8286	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-16	8287-8294	several	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-17	8295-8300	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-18	8301-8305	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-19	8306-8313	regular	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-20	8314-8326	appointments	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-21	8327-8331	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-22	8332-8333	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-23	8334-8345	specialized	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-24	8346-8358	psychiatrist	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-25	8359-8363	once	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-26	8364-8365	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-27	8366-8370	week	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-28	8371-8374	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-29	8375-8377	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-30	8378-8386	clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-31	8387-8395	evidence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-32	8396-8399	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-33	8400-8401	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-34	8402-8410	comorbid	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-35	8411-8422	psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-36	8423-8431	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-37	8431-8432	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	

#Text=Patients were all HIV negative, but four were tested positive for hepatitis C virus (HCV) antibodies.
43-1	8433-8441	Patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
43-2	8442-8446	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
43-3	8447-8450	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
43-4	8451-8454	HIV	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
43-5	8455-8463	negative	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
43-6	8463-8464	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
43-7	8465-8468	but	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
43-8	8469-8473	four	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
43-9	8474-8478	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
43-10	8479-8485	tested	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
43-11	8486-8494	positive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
43-12	8495-8498	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
43-13	8499-8508	hepatitis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
43-14	8509-8510	C	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
43-15	8511-8516	virus	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
43-16	8517-8518	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
43-17	8518-8521	HCV	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
43-18	8521-8522	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
43-19	8523-8533	antibodies	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
43-20	8533-8534	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	

#Text=Fourteen patients were treated with methadone and n = 5 with buprenorphine, the mean methadone equivalence dose was 63.35 mg/d (± 36.26 mg/d standard deviation (s.d.)).
44-1	8535-8543	Fourteen	_	
44-2	8544-8552	patients	_	
44-3	8553-8557	were	_	
44-4	8558-8565	treated	_	
44-5	8566-8570	with	_	
44-6	8571-8580	methadone	_	
44-7	8581-8584	and	_	
44-8	8585-8586	n	_	
44-9	8587-8588	=	_	
44-10	8589-8590	5	_	
44-11	8591-8595	with	_	
44-12	8596-8609	buprenorphine	_	
44-13	8609-8610	,	_	
44-14	8611-8614	the	_	
44-15	8615-8619	mean	_	
44-16	8620-8629	methadone	_	
44-17	8630-8641	equivalence	_	
44-18	8642-8646	dose	_	
44-19	8647-8650	was	_	
44-20	8651-8656	63.35	_	
44-21	8656-8657	 	_	
44-22	8657-8659	mg	_	
44-23	8659-8660	/	_	
44-24	8660-8661	d	_	
44-25	8662-8663	(	_	
44-26	8663-8664	±	_	
44-27	8665-8670	36.26	_	
44-28	8670-8671	 	_	
44-29	8671-8673	mg	_	
44-30	8673-8674	/	_	
44-31	8674-8675	d	_	
44-32	8676-8684	standard	_	
44-33	8685-8694	deviation	_	
44-34	8695-8696	(	_	
44-35	8696-8699	s.d	_	
44-36	8699-8700	.	_	
44-37	8700-8701	)	_	
44-38	8701-8702	)	_	
44-39	8702-8703	.	_	

#Text=Further clinical and social characteristics are displayed in Table 1.
45-1	8704-8711	Further	_	
45-2	8712-8720	clinical	_	
45-3	8721-8724	and	_	
45-4	8725-8731	social	_	
45-5	8732-8747	characteristics	_	
45-6	8748-8751	are	_	
45-7	8752-8761	displayed	_	
45-8	8762-8764	in	_	
45-9	8765-8770	Table	_	
45-10	8771-8772	1	_	
45-11	8772-8773	.	_	

#Text=At the time of scanning, urine sampling was conducted to detect other (non-prescribed) psychoactive substances (see Table 1), and 9 out of 19 patients reported to use substances other than the prescribed opioid (methadone or buprenorphine), such as benzodiazepines, cocaine, alcohol or cannabis.
46-1	8774-8776	At	_	
46-2	8777-8780	the	_	
46-3	8781-8785	time	_	
46-4	8786-8788	of	_	
46-5	8789-8797	scanning	_	
46-6	8797-8798	,	_	
46-7	8799-8804	urine	_	
46-8	8805-8813	sampling	_	
46-9	8814-8817	was	_	
46-10	8818-8827	conducted	_	
46-11	8828-8830	to	_	
46-12	8831-8837	detect	_	
46-13	8838-8843	other	_	
46-14	8844-8845	(	_	
46-15	8845-8859	non-prescribed	_	
46-16	8859-8860	)	_	
46-17	8861-8873	psychoactive	_	
46-18	8874-8884	substances	_	
46-19	8885-8886	(	_	
46-20	8886-8889	see	_	
46-21	8890-8895	Table	_	
46-22	8896-8897	1	_	
46-23	8897-8898	)	_	
46-24	8898-8899	,	_	
46-25	8900-8903	and	_	
46-26	8904-8905	9	_	
46-27	8906-8909	out	_	
46-28	8910-8912	of	_	
46-29	8913-8915	19	_	
46-30	8916-8924	patients	_	
46-31	8925-8933	reported	_	
46-32	8934-8936	to	_	
46-33	8937-8940	use	_	
46-34	8941-8951	substances	_	
46-35	8952-8957	other	_	
46-36	8958-8962	than	_	
46-37	8963-8966	the	_	
46-38	8967-8977	prescribed	_	
46-39	8978-8984	opioid	_	
46-40	8985-8986	(	_	
46-41	8986-8995	methadone	_	
46-42	8996-8998	or	_	
46-43	8999-9012	buprenorphine	_	
46-44	9012-9013	)	_	
46-45	9013-9014	,	_	
46-46	9015-9019	such	_	
46-47	9020-9022	as	_	
46-48	9023-9038	benzodiazepines	_	
46-49	9038-9039	,	_	
46-50	9040-9047	cocaine	_	
46-51	9047-9048	,	_	
46-52	9049-9056	alcohol	_	
46-53	9057-9059	or	_	
46-54	9060-9068	cannabis	_	
46-55	9068-9069	.	_	

#Text=Clinical characteristics of study participants
#Text=Variable\tOpioid-dependent patients (N = 19)\t\tHealthy controls (N = 20)\t\tStatistics\tP\t \t\tN\t\tN\t\t\t\t \tSex (male/female)\t18:1\t\t18:2\t\tChi2(1) = 0.171\t0.581\t \tEducation (no post-secondary education/apprenticeship only/attended college or higher)\t13/6/0\t\t2/9/9\t\tChi2(2) = 17.653\t0.001*\t \tMedication (methadone/buprenorphine)\t15:4\t\t—\t\t—\t—\t \tSubstance use other than nicotine and methadone (yes/no)\t9:10\t\t—\t\t—\t—\t \tDrugs used other than methadone (absolute numbers)a\tBZD = 4, OPT = 7, ALC = 5, THC = 2, COC = 2\t\t—\t\t—\t—\t \tVariable\tMean\ts.d.
47-1	9070-9078	Clinical	_	
47-2	9079-9094	characteristics	_	
47-3	9095-9097	of	_	
47-4	9098-9103	study	_	
47-5	9104-9116	participants	_	
47-6	9117-9125	Variable	_	
47-7	9126-9142	Opioid-dependent	_	
47-8	9143-9151	patients	_	
47-9	9152-9153	(	_	
47-10	9153-9154	N	_	
47-11	9155-9156	=	_	
47-12	9157-9159	19	_	
47-13	9159-9160	)	_	
47-14	9162-9169	Healthy	_	
47-15	9170-9178	controls	_	
47-16	9179-9180	(	_	
47-17	9180-9181	N	_	
47-18	9182-9183	=	_	
47-19	9184-9186	20	_	
47-20	9186-9187	)	_	
47-21	9189-9199	Statistics	_	
47-22	9200-9201	P	_	
47-23	9205-9206	N	_	
47-24	9208-9209	N	_	
47-25	9215-9218	Sex	_	
47-26	9219-9220	(	_	
47-27	9220-9224	male	_	
47-28	9224-9225	/	_	
47-29	9225-9231	female	_	
47-30	9231-9232	)	_	
47-31	9233-9235	18	_	
47-32	9235-9236	:	_	
47-33	9236-9237	1	_	
47-34	9239-9241	18	_	
47-35	9241-9242	:	_	
47-36	9242-9243	2	_	
47-37	9245-9249	Chi2	_	
47-38	9249-9250	(	_	
47-39	9250-9251	1	_	
47-40	9251-9252	)	_	
47-41	9253-9254	=	_	
47-42	9255-9260	0.171	_	
47-43	9261-9266	0.581	_	
47-44	9269-9278	Education	_	
47-45	9279-9280	(	_	
47-46	9280-9282	no	_	
47-47	9283-9297	post-secondary	_	
47-48	9298-9307	education	_	
47-49	9307-9308	/	_	
47-50	9308-9322	apprenticeship	_	
47-51	9323-9327	only	_	
47-52	9327-9328	/	_	
47-53	9328-9336	attended	_	
47-54	9337-9344	college	_	
47-55	9345-9347	or	_	
47-56	9348-9354	higher	_	
47-57	9354-9355	)	_	
47-58	9356-9358	13	_	
47-59	9358-9359	/	_	
47-60	9359-9360	6	_	
47-61	9360-9361	/	_	
47-62	9361-9362	0	_	
47-63	9364-9365	2	_	
47-64	9365-9366	/	_	
47-65	9366-9367	9	_	
47-66	9367-9368	/	_	
47-67	9368-9369	9	_	
47-68	9371-9375	Chi2	_	
47-69	9375-9376	(	_	
47-70	9376-9377	2	_	
47-71	9377-9378	)	_	
47-72	9379-9380	=	_	
47-73	9381-9387	17.653	_	
47-74	9388-9393	0.001	_	
47-75	9393-9394	*	_	
47-76	9397-9407	Medication	_	
47-77	9408-9409	(	_	
47-78	9409-9418	methadone	_	
47-79	9418-9419	/	_	
47-80	9419-9432	buprenorphine	_	
47-81	9432-9433	)	_	
47-82	9434-9436	15	_	
47-83	9436-9437	:	_	
47-84	9437-9438	4	_	
47-85	9440-9441	—	_	
47-86	9443-9444	—	_	
47-87	9445-9446	—	_	
47-88	9449-9458	Substance	_	
47-89	9459-9462	use	_	
47-90	9463-9468	other	_	
47-91	9469-9473	than	_	
47-92	9474-9482	nicotine	_	
47-93	9483-9486	and	_	
47-94	9487-9496	methadone	_	
47-95	9497-9498	(	_	
47-96	9498-9501	yes	_	
47-97	9501-9502	/	_	
47-98	9502-9504	no	_	
47-99	9504-9505	)	_	
47-100	9506-9507	9	_	
47-101	9507-9508	:	_	
47-102	9508-9510	10	_	
47-103	9512-9513	—	_	
47-104	9515-9516	—	_	
47-105	9517-9518	—	_	
47-106	9521-9526	Drugs	_	
47-107	9527-9531	used	_	
47-108	9532-9537	other	_	
47-109	9538-9542	than	_	
47-110	9543-9552	methadone	_	
47-111	9553-9554	(	_	
47-112	9554-9562	absolute	_	
47-113	9563-9570	numbers	_	
47-114	9570-9571	)	_	
47-115	9571-9572	a	_	
47-116	9573-9576	BZD	_	
47-117	9577-9578	=	_	
47-118	9579-9580	4	_	
47-119	9580-9581	,	_	
47-120	9582-9585	OPT	_	
47-121	9585-9586	 	_	
47-122	9586-9587	=	_	
47-123	9588-9589	7	_	
47-124	9589-9590	,	_	
47-125	9591-9594	ALC	_	
47-126	9595-9596	=	_	
47-127	9597-9598	5	_	
47-128	9598-9599	,	_	
47-129	9600-9603	THC	_	
47-130	9604-9605	=	_	
47-131	9606-9607	2	_	
47-132	9607-9608	,	_	
47-133	9609-9612	COC	_	
47-134	9613-9614	=	_	
47-135	9615-9616	2	_	
47-136	9618-9619	—	_	
47-137	9621-9622	—	_	
47-138	9623-9624	—	_	
47-139	9627-9635	Variable	_	
47-140	9636-9640	Mean	_	
47-141	9641-9644	s.d	_	
47-142	9644-9645	.	_	

#Text=Mean\ts.d.
48-1	9646-9650	Mean	_	
48-2	9651-9654	s.d	_	
48-3	9654-9655	.	_	

#Text=Age (years)\t37.42\t8.23\t38.35\t8.28\tt(37) = 0.351\t0.727\t \tDuration of heroin abuse (years)\t14.4\t7.10\t—\t\t—\t—\t \tMethadone equivalence dose (mg)\t63.35\t36.26\t—\t\t—\t—\t \tSPS (sum score)\t14.11\t19.76\t4.00\t3.67\tt(37) = 2.248\t0.016*,#,†\t \tRSQ (sum score)\t9.75\t5.96\t5.08\t3.53\tt(37) = 4.670\t0.003*,#,†,°\t \tSIAS (sum score)\t22.00\t17.76\t13.45\t7.22\tt(37) = 1.988\t0.027*,#\t \tBSI (global severity score)\t35.47\t39.34\t4.85\t5.21\tt(37) = 3.452\t0.001*,#\t \tBSI—subscale interpersonal sensitivity (score)\t2.74\t3.72\t0.60\t1.10\tt(37) = 2.137\t0.019*,#\t \tBSI—subscale anxiety (score)\t3.53\t4.50\t0.80\t1.01\tt(37) = 2.726\t0.012*,#\t \tBSI—subscale phobic anxiety (score)\t2.63\t4.51\t0.15\t0.49\tt(37) = 2.482\t0.019*,#\t \t
#Text=BZD = benzodiazepine, OPT = opiates other than methadone/buprenorphine, ALC = alcohol, THC = tetrahydrocannabinol, COC = cocaine.
49-1	9660-9663	Age	_	
49-2	9664-9665	(	_	
49-3	9665-9670	years	_	
49-4	9670-9671	)	_	
49-5	9672-9677	37.42	_	
49-6	9678-9682	8.23	_	
49-7	9683-9688	38.35	_	
49-8	9689-9693	8.28	_	
49-9	9694-9695	t	_	
49-10	9695-9696	(	_	
49-11	9696-9698	37	_	
49-12	9698-9699	)	_	
49-13	9700-9701	=	_	
49-14	9702-9707	0.351	_	
49-15	9708-9713	0.727	_	
49-16	9716-9724	Duration	_	
49-17	9725-9727	of	_	
49-18	9728-9734	heroin	_	
49-19	9735-9740	abuse	_	
49-20	9741-9742	(	_	
49-21	9742-9747	years	_	
49-22	9747-9748	)	_	
49-23	9749-9753	14.4	_	
49-24	9754-9758	7.10	_	
49-25	9759-9760	—	_	
49-26	9762-9763	—	_	
49-27	9764-9765	—	_	
49-28	9768-9777	Methadone	_	
49-29	9778-9789	equivalence	_	
49-30	9790-9794	dose	_	
49-31	9795-9796	(	_	
49-32	9796-9798	mg	_	
49-33	9798-9799	)	_	
49-34	9800-9805	63.35	_	
49-35	9806-9811	36.26	_	
49-36	9812-9813	—	_	
49-37	9815-9816	—	_	
49-38	9817-9818	—	_	
49-39	9821-9824	SPS	_	
49-40	9825-9826	(	_	
49-41	9826-9829	sum	_	
49-42	9830-9835	score	_	
49-43	9835-9836	)	_	
49-44	9837-9842	14.11	_	
49-45	9843-9848	19.76	_	
49-46	9849-9853	4.00	_	
49-47	9854-9858	3.67	_	
49-48	9859-9860	t	_	
49-49	9860-9861	(	_	
49-50	9861-9863	37	_	
49-51	9863-9864	)	_	
49-52	9865-9866	=	_	
49-53	9867-9872	2.248	_	
49-54	9873-9878	0.016	_	
49-55	9878-9879	*	_	
49-56	9879-9880	,	_	
49-57	9880-9881	#	_	
49-58	9881-9882	,	_	
49-59	9882-9883	†	_	
49-60	9886-9889	RSQ	_	
49-61	9890-9891	(	_	
49-62	9891-9894	sum	_	
49-63	9895-9900	score	_	
49-64	9900-9901	)	_	
49-65	9902-9906	9.75	_	
49-66	9907-9911	5.96	_	
49-67	9912-9916	5.08	_	
49-68	9917-9921	3.53	_	
49-69	9922-9923	t	_	
49-70	9923-9924	(	_	
49-71	9924-9926	37	_	
49-72	9926-9927	)	_	
49-73	9928-9929	=	_	
49-74	9930-9935	4.670	_	
49-75	9936-9941	0.003	_	
49-76	9941-9942	*	_	
49-77	9942-9943	,	_	
49-78	9943-9944	#	_	
49-79	9944-9945	,	_	
49-80	9945-9946	†	_	
49-81	9946-9947	,	_	
49-82	9947-9948	°	_	
49-83	9951-9955	SIAS	_	
49-84	9956-9957	(	_	
49-85	9957-9960	sum	_	
49-86	9961-9966	score	_	
49-87	9966-9967	)	_	
49-88	9968-9973	22.00	_	
49-89	9974-9979	17.76	_	
49-90	9980-9985	13.45	_	
49-91	9986-9990	7.22	_	
49-92	9991-9992	t	_	
49-93	9992-9993	(	_	
49-94	9993-9995	37	_	
49-95	9995-9996	)	_	
49-96	9997-9998	=	_	
49-97	9999-10004	1.988	_	
49-98	10005-10010	0.027	_	
49-99	10010-10011	*	_	
49-100	10011-10012	,	_	
49-101	10012-10013	#	_	
49-102	10016-10019	BSI	_	
49-103	10020-10021	(	_	
49-104	10021-10027	global	_	
49-105	10028-10036	severity	_	
49-106	10037-10042	score	_	
49-107	10042-10043	)	_	
49-108	10044-10049	35.47	_	
49-109	10050-10055	39.34	_	
49-110	10056-10060	4.85	_	
49-111	10061-10065	5.21	_	
49-112	10066-10067	t	_	
49-113	10067-10068	(	_	
49-114	10068-10070	37	_	
49-115	10070-10071	)	_	
49-116	10072-10073	=	_	
49-117	10074-10079	3.452	_	
49-118	10080-10085	0.001	_	
49-119	10085-10086	*	_	
49-120	10086-10087	,	_	
49-121	10087-10088	#	_	
49-122	10091-10103	BSI—subscale	_	
49-123	10104-10117	interpersonal	_	
49-124	10118-10129	sensitivity	_	
49-125	10130-10131	(	_	
49-126	10131-10136	score	_	
49-127	10136-10137	)	_	
49-128	10138-10142	2.74	_	
49-129	10143-10147	3.72	_	
49-130	10148-10152	0.60	_	
49-131	10153-10157	1.10	_	
49-132	10158-10159	t	_	
49-133	10159-10160	(	_	
49-134	10160-10162	37	_	
49-135	10162-10163	)	_	
49-136	10164-10165	=	_	
49-137	10166-10171	2.137	_	
49-138	10172-10177	0.019	_	
49-139	10177-10178	*	_	
49-140	10178-10179	,	_	
49-141	10179-10180	#	_	
49-142	10183-10195	BSI—subscale	_	
49-143	10196-10203	anxiety	_	
49-144	10204-10205	(	_	
49-145	10205-10210	score	_	
49-146	10210-10211	)	_	
49-147	10212-10216	3.53	_	
49-148	10217-10221	4.50	_	
49-149	10222-10226	0.80	_	
49-150	10227-10231	1.01	_	
49-151	10232-10233	t	_	
49-152	10233-10234	(	_	
49-153	10234-10236	37	_	
49-154	10236-10237	)	_	
49-155	10238-10239	=	_	
49-156	10240-10245	2.726	_	
49-157	10246-10251	0.012	_	
49-158	10251-10252	*	_	
49-159	10252-10253	,	_	
49-160	10253-10254	#	_	
49-161	10257-10269	BSI—subscale	_	
49-162	10270-10276	phobic	_	
49-163	10277-10284	anxiety	_	
49-164	10285-10286	(	_	
49-165	10286-10291	score	_	
49-166	10291-10292	)	_	
49-167	10293-10297	2.63	_	
49-168	10298-10302	4.51	_	
49-169	10303-10307	0.15	_	
49-170	10308-10312	0.49	_	
49-171	10313-10314	t	_	
49-172	10314-10315	(	_	
49-173	10315-10317	37	_	
49-174	10317-10318	)	_	
49-175	10319-10320	=	_	
49-176	10321-10326	2.482	_	
49-177	10327-10332	0.019	_	
49-178	10332-10333	*	_	
49-179	10333-10334	,	_	
49-180	10334-10335	#	_	
49-181	10339-10342	BZD	_	
49-182	10343-10344	=	_	
49-183	10345-10359	benzodiazepine	_	
49-184	10359-10360	,	_	
49-185	10361-10364	OPT	_	
49-186	10365-10366	=	_	
49-187	10367-10374	opiates	_	
49-188	10375-10380	other	_	
49-189	10381-10385	than	_	
49-190	10386-10395	methadone	_	
49-191	10395-10396	/	_	
49-192	10396-10409	buprenorphine	_	
49-193	10409-10410	,	_	
49-194	10411-10414	ALC	_	
49-195	10415-10416	=	_	
49-196	10417-10424	alcohol	_	
49-197	10424-10425	,	_	
49-198	10426-10429	THC	_	
49-199	10430-10431	=	_	
49-200	10432-10452	tetrahydrocannabinol	_	
49-201	10452-10453	,	_	
49-202	10454-10457	COC	_	
49-203	10458-10459	=	_	
49-204	10460-10467	cocaine	_	
49-205	10467-10468	.	_	

#Text=Methadone equivalence dose was calculated with 100 mg methadone = 16 mg buprenorphine.
50-1	10469-10478	Methadone	_	
50-2	10479-10490	equivalence	_	
50-3	10491-10495	dose	_	
50-4	10496-10499	was	_	
50-5	10500-10510	calculated	_	
50-6	10511-10515	with	_	
50-7	10516-10519	100	_	
50-8	10519-10520	 	_	
50-9	10520-10522	mg	_	
50-10	10523-10532	methadone	_	
50-11	10533-10534	=	_	
50-12	10535-10537	16	_	
50-13	10537-10538	 	_	
50-14	10538-10540	mg	_	
50-15	10541-10554	buprenorphine	_	
50-16	10554-10555	.	_	

#Text=a
#Text=n = 8 patients consumed more than one drug other than methadone and nicotine concurrently.
51-1	10557-10558	a	_	
51-2	10559-10560	n	_	
51-3	10561-10562	=	_	
51-4	10563-10564	8	_	
51-5	10565-10573	patients	_	
51-6	10574-10582	consumed	_	
51-7	10583-10587	more	_	
51-8	10588-10592	than	_	
51-9	10593-10596	one	_	
51-10	10597-10601	drug	_	
51-11	10602-10607	other	_	
51-12	10608-10612	than	_	
51-13	10613-10622	methadone	_	
51-14	10623-10626	and	_	
51-15	10627-10635	nicotine	_	
51-16	10636-10648	concurrently	_	
51-17	10648-10649	.	_	

#Text=*Significant group differences at P < 0.05.
52-1	10651-10652	*	_	
52-2	10652-10663	Significant	_	
52-3	10664-10669	group	_	
52-4	10670-10681	differences	_	
52-5	10682-10684	at	_	
52-6	10685-10686	P	_	
52-7	10687-10688	<	_	
52-8	10689-10693	0.05	_	
52-9	10693-10694	.	_	

#Text=#Significant group differences at P < 0.05 after controlling for partnership status.
53-1	10696-10697	#	_	
53-2	10697-10708	Significant	_	
53-3	10709-10714	group	_	
53-4	10715-10726	differences	_	
53-5	10727-10729	at	_	
53-6	10730-10731	P	_	
53-7	10732-10733	<	_	
53-8	10734-10738	0.05	_	
53-9	10739-10744	after	_	
53-10	10745-10756	controlling	_	
53-11	10757-10760	for	_	
53-12	10761-10772	partnership	_	
53-13	10773-10779	status	_	
53-14	10779-10780	.	_	

#Text=†Significant group differences at P < 0.05 after controlling for education level.
54-1	10782-10783	†	_	
54-2	10783-10794	Significant	_	
54-3	10795-10800	group	_	
54-4	10801-10812	differences	_	
54-5	10813-10815	at	_	
54-6	10816-10817	P	_	
54-7	10818-10819	<	_	
54-8	10820-10824	0.05	_	
54-9	10825-10830	after	_	
54-10	10831-10842	controlling	_	
54-11	10843-10846	for	_	
54-12	10847-10856	education	_	
54-13	10857-10862	level	_	
54-14	10862-10863	.	_	

#Text=°Significant group differences at P < 0.05 after controlling for partnership status and education level concurrently.
55-1	10865-10866	°	_	
55-2	10866-10877	Significant	_	
55-3	10878-10883	group	_	
55-4	10884-10895	differences	_	
55-5	10896-10898	at	_	
55-6	10899-10900	P	_	
55-7	10901-10902	<	_	
55-8	10903-10907	0.05	_	
55-9	10908-10913	after	_	
55-10	10914-10925	controlling	_	
55-11	10926-10929	for	_	
55-12	10930-10941	partnership	_	
55-13	10942-10948	status	_	
55-14	10949-10952	and	_	
55-15	10953-10962	education	_	
55-16	10963-10968	level	_	
55-17	10969-10981	concurrently	_	
55-18	10981-10982	.	_	

#Text=Study design
#Text=Eligible participants were asked to complete several questionnaires before performing magnetic resonance imaging (MRI) with structural and functional scans.
56-1	10983-10988	Study	_	
56-2	10989-10995	design	_	
56-3	10996-11004	Eligible	_	
56-4	11005-11017	participants	_	
56-5	11018-11022	were	_	
56-6	11023-11028	asked	_	
56-7	11029-11031	to	_	
56-8	11032-11040	complete	_	
56-9	11041-11048	several	_	
56-10	11049-11063	questionnaires	_	
56-11	11064-11070	before	_	
56-12	11071-11081	performing	_	
56-13	11082-11090	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[20]	
56-14	11091-11100	resonance	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[20]	
56-15	11101-11108	imaging	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[20]	
56-16	11109-11110	(	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[20]	
56-17	11110-11113	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[20]	
56-18	11113-11114	)	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[20]	
56-19	11115-11119	with	_	
56-20	11120-11130	structural	_	
56-21	11131-11134	and	_	
56-22	11135-11145	functional	_	
56-23	11146-11151	scans	_	
56-24	11151-11152	.	_	

#Text=The psychometric measures included the social phobia scale (SPS), the social interaction anxiety scale (SIAS), the rejection sensitivity questionnaire (RSQ) and the brief symptom inventory (BSI).
57-1	11153-11156	The	_	
57-2	11157-11169	psychometric	_	
57-3	11170-11178	measures	_	
57-4	11179-11187	included	_	
57-5	11188-11191	the	_	
57-6	11192-11198	social	_	
57-7	11199-11205	phobia	_	
57-8	11206-11211	scale	_	
57-9	11212-11213	(	_	
57-10	11213-11216	SPS	_	
57-11	11216-11217	)	_	
57-12	11217-11218	,	_	
57-13	11219-11222	the	_	
57-14	11223-11229	social	_	
57-15	11230-11241	interaction	_	
57-16	11242-11249	anxiety	_	
57-17	11250-11255	scale	_	
57-18	11256-11257	(	_	
57-19	11257-11261	SIAS	_	
57-20	11261-11262	)	_	
57-21	11262-11263	,	_	
57-22	11264-11267	the	_	
57-23	11268-11277	rejection	_	
57-24	11278-11289	sensitivity	_	
57-25	11290-11303	questionnaire	_	
57-26	11304-11305	(	_	
57-27	11305-11308	RSQ	_	
57-28	11308-11309	)	_	
57-29	11310-11313	and	_	
57-30	11314-11317	the	_	
57-31	11318-11323	brief	_	
57-32	11324-11331	symptom	_	
57-33	11332-11341	inventory	_	
57-34	11342-11343	(	_	
57-35	11343-11346	BSI	_	
57-36	11346-11347	)	_	
57-37	11347-11348	.	_	

#Text=All participants underwent structural MRI scanning and performed an fMRI Cyberball task that simulates social inclusion and social exclusion while applying painful and neutral reference temperature stimuli as used in previous studies.
58-1	11349-11352	All	_	
58-2	11353-11365	participants	_	
58-3	11366-11375	underwent	_	
58-4	11376-11386	structural	_	
58-5	11387-11390	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging	
58-6	11391-11399	scanning	_	
58-7	11400-11403	and	_	
58-8	11404-11413	performed	_	
58-9	11414-11416	an	_	
58-10	11417-11421	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[21]	
58-11	11422-11431	Cyberball	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[21]	
58-12	11432-11436	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[21]	
58-13	11437-11441	that	_	
58-14	11442-11451	simulates	_	
58-15	11452-11458	social	_	
58-16	11459-11468	inclusion	_	
58-17	11469-11472	and	_	
58-18	11473-11479	social	_	
58-19	11480-11489	exclusion	_	
58-20	11490-11495	while	_	
58-21	11496-11504	applying	_	
58-22	11505-11512	painful	_	
58-23	11513-11516	and	_	
58-24	11517-11524	neutral	_	
58-25	11525-11534	reference	_	
58-26	11535-11546	temperature	_	
58-27	11547-11554	stimuli	_	
58-28	11555-11557	as	_	
58-29	11558-11562	used	_	
58-30	11563-11565	in	_	
58-31	11566-11574	previous	_	
58-32	11575-11582	studies	_	
58-33	11582-11583	.	_	

#Text=MRI acquisition
#Text=High-resolution anatomical scans using a T1-weighted 3D magnetization-prepared rapid acquisition gradient-echo seq-uence (1 × 1 × 1 mm3 voxel size, slice thickness 1 mm, Field of view (FOV) 256 × 256 mm, Repetition Time (TR) = 2300 ms, Echo Time (TE) = 3.03 ms, Inversion Time (TI) = 900 ms) were performed using a 3 T whole-body tomograph (MAGNETOM Trio, Siemens Medical Systems, Erlangen, Germany).
59-1	11584-11587	MRI	_	
59-2	11588-11599	acquisition	_	
59-3	11600-11615	High-resolution	_	
59-4	11616-11626	anatomical	_	
59-5	11627-11632	scans	_	
59-6	11633-11638	using	_	
59-7	11639-11640	a	_	
59-8	11641-11643	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[22]	
59-9	11643-11644	-	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[22]	
59-10	11644-11652	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[22]	
59-11	11653-11655	3D	_	
59-12	11656-11678	magnetization-prepared	_	
59-13	11679-11684	rapid	_	
59-14	11685-11696	acquisition	_	
59-15	11697-11710	gradient-echo	_	
59-16	11711-11720	seq-uence	_	
59-17	11721-11722	(	_	
59-18	11722-11723	1	_	
59-19	11724-11725	×	_	
59-20	11726-11727	1	_	
59-21	11728-11729	×	_	
59-22	11730-11731	1	_	
59-23	11731-11732	 	_	
59-24	11732-11735	mm3	_	
59-25	11736-11741	voxel	_	
59-26	11742-11746	size	_	
59-27	11746-11747	,	_	
59-28	11748-11753	slice	_	
59-29	11754-11763	thickness	_	
59-30	11764-11765	1	_	
59-31	11765-11766	 	_	
59-32	11766-11768	mm	_	
59-33	11768-11769	,	_	
59-34	11770-11775	Field	_	
59-35	11776-11778	of	_	
59-36	11779-11783	view	_	
59-37	11784-11785	(	_	
59-38	11785-11788	FOV	_	
59-39	11788-11789	)	_	
59-40	11790-11793	256	_	
59-41	11794-11795	×	_	
59-42	11796-11799	256	_	
59-43	11799-11800	 	_	
59-44	11800-11802	mm	_	
59-45	11802-11803	,	_	
59-46	11804-11814	Repetition	_	
59-47	11815-11819	Time	_	
59-48	11820-11821	(	_	
59-49	11821-11823	TR	_	
59-50	11823-11824	)	_	
59-51	11825-11826	=	_	
59-52	11827-11831	2300	_	
59-53	11831-11832	 	_	
59-54	11832-11834	ms	_	
59-55	11834-11835	,	_	
59-56	11836-11840	Echo	_	
59-57	11841-11845	Time	_	
59-58	11846-11847	(	_	
59-59	11847-11849	TE	_	
59-60	11849-11850	)	_	
59-61	11851-11852	=	_	
59-62	11853-11857	3.03	_	
59-63	11857-11858	 	_	
59-64	11858-11860	ms	_	
59-65	11860-11861	,	_	
59-66	11862-11871	Inversion	_	
59-67	11872-11876	Time	_	
59-68	11877-11878	(	_	
59-69	11878-11880	TI	_	
59-70	11880-11881	)	_	
59-71	11882-11883	=	_	
59-72	11884-11887	900	_	
59-73	11887-11888	 	_	
59-74	11888-11890	ms	_	
59-75	11890-11891	)	_	
59-76	11892-11896	were	_	
59-77	11897-11906	performed	_	
59-78	11907-11912	using	_	
59-79	11913-11914	a	_	
59-80	11915-11916	3	_	
59-81	11916-11917	 	_	
59-82	11917-11918	T	_	
59-83	11919-11929	whole-body	_	
59-84	11930-11939	tomograph	_	
59-85	11940-11941	(	_	
59-86	11941-11949	MAGNETOM	_	
59-87	11950-11954	Trio	_	
59-88	11954-11955	,	_	
59-89	11956-11963	Siemens	_	
59-90	11964-11971	Medical	_	
59-91	11972-11979	Systems	_	
59-92	11979-11980	,	_	
59-93	11981-11989	Erlangen	_	
59-94	11989-11990	,	_	
59-95	11991-11998	Germany	_	
59-96	11998-11999	)	_	
59-97	11999-12000	.	_	

#Text=VBM pre-processing and statistical analyses
#Text=All image analyses of structural data were conducted using the latest version of the statistical parametric mapping software (SPM) for Matlab (version 12, Wellcome Department of Cognitive Neurology, London, UK).
60-1	12001-12004	VBM	_	
60-2	12005-12019	pre-processing	_	
60-3	12020-12023	and	_	
60-4	12024-12035	statistical	_	
60-5	12036-12044	analyses	_	
60-6	12045-12048	All	_	
60-7	12049-12054	image	_	
60-8	12055-12063	analyses	_	
60-9	12064-12066	of	_	
60-10	12067-12077	structural	_	
60-11	12078-12082	data	_	
60-12	12083-12087	were	_	
60-13	12088-12097	conducted	_	
60-14	12098-12103	using	_	
60-15	12104-12107	the	_	
60-16	12108-12114	latest	_	
60-17	12115-12122	version	_	
60-18	12123-12125	of	_	
60-19	12126-12129	the	_	
60-20	12130-12141	statistical	_	
60-21	12142-12152	parametric	_	
60-22	12153-12160	mapping	_	
60-23	12161-12169	software	_	
60-24	12170-12171	(	_	
60-25	12171-12174	SPM	_	
60-26	12174-12175	)	_	
60-27	12176-12179	for	_	
60-28	12180-12186	Matlab	_	
60-29	12187-12188	(	_	
60-30	12188-12195	version	_	
60-31	12196-12198	12	_	
60-32	12198-12199	,	_	
60-33	12200-12208	Wellcome	_	
60-34	12209-12219	Department	_	
60-35	12220-12222	of	_	
60-36	12223-12232	Cognitive	_	
60-37	12233-12242	Neurology	_	
60-38	12242-12243	,	_	
60-39	12244-12250	London	_	
60-40	12250-12251	,	_	
60-41	12252-12254	UK	_	
60-42	12254-12255	)	_	
60-43	12255-12256	.	_	

#Text=Current methodological studies indicated that the Computational Anatomy Toolbox (CAT12, http://www.neuro.uni-jena.de/cat/index.html) for SPM12 provides a more accurate volumetric analysis of brain regions and is more robust and accurate against volumetric alterations than the VBM8 toolbox.
61-1	12257-12264	Current	_	
61-2	12265-12279	methodological	_	
61-3	12280-12287	studies	_	
61-4	12288-12297	indicated	_	
61-5	12298-12302	that	_	
61-6	12303-12306	the	_	
61-7	12307-12320	Computational	_	
61-8	12321-12328	Anatomy	_	
61-9	12329-12336	Toolbox	_	
61-10	12337-12338	(	_	
61-11	12338-12343	CAT12	_	
61-12	12343-12344	,	_	
61-13	12345-12349	http	_	
61-14	12349-12350	:	_	
61-15	12350-12351	/	_	
61-16	12351-12352	/	_	
61-17	12352-12373	www.neuro.uni-jena.de	_	
61-18	12373-12374	/	_	
61-19	12374-12377	cat	_	
61-20	12377-12378	/	_	
61-21	12378-12388	index.html	_	
61-22	12388-12389	)	_	
61-23	12390-12393	for	_	
61-24	12394-12399	SPM12	_	
61-25	12400-12408	provides	_	
61-26	12409-12410	a	_	
61-27	12411-12415	more	_	
61-28	12416-12424	accurate	_	
61-29	12425-12435	volumetric	_	
61-30	12436-12444	analysis	_	
61-31	12445-12447	of	_	
61-32	12448-12453	brain	_	
61-33	12454-12461	regions	_	
61-34	12462-12465	and	_	
61-35	12466-12468	is	_	
61-36	12469-12473	more	_	
61-37	12474-12480	robust	_	
61-38	12481-12484	and	_	
61-39	12485-12493	accurate	_	
61-40	12494-12501	against	_	
61-41	12502-12512	volumetric	_	
61-42	12513-12524	alterations	_	
61-43	12525-12529	than	_	
61-44	12530-12533	the	_	
61-45	12534-12538	VBM8	_	
61-46	12539-12546	toolbox	_	
61-47	12546-12547	.	_	

#Text=Considering these findings, we performed our VBM analyses using the CAT12 toolbox for SPM12, applying the default settings and proceeding according to the authors’ manual.
62-1	12548-12559	Considering	_	
62-2	12560-12565	these	_	
62-3	12566-12574	findings	_	
62-4	12574-12575	,	_	
62-5	12576-12578	we	_	
62-6	12579-12588	performed	_	
62-7	12589-12592	our	_	
62-8	12593-12596	VBM	_	
62-9	12597-12605	analyses	_	
62-10	12606-12611	using	_	
62-11	12612-12615	the	_	
62-12	12616-12621	CAT12	_	
62-13	12622-12629	toolbox	_	
62-14	12630-12633	for	_	
62-15	12634-12639	SPM12	_	
62-16	12639-12640	,	_	
62-17	12641-12649	applying	_	
62-18	12650-12653	the	_	
62-19	12654-12661	default	_	
62-20	12662-12670	settings	_	
62-21	12671-12674	and	_	
62-22	12675-12685	proceeding	_	
62-23	12686-12695	according	_	
62-24	12696-12698	to	_	
62-25	12699-12702	the	_	
62-26	12703-12710	authors	_	
62-27	12710-12711	’	_	
62-28	12712-12718	manual	_	
62-29	12718-12719	.	_	

#Text=Before image analyses, all image datasets were inspected by at least one medical technical radiology assistant to check for any gross structural abnormalities or imaging artifacts and referred to a neuroradiologist if necessary.
63-1	12720-12726	Before	_	
63-2	12727-12732	image	_	
63-3	12733-12741	analyses	_	
63-4	12741-12742	,	_	
63-5	12743-12746	all	_	
63-6	12747-12752	image	_	
63-7	12753-12761	datasets	_	
63-8	12762-12766	were	_	
63-9	12767-12776	inspected	_	
63-10	12777-12779	by	_	
63-11	12780-12782	at	_	
63-12	12783-12788	least	_	
63-13	12789-12792	one	_	
63-14	12793-12800	medical	_	
63-15	12801-12810	technical	_	
63-16	12811-12820	radiology	_	
63-17	12821-12830	assistant	_	
63-18	12831-12833	to	_	
63-19	12834-12839	check	_	
63-20	12840-12843	for	_	
63-21	12844-12847	any	_	
63-22	12848-12853	gross	_	
63-23	12854-12864	structural	_	
63-24	12865-12878	abnormalities	_	
63-25	12879-12881	or	_	
63-26	12882-12889	imaging	_	
63-27	12890-12899	artifacts	_	
63-28	12900-12903	and	_	
63-29	12904-12912	referred	_	
63-30	12913-12915	to	_	
63-31	12916-12917	a	_	
63-32	12918-12934	neuroradiologist	_	
63-33	12935-12937	if	_	
63-34	12938-12947	necessary	_	
63-35	12947-12948	.	_	

#Text=All 3D T1-weighted MRI scans were normalized using an affine registration followed by non-linear registration, corrected for bias field inhomogeneity and then segmented into GM, white matter (WM) and cerebrospinal fluid components.
64-1	12949-12952	All	_	
64-2	12953-12955	3D	_	
64-3	12956-12958	T1	_	
64-4	12958-12959	-	_	
64-5	12959-12967	weighted	_	
64-6	12968-12971	MRI	_	
64-7	12972-12977	scans	_	
64-8	12978-12982	were	_	
64-9	12983-12993	normalized	_	
64-10	12994-12999	using	_	
64-11	13000-13002	an	_	
64-12	13003-13009	affine	_	
64-13	13010-13022	registration	_	
64-14	13023-13031	followed	_	
64-15	13032-13034	by	_	
64-16	13035-13045	non-linear	_	
64-17	13046-13058	registration	_	
64-18	13058-13059	,	_	
64-19	13060-13069	corrected	_	
64-20	13070-13073	for	_	
64-21	13074-13078	bias	_	
64-22	13079-13084	field	_	
64-23	13085-13098	inhomogeneity	_	
64-24	13099-13102	and	_	
64-25	13103-13107	then	_	
64-26	13108-13117	segmented	_	
64-27	13118-13122	into	_	
64-28	13123-13125	GM	_	
64-29	13125-13126	,	_	
64-30	13127-13132	white	_	
64-31	13133-13139	matter	_	
64-32	13140-13141	(	_	
64-33	13141-13143	WM	_	
64-34	13143-13144	)	_	
64-35	13145-13148	and	_	
64-36	13149-13162	cerebrospinal	_	
64-37	13163-13168	fluid	_	
64-38	13169-13179	components	_	
64-39	13179-13180	.	_	

#Text=We used the Diffeomorphic Anatomic Registration Through Exponentiated Lie (DARTEL) algebra algorithm to normalize the segmented scans into a standard Montreal Neurological Institute (MNI) space.
65-1	13181-13183	We	_	
65-2	13184-13188	used	_	
65-3	13189-13192	the	_	
65-4	13193-13206	Diffeomorphic	_	
65-5	13207-13215	Anatomic	_	
65-6	13216-13228	Registration	_	
65-7	13229-13236	Through	_	
65-8	13237-13250	Exponentiated	_	
65-9	13251-13254	Lie	_	
65-10	13255-13256	(	_	
65-11	13256-13262	DARTEL	_	
65-12	13262-13263	)	_	
65-13	13264-13271	algebra	_	
65-14	13272-13281	algorithm	_	
65-15	13282-13284	to	_	
65-16	13285-13294	normalize	_	
65-17	13295-13298	the	_	
65-18	13299-13308	segmented	_	
65-19	13309-13314	scans	_	
65-20	13315-13319	into	_	
65-21	13320-13321	a	_	
65-22	13322-13330	standard	_	
65-23	13331-13339	Montreal	_	
65-24	13340-13352	Neurological	_	
65-25	13353-13362	Institute	_	
65-26	13363-13364	(	_	
65-27	13364-13367	MNI	_	
65-28	13367-13368	)	_	
65-29	13369-13374	space	_	
65-30	13374-13375	.	_	

#Text=Compared to the conventional algorithm, the DARTEL approach provides more precise spatial normalization to the template than standard registration methods.
66-1	13376-13384	Compared	_	
66-2	13385-13387	to	_	
66-3	13388-13391	the	_	
66-4	13392-13404	conventional	_	
66-5	13405-13414	algorithm	_	
66-6	13414-13415	,	_	
66-7	13416-13419	the	_	
66-8	13420-13426	DARTEL	_	
66-9	13427-13435	approach	_	
66-10	13436-13444	provides	_	
66-11	13445-13449	more	_	
66-12	13450-13457	precise	_	
66-13	13458-13465	spatial	_	
66-14	13466-13479	normalization	_	
66-15	13480-13482	to	_	
66-16	13483-13486	the	_	
66-17	13487-13495	template	_	
66-18	13496-13500	than	_	
66-19	13501-13509	standard	_	
66-20	13510-13522	registration	_	
66-21	13523-13530	methods	_	
66-22	13530-13531	.	_	

#Text=Following this step, images were visually inspected for sample homogeneity of the unsmoothed data.
67-1	13532-13541	Following	_	
67-2	13542-13546	this	_	
67-3	13547-13551	step	_	
67-4	13551-13552	,	_	
67-5	13553-13559	images	_	
67-6	13560-13564	were	_	
67-7	13565-13573	visually	_	
67-8	13574-13583	inspected	_	
67-9	13584-13587	for	_	
67-10	13588-13594	sample	_	
67-11	13595-13606	homogeneity	_	
67-12	13607-13609	of	_	
67-13	13610-13613	the	_	
67-14	13614-13624	unsmoothed	_	
67-15	13625-13629	data	_	
67-16	13629-13630	.	_	

#Text=This was evaluated using the procedure included in the CAT12 toolbox.
68-1	13631-13635	This	_	
68-2	13636-13639	was	_	
68-3	13640-13649	evaluated	_	
68-4	13650-13655	using	_	
68-5	13656-13659	the	_	
68-6	13660-13669	procedure	_	
68-7	13670-13678	included	_	
68-8	13679-13681	in	_	
68-9	13682-13685	the	_	
68-10	13686-13691	CAT12	_	
68-11	13692-13699	toolbox	_	
68-12	13699-13700	.	_	

#Text=Mahalanobis distance, combining the mean correlation and weighted overall image quality were inspected and outliers (>2 standard deviations) excluded from further analyses (n = 3).
69-1	13701-13712	Mahalanobis	_	
69-2	13713-13721	distance	_	
69-3	13721-13722	,	_	
69-4	13723-13732	combining	_	
69-5	13733-13736	the	_	
69-6	13737-13741	mean	_	
69-7	13742-13753	correlation	_	
69-8	13754-13757	and	_	
69-9	13758-13766	weighted	_	
69-10	13767-13774	overall	_	
69-11	13775-13780	image	_	
69-12	13781-13788	quality	_	
69-13	13789-13793	were	_	
69-14	13794-13803	inspected	_	
69-15	13804-13807	and	_	
69-16	13808-13816	outliers	_	
69-17	13817-13818	(	_	
69-18	13818-13819	>	_	
69-19	13819-13820	2	_	
69-20	13821-13829	standard	_	
69-21	13830-13840	deviations	_	
69-22	13840-13841	)	_	
69-23	13842-13850	excluded	_	
69-24	13851-13855	from	_	
69-25	13856-13863	further	_	
69-26	13864-13872	analyses	_	
69-27	13873-13874	(	_	
69-28	13874-13875	n	_	
69-29	13876-13877	=	_	
69-30	13878-13879	3	_	
69-31	13879-13880	)	_	
69-32	13880-13881	.	_	

#Text=The remaining segmented, modulated and normalized datasets were smoothed using an 8 mm full-width half-maximum Gaussian smoothing kernel and then fed into second-level two-sample t-test analyses, considering total intracranial volume (TIV) and age as covariates.
70-1	13882-13885	The	_	
70-2	13886-13895	remaining	_	
70-3	13896-13905	segmented	_	
70-4	13905-13906	,	_	
70-5	13907-13916	modulated	_	
70-6	13917-13920	and	_	
70-7	13921-13931	normalized	_	
70-8	13932-13940	datasets	_	
70-9	13941-13945	were	_	
70-10	13946-13954	smoothed	_	
70-11	13955-13960	using	_	
70-12	13961-13963	an	_	
70-13	13964-13965	8	_	
70-14	13966-13968	mm	_	
70-15	13969-13979	full-width	_	
70-16	13980-13992	half-maximum	_	
70-17	13993-14001	Gaussian	_	
70-18	14002-14011	smoothing	_	
70-19	14012-14018	kernel	_	
70-20	14019-14022	and	_	
70-21	14023-14027	then	_	
70-22	14028-14031	fed	_	
70-23	14032-14036	into	_	
70-24	14037-14049	second-level	_	
70-25	14050-14060	two-sample	_	
70-26	14061-14067	t-test	_	
70-27	14068-14076	analyses	_	
70-28	14076-14077	,	_	
70-29	14078-14089	considering	_	
70-30	14090-14095	total	_	
70-31	14096-14108	intracranial	_	
70-32	14109-14115	volume	_	
70-33	14116-14117	(	_	
70-34	14117-14120	TIV	_	
70-35	14120-14121	)	_	
70-36	14122-14125	and	_	
70-37	14126-14129	age	_	
70-38	14130-14132	as	_	
70-39	14133-14143	covariates	_	
70-40	14143-14144	.	_	

#Text=In order to control for multiple comparisons, a combined cluster-extent and voxel-wise threshold, corresponding to a family-wise error (FWE) rate of pFWE <0.05, was determined using the AlphaSim module of the NeuroElf toolbox (www.neuroelf.net) for Matlab.
71-1	14145-14147	In	_	
71-2	14148-14153	order	_	
71-3	14154-14156	to	_	
71-4	14157-14164	control	_	
71-5	14165-14168	for	_	
71-6	14169-14177	multiple	_	
71-7	14178-14189	comparisons	_	
71-8	14189-14190	,	_	
71-9	14191-14192	a	_	
71-10	14193-14201	combined	_	
71-11	14202-14216	cluster-extent	_	
71-12	14217-14220	and	_	
71-13	14221-14231	voxel-wise	_	
71-14	14232-14241	threshold	_	
71-15	14241-14242	,	_	
71-16	14243-14256	corresponding	_	
71-17	14257-14259	to	_	
71-18	14260-14261	a	_	
71-19	14262-14273	family-wise	_	
71-20	14274-14279	error	_	
71-21	14280-14281	(	_	
71-22	14281-14284	FWE	_	
71-23	14284-14285	)	_	
71-24	14286-14290	rate	_	
71-25	14291-14293	of	_	
71-26	14294-14298	pFWE	_	
71-27	14299-14300	<	_	
71-28	14300-14304	0.05	_	
71-29	14304-14305	,	_	
71-30	14306-14309	was	_	
71-31	14310-14320	determined	_	
71-32	14321-14326	using	_	
71-33	14327-14330	the	_	
71-34	14331-14339	AlphaSim	_	
71-35	14340-14346	module	_	
71-36	14347-14349	of	_	
71-37	14350-14353	the	_	
71-38	14354-14362	NeuroElf	_	
71-39	14363-14370	toolbox	_	
71-40	14371-14372	(	_	
71-41	14372-14388	www.neuroelf.net	_	
71-42	14388-14389	)	_	
71-43	14390-14393	for	_	
71-44	14394-14400	Matlab	_	
71-45	14400-14401	.	_	

#Text=For a pre-set voxel-wise threshold of P < 0.001, the AlphaSim procedure determined a cluster-extent threshold of 103 voxels (10.000 Monte Carlo simulations, smoothing kernel of x = 8 mm, y = 8 mm, z = 8 mm).
72-1	14402-14405	For	_	
72-2	14406-14407	a	_	
72-3	14408-14415	pre-set	_	
72-4	14416-14426	voxel-wise	_	
72-5	14427-14436	threshold	_	
72-6	14437-14439	of	_	
72-7	14440-14441	P	_	
72-8	14442-14443	<	_	
72-9	14444-14449	0.001	_	
72-10	14449-14450	,	_	
72-11	14451-14454	the	_	
72-12	14455-14463	AlphaSim	_	
72-13	14464-14473	procedure	_	
72-14	14474-14484	determined	_	
72-15	14485-14486	a	_	
72-16	14487-14501	cluster-extent	_	
72-17	14502-14511	threshold	_	
72-18	14512-14514	of	_	
72-19	14515-14518	103	_	
72-20	14519-14525	voxels	_	
72-21	14526-14527	(	_	
72-22	14527-14533	10.000	_	
72-23	14534-14539	Monte	_	
72-24	14540-14545	Carlo	_	
72-25	14546-14557	simulations	_	
72-26	14557-14558	,	_	
72-27	14559-14568	smoothing	_	
72-28	14569-14575	kernel	_	
72-29	14576-14578	of	_	
72-30	14579-14580	x	_	
72-31	14581-14582	=	_	
72-32	14583-14584	8	_	
72-33	14584-14585	 	_	
72-34	14585-14587	mm	_	
72-35	14587-14588	,	_	
72-36	14589-14590	y	_	
72-37	14591-14592	=	_	
72-38	14593-14594	8	_	
72-39	14594-14595	 	_	
72-40	14595-14597	mm	_	
72-41	14597-14598	,	_	
72-42	14599-14600	z	_	
72-43	14601-14602	=	_	
72-44	14603-14604	8	_	
72-45	14604-14605	 	_	
72-46	14605-14607	mm	_	
72-47	14607-14608	)	_	
72-48	14608-14609	.	_	

#Text=In order to follow up on the results of the whole-brain analyses, standardized anatomical masks were used to extract GM volume data from the respective brain regions that showed significant group effects (contrast: healthy participants > OMT patients).
73-1	14610-14612	In	_	
73-2	14613-14618	order	_	
73-3	14619-14621	to	_	
73-4	14622-14628	follow	_	
73-5	14629-14631	up	_	
73-6	14632-14634	on	_	
73-7	14635-14638	the	_	
73-8	14639-14646	results	_	
73-9	14647-14649	of	_	
73-10	14650-14653	the	_	
73-11	14654-14665	whole-brain	_	
73-12	14666-14674	analyses	_	
73-13	14674-14675	,	_	
73-14	14676-14688	standardized	_	
73-15	14689-14699	anatomical	_	
73-16	14700-14705	masks	_	
73-17	14706-14710	were	_	
73-18	14711-14715	used	_	
73-19	14716-14718	to	_	
73-20	14719-14726	extract	_	
73-21	14727-14729	GM	_	
73-22	14730-14736	volume	_	
73-23	14737-14741	data	_	
73-24	14742-14746	from	_	
73-25	14747-14750	the	_	
73-26	14751-14761	respective	_	
73-27	14762-14767	brain	_	
73-28	14768-14775	regions	_	
73-29	14776-14780	that	_	
73-30	14781-14787	showed	_	
73-31	14788-14799	significant	_	
73-32	14800-14805	group	_	
73-33	14806-14813	effects	_	
73-34	14814-14815	(	_	
73-35	14815-14823	contrast	_	
73-36	14823-14824	:	_	
73-37	14825-14832	healthy	_	
73-38	14833-14845	participants	_	
73-39	14846-14847	>	_	
73-40	14848-14851	OMT	_	
73-41	14852-14860	patients	_	
73-42	14860-14861	)	_	
73-43	14861-14862	.	_	

#Text=The masks that defined the regions of interest (ROI) were derived from the Hammers brain atlas.
74-1	14863-14866	The	_	
74-2	14867-14872	masks	_	
74-3	14873-14877	that	_	
74-4	14878-14885	defined	_	
74-5	14886-14889	the	_	
74-6	14890-14897	regions	_	
74-7	14898-14900	of	_	
74-8	14901-14909	interest	_	
74-9	14910-14911	(	_	
74-10	14911-14914	ROI	_	
74-11	14914-14915	)	_	
74-12	14916-14920	were	_	
74-13	14921-14928	derived	_	
74-14	14929-14933	from	_	
74-15	14934-14937	the	_	
74-16	14938-14945	Hammers	_	
74-17	14946-14951	brain	_	
74-18	14952-14957	atlas	_	
74-19	14957-14958	.	_	

#Text=Specifically, GM volume data were extracted from the (i) left insula [BA13], (ii) right insula [BA13], (iii) left inferior frontal gyrus [BA47] and (iv) right inferior frontal gyrus [BA47] using the standard procedure of the CAT12 toolbox for GM volume data extraction from ROIs.
75-1	14959-14971	Specifically	_	
75-2	14971-14972	,	_	
75-3	14973-14975	GM	_	
75-4	14976-14982	volume	_	
75-5	14983-14987	data	_	
75-6	14988-14992	were	_	
75-7	14993-15002	extracted	_	
75-8	15003-15007	from	_	
75-9	15008-15011	the	_	
75-10	15012-15013	(	_	
75-11	15013-15014	i	_	
75-12	15014-15015	)	_	
75-13	15016-15020	left	_	
75-14	15021-15027	insula	_	
75-15	15028-15029	[	_	
75-16	15029-15033	BA13	_	
75-17	15033-15034	]	_	
75-18	15034-15035	,	_	
75-19	15036-15037	(	_	
75-20	15037-15039	ii	_	
75-21	15039-15040	)	_	
75-22	15041-15046	right	_	
75-23	15047-15053	insula	_	
75-24	15054-15055	[	_	
75-25	15055-15059	BA13	_	
75-26	15059-15060	]	_	
75-27	15060-15061	,	_	
75-28	15062-15063	(	_	
75-29	15063-15066	iii	_	
75-30	15066-15067	)	_	
75-31	15068-15072	left	_	
75-32	15073-15081	inferior	_	
75-33	15082-15089	frontal	_	
75-34	15090-15095	gyrus	_	
75-35	15096-15097	[	_	
75-36	15097-15101	BA47	_	
75-37	15101-15102	]	_	
75-38	15103-15106	and	_	
75-39	15107-15108	(	_	
75-40	15108-15110	iv	_	
75-41	15110-15111	)	_	
75-42	15112-15117	right	_	
75-43	15118-15126	inferior	_	
75-44	15127-15134	frontal	_	
75-45	15135-15140	gyrus	_	
75-46	15141-15142	[	_	
75-47	15142-15146	BA47	_	
75-48	15146-15147	]	_	
75-49	15148-15153	using	_	
75-50	15154-15157	the	_	
75-51	15158-15166	standard	_	
75-52	15167-15176	procedure	_	
75-53	15177-15179	of	_	
75-54	15180-15183	the	_	
75-55	15184-15189	CAT12	_	
75-56	15190-15197	toolbox	_	
75-57	15198-15201	for	_	
75-58	15202-15204	GM	_	
75-59	15205-15211	volume	_	
75-60	15212-15216	data	_	
75-61	15217-15227	extraction	_	
75-62	15228-15232	from	_	
75-63	15233-15237	ROIs	_	
75-64	15237-15238	.	_	

#Text=Data were imported into SPSS version 24.0 for further correlation analyses (SPSS, IBM Corp., Somers, NY, USA).
76-1	15239-15243	Data	_	
76-2	15244-15248	were	_	
76-3	15249-15257	imported	_	
76-4	15258-15262	into	_	
76-5	15263-15267	SPSS	_	
76-6	15268-15275	version	_	
76-7	15276-15280	24.0	_	
76-8	15281-15284	for	_	
76-9	15285-15292	further	_	
76-10	15293-15304	correlation	_	
76-11	15305-15313	analyses	_	
76-12	15314-15315	(	_	
76-13	15315-15319	SPSS	_	
76-14	15319-15320	,	_	
76-15	15321-15324	IBM	_	
76-16	15325-15329	Corp	_	
76-17	15329-15330	.	_	
76-18	15330-15331	,	_	
76-19	15332-15338	Somers	_	
76-20	15338-15339	,	_	
76-21	15340-15342	NY	_	
76-22	15342-15343	,	_	
76-23	15344-15347	USA	_	
76-24	15347-15348	)	_	
76-25	15348-15349	.	_	

#Text=Statistical analyses
#Text=Demographical data and psychometric scales were analyzed using SPSS 24.0 and by applying two-sample t-tests and chi-squared tests.
77-1	15350-15361	Statistical	_	
77-2	15362-15370	analyses	_	
77-3	15371-15384	Demographical	_	
77-4	15385-15389	data	_	
77-5	15390-15393	and	_	
77-6	15394-15406	psychometric	_	
77-7	15407-15413	scales	_	
77-8	15414-15418	were	_	
77-9	15419-15427	analyzed	_	
77-10	15428-15433	using	_	
77-11	15434-15438	SPSS	_	
77-12	15439-15443	24.0	_	
77-13	15444-15447	and	_	
77-14	15448-15450	by	_	
77-15	15451-15459	applying	_	
77-16	15460-15470	two-sample	_	
77-17	15471-15478	t-tests	_	
77-18	15479-15482	and	_	
77-19	15483-15494	chi-squared	_	
77-20	15495-15500	tests	_	
77-21	15500-15501	.	_	

#Text=Group differences in GM volume were analyzed using two-sample t-tests correcting for TIV and age.
78-1	15502-15507	Group	_	
78-2	15508-15519	differences	_	
78-3	15520-15522	in	_	
78-4	15523-15525	GM	_	
78-5	15526-15532	volume	_	
78-6	15533-15537	were	_	
78-7	15538-15546	analyzed	_	
78-8	15547-15552	using	_	
78-9	15553-15563	two-sample	_	
78-10	15564-15571	t-tests	_	
78-11	15572-15582	correcting	_	
78-12	15583-15586	for	_	
78-13	15587-15590	TIV	_	
78-14	15591-15594	and	_	
78-15	15595-15598	age	_	
78-16	15598-15599	.	_	

#Text=Results are depicted in Table 1.
79-1	15600-15607	Results	_	
79-2	15608-15611	are	_	
79-3	15612-15620	depicted	_	
79-4	15621-15623	in	_	
79-5	15624-15629	Table	_	
79-6	15630-15631	1	_	
79-7	15631-15632	.	_	

#Text=Associations between GM volume in areas that displayed significant whole-brain differences in two-sample t-tests between opioid-dependent patients and healthy participants (i.e. bilateral insula and right inferior frontal gyrus) and psychometric scales covering social anxiety and rejection sensitivity (SIAS, RSQ, SPS) and Cyberball task-related changes in feelings of being excluded or included were investigated using partial correlation analyses, controlling for age and TIV (because both were related to GM volume variability in previous studies).
80-1	15633-15645	Associations	_	
80-2	15646-15653	between	_	
80-3	15654-15656	GM	_	
80-4	15657-15663	volume	_	
80-5	15664-15666	in	_	
80-6	15667-15672	areas	_	
80-7	15673-15677	that	_	
80-8	15678-15687	displayed	_	
80-9	15688-15699	significant	_	
80-10	15700-15711	whole-brain	_	
80-11	15712-15723	differences	_	
80-12	15724-15726	in	_	
80-13	15727-15737	two-sample	_	
80-14	15738-15745	t-tests	_	
80-15	15746-15753	between	_	
80-16	15754-15770	opioid-dependent	_	
80-17	15771-15779	patients	_	
80-18	15780-15783	and	_	
80-19	15784-15791	healthy	_	
80-20	15792-15804	participants	_	
80-21	15805-15806	(	_	
80-22	15806-15809	i.e	_	
80-23	15809-15810	.	_	
80-24	15811-15820	bilateral	_	
80-25	15821-15827	insula	_	
80-26	15828-15831	and	_	
80-27	15832-15837	right	_	
80-28	15838-15846	inferior	_	
80-29	15847-15854	frontal	_	
80-30	15855-15860	gyrus	_	
80-31	15860-15861	)	_	
80-32	15862-15865	and	_	
80-33	15866-15878	psychometric	_	
80-34	15879-15885	scales	_	
80-35	15886-15894	covering	_	
80-36	15895-15901	social	_	
80-37	15902-15909	anxiety	_	
80-38	15910-15913	and	_	
80-39	15914-15923	rejection	_	
80-40	15924-15935	sensitivity	_	
80-41	15936-15937	(	_	
80-42	15937-15941	SIAS	_	
80-43	15941-15942	,	_	
80-44	15943-15946	RSQ	_	
80-45	15946-15947	,	_	
80-46	15948-15951	SPS	_	
80-47	15951-15952	)	_	
80-48	15953-15956	and	_	
80-49	15957-15966	Cyberball	_	
80-50	15967-15979	task-related	_	
80-51	15980-15987	changes	_	
80-52	15988-15990	in	_	
80-53	15991-15999	feelings	_	
80-54	16000-16002	of	_	
80-55	16003-16008	being	_	
80-56	16009-16017	excluded	_	
80-57	16018-16020	or	_	
80-58	16021-16029	included	_	
80-59	16030-16034	were	_	
80-60	16035-16047	investigated	_	
80-61	16048-16053	using	_	
80-62	16054-16061	partial	_	
80-63	16062-16073	correlation	_	
80-64	16074-16082	analyses	_	
80-65	16082-16083	,	_	
80-66	16084-16095	controlling	_	
80-67	16096-16099	for	_	
80-68	16100-16103	age	_	
80-69	16104-16107	and	_	
80-70	16108-16111	TIV	_	
80-71	16112-16113	(	_	
80-72	16113-16120	because	_	
80-73	16121-16125	both	_	
80-74	16126-16130	were	_	
80-75	16131-16138	related	_	
80-76	16139-16141	to	_	
80-77	16142-16144	GM	_	
80-78	16145-16151	volume	_	
80-79	16152-16163	variability	_	
80-80	16164-16166	in	_	
80-81	16167-16175	previous	_	
80-82	16176-16183	studies	_	
80-83	16183-16184	)	_	
80-84	16184-16185	.	_	

#Text=Prior, exploratory data analyses were conducted to identify potential outliers.
81-1	16186-16191	Prior	_	
81-2	16191-16192	,	_	
81-3	16193-16204	exploratory	_	
81-4	16205-16209	data	_	
81-5	16210-16218	analyses	_	
81-6	16219-16223	were	_	
81-7	16224-16233	conducted	_	
81-8	16234-16236	to	_	
81-9	16237-16245	identify	_	
81-10	16246-16255	potential	_	
81-11	16256-16264	outliers	_	
81-12	16264-16265	.	_	

#Text=One patient had low values on the variable encoding left insula GM volume (>1.5× interquartile range).
82-1	16266-16269	One	_	
82-2	16270-16277	patient	_	
82-3	16278-16281	had	_	
82-4	16282-16285	low	_	
82-5	16286-16292	values	_	
82-6	16293-16295	on	_	
82-7	16296-16299	the	_	
82-8	16300-16308	variable	_	
82-9	16309-16317	encoding	_	
82-10	16318-16322	left	_	
82-11	16323-16329	insula	_	
82-12	16330-16332	GM	_	
82-13	16333-16339	volume	_	
82-14	16340-16341	(	_	
82-15	16341-16342	>	_	
82-16	16342-16345	1.5	_	
82-17	16345-16346	×	_	
82-18	16347-16360	interquartile	_	
82-19	16361-16366	range	_	
82-20	16366-16367	)	_	
82-21	16367-16368	.	_	

#Text=As the inspection of the raw imaging data and pre-processing quality indices indicated good quality of the anatomical data, we considered this value to reflect the true value of the participant and opted to include that participant in the correlation analyses.
83-1	16369-16371	As	_	
83-2	16372-16375	the	_	
83-3	16376-16386	inspection	_	
83-4	16387-16389	of	_	
83-5	16390-16393	the	_	
83-6	16394-16397	raw	_	
83-7	16398-16405	imaging	_	
83-8	16406-16410	data	_	
83-9	16411-16414	and	_	
83-10	16415-16429	pre-processing	_	
83-11	16430-16437	quality	_	
83-12	16438-16445	indices	_	
83-13	16446-16455	indicated	_	
83-14	16456-16460	good	_	
83-15	16461-16468	quality	_	
83-16	16469-16471	of	_	
83-17	16472-16475	the	_	
83-18	16476-16486	anatomical	_	
83-19	16487-16491	data	_	
83-20	16491-16492	,	_	
83-21	16493-16495	we	_	
83-22	16496-16506	considered	_	
83-23	16507-16511	this	_	
83-24	16512-16517	value	_	
83-25	16518-16520	to	_	
83-26	16521-16528	reflect	_	
83-27	16529-16532	the	_	
83-28	16533-16537	true	_	
83-29	16538-16543	value	_	
83-30	16544-16546	of	_	
83-31	16547-16550	the	_	
83-32	16551-16562	participant	_	
83-33	16563-16566	and	_	
83-34	16567-16572	opted	_	
83-35	16573-16575	to	_	
83-36	16576-16583	include	_	
83-37	16584-16588	that	_	
83-38	16589-16600	participant	_	
83-39	16601-16603	in	_	
83-40	16604-16607	the	_	
83-41	16608-16619	correlation	_	
83-42	16620-16628	analyses	_	
83-43	16628-16629	.	_	

#Text=Partial correlations between (i) psychometric scales and (ii) subjective ratings of inclusion and exclusion during the Cyberball task inclusion condition and GM volume were corrected for multiple comparisons [i.e.
84-1	16630-16637	Partial	_	
84-2	16638-16650	correlations	_	
84-3	16651-16658	between	_	
84-4	16659-16660	(	_	
84-5	16660-16661	i	_	
84-6	16661-16662	)	_	
84-7	16663-16675	psychometric	_	
84-8	16676-16682	scales	_	
84-9	16683-16686	and	_	
84-10	16687-16688	(	_	
84-11	16688-16690	ii	_	
84-12	16690-16691	)	_	
84-13	16692-16702	subjective	_	
84-14	16703-16710	ratings	_	
84-15	16711-16713	of	_	
84-16	16714-16723	inclusion	_	
84-17	16724-16727	and	_	
84-18	16728-16737	exclusion	_	
84-19	16738-16744	during	_	
84-20	16745-16748	the	_	
84-21	16749-16758	Cyberball	_	
84-22	16759-16763	task	_	
84-23	16764-16773	inclusion	_	
84-24	16774-16783	condition	_	
84-25	16784-16787	and	_	
84-26	16788-16790	GM	_	
84-27	16791-16797	volume	_	
84-28	16798-16802	were	_	
84-29	16803-16812	corrected	_	
84-30	16813-16816	for	_	
84-31	16817-16825	multiple	_	
84-32	16826-16837	comparisons	_	
84-33	16838-16839	[	_	
84-34	16839-16842	i.e	_	
84-35	16842-16843	.	_	

#Text=(i) four independent partial correlations per brain area, left insula, right insula, inferior frontal gyrus, (ii) two independent partial correlations per brain area] using the Benjamini and Hochberg procedure as implemented in the Matlab ‘mafdr’ function.
85-1	16844-16845	(	_	
85-2	16845-16846	i	_	
85-3	16846-16847	)	_	
85-4	16848-16852	four	_	
85-5	16853-16864	independent	_	
85-6	16865-16872	partial	_	
85-7	16873-16885	correlations	_	
85-8	16886-16889	per	_	
85-9	16890-16895	brain	_	
85-10	16896-16900	area	_	
85-11	16900-16901	,	_	
85-12	16902-16906	left	_	
85-13	16907-16913	insula	_	
85-14	16913-16914	,	_	
85-15	16915-16920	right	_	
85-16	16921-16927	insula	_	
85-17	16927-16928	,	_	
85-18	16929-16937	inferior	_	
85-19	16938-16945	frontal	_	
85-20	16946-16951	gyrus	_	
85-21	16951-16952	,	_	
85-22	16953-16954	(	_	
85-23	16954-16956	ii	_	
85-24	16956-16957	)	_	
85-25	16958-16961	two	_	
85-26	16962-16973	independent	_	
85-27	16974-16981	partial	_	
85-28	16982-16994	correlations	_	
85-29	16995-16998	per	_	
85-30	16999-17004	brain	_	
85-31	17005-17009	area	_	
85-32	17009-17010	]	_	
85-33	17011-17016	using	_	
85-34	17017-17020	the	_	
85-35	17021-17030	Benjamini	_	
85-36	17031-17034	and	_	
85-37	17035-17043	Hochberg	_	
85-38	17044-17053	procedure	_	
85-39	17054-17056	as	_	
85-40	17057-17068	implemented	_	
85-41	17069-17071	in	_	
85-42	17072-17075	the	_	
85-43	17076-17082	Matlab	_	
85-44	17083-17084	‘	_	
85-45	17084-17089	mafdr	_	
85-46	17089-17090	’	_	
85-47	17091-17099	function	_	
85-48	17099-17100	.	_	

#Text=Results
#Text=Group characteristics
#Text=Analyses of demographical data and psychometric scales indicated no significant deviation between groups with regard to age and gender distribution, but—as expected—more patients reported living without a partner and having fewer years of education.
86-1	17101-17108	Results	_	
86-2	17109-17114	Group	_	
86-3	17115-17130	characteristics	_	
86-4	17131-17139	Analyses	_	
86-5	17140-17142	of	_	
86-6	17143-17156	demographical	_	
86-7	17157-17161	data	_	
86-8	17162-17165	and	_	
86-9	17166-17178	psychometric	_	
86-10	17179-17185	scales	_	
86-11	17186-17195	indicated	_	
86-12	17196-17198	no	_	
86-13	17199-17210	significant	_	
86-14	17211-17220	deviation	_	
86-15	17221-17228	between	_	
86-16	17229-17235	groups	_	
86-17	17236-17240	with	_	
86-18	17241-17247	regard	_	
86-19	17248-17250	to	_	
86-20	17251-17254	age	_	
86-21	17255-17258	and	_	
86-22	17259-17265	gender	_	
86-23	17266-17278	distribution	_	
86-24	17278-17279	,	_	
86-25	17280-17286	but—as	_	
86-26	17287-17300	expected—more	_	
86-27	17301-17309	patients	_	
86-28	17310-17318	reported	_	
86-29	17319-17325	living	_	
86-30	17326-17333	without	_	
86-31	17334-17335	a	_	
86-32	17336-17343	partner	_	
86-33	17344-17347	and	_	
86-34	17348-17354	having	_	
86-35	17355-17360	fewer	_	
86-36	17361-17366	years	_	
86-37	17367-17369	of	_	
86-38	17370-17379	education	_	
86-39	17379-17380	.	_	

#Text=Patients also scored higher on psychometric scales measuring social anxiety (SIAS and BSI subscale anxiety) and symptoms of social phobia (SPS, BSI subscale phobic anxiety), as well as depressive symptoms (BDI, BSI subscale depression) and social rejection sensitivity (RSQ, BSI subscale interpersonal sensitivity).
87-1	17381-17389	Patients	_	
87-2	17390-17394	also	_	
87-3	17395-17401	scored	_	
87-4	17402-17408	higher	_	
87-5	17409-17411	on	_	
87-6	17412-17424	psychometric	_	
87-7	17425-17431	scales	_	
87-8	17432-17441	measuring	_	
87-9	17442-17448	social	_	
87-10	17449-17456	anxiety	_	
87-11	17457-17458	(	_	
87-12	17458-17462	SIAS	_	
87-13	17463-17466	and	_	
87-14	17467-17470	BSI	_	
87-15	17471-17479	subscale	_	
87-16	17480-17487	anxiety	_	
87-17	17487-17488	)	_	
87-18	17489-17492	and	_	
87-19	17493-17501	symptoms	_	
87-20	17502-17504	of	_	
87-21	17505-17511	social	_	
87-22	17512-17518	phobia	_	
87-23	17519-17520	(	_	
87-24	17520-17523	SPS	_	
87-25	17523-17524	,	_	
87-26	17525-17528	BSI	_	
87-27	17529-17537	subscale	_	
87-28	17538-17544	phobic	_	
87-29	17545-17552	anxiety	_	
87-30	17552-17553	)	_	
87-31	17553-17554	,	_	
87-32	17555-17557	as	_	
87-33	17558-17562	well	_	
87-34	17563-17565	as	_	
87-35	17566-17576	depressive	_	
87-36	17577-17585	symptoms	_	
87-37	17586-17587	(	_	
87-38	17587-17590	BDI	_	
87-39	17590-17591	,	_	
87-40	17592-17595	BSI	_	
87-41	17596-17604	subscale	_	
87-42	17605-17615	depression	_	
87-43	17615-17616	)	_	
87-44	17617-17620	and	_	
87-45	17621-17627	social	_	
87-46	17628-17637	rejection	_	
87-47	17638-17649	sensitivity	_	
87-48	17650-17651	(	_	
87-49	17651-17654	RSQ	_	
87-50	17654-17655	,	_	
87-51	17656-17659	BSI	_	
87-52	17660-17668	subscale	_	
87-53	17669-17682	interpersonal	_	
87-54	17683-17694	sensitivity	_	
87-55	17694-17695	)	_	
87-56	17695-17696	.	_	

#Text=Regional GM volume differences between groups
#Text=Overall TIV, GM and WM were descriptively smaller in OMT patients, but not statistically significant (tmax = 1.536, Pmin = 0.133).
88-1	17697-17705	Regional	_	
88-2	17706-17708	GM	_	
88-3	17709-17715	volume	_	
88-4	17716-17727	differences	_	
88-5	17728-17735	between	_	
88-6	17736-17742	groups	_	
88-7	17743-17750	Overall	_	
88-8	17751-17754	TIV	_	
88-9	17754-17755	,	_	
88-10	17756-17758	GM	_	
88-11	17759-17762	and	_	
88-12	17763-17765	WM	_	
88-13	17766-17770	were	_	
88-14	17771-17784	descriptively	_	
88-15	17785-17792	smaller	_	
88-16	17793-17795	in	_	
88-17	17796-17799	OMT	_	
88-18	17800-17808	patients	_	
88-19	17808-17809	,	_	
88-20	17810-17813	but	_	
88-21	17814-17817	not	_	
88-22	17818-17831	statistically	_	
88-23	17832-17843	significant	_	
88-24	17844-17845	(	_	
88-25	17845-17849	tmax	_	
88-26	17850-17851	=	_	
88-27	17852-17857	1.536	_	
88-28	17857-17858	,	_	
88-29	17859-17863	Pmin	_	
88-30	17864-17865	=	_	
88-31	17866-17871	0.133	_	
88-32	17871-17872	)	_	
88-33	17872-17873	.	_	

#Text=The location and extent of brain areas that showed significant local GM volume differences between groups are presented in Table 2 and Figure 1a.
89-1	17874-17877	The	_	
89-2	17878-17886	location	_	
89-3	17887-17890	and	_	
89-4	17891-17897	extent	_	
89-5	17898-17900	of	_	
89-6	17901-17906	brain	_	
89-7	17907-17912	areas	_	
89-8	17913-17917	that	_	
89-9	17918-17924	showed	_	
89-10	17925-17936	significant	_	
89-11	17937-17942	local	_	
89-12	17943-17945	GM	_	
89-13	17946-17952	volume	_	
89-14	17953-17964	differences	_	
89-15	17965-17972	between	_	
89-16	17973-17979	groups	_	
89-17	17980-17983	are	_	
89-18	17984-17993	presented	_	
89-19	17994-17996	in	_	
89-20	17997-18002	Table	_	
89-21	18003-18004	2	_	
89-22	18005-18008	and	_	
89-23	18009-18015	Figure	_	
89-24	18016-18018	1a	_	
89-25	18018-18019	.	_	

#Text=OMT patients showed significantly smaller GM volume in the left and right anterior insula (BA13); the left inferior frontal gyrus (BA47) and right frontal lobe, including the orbitofrontal parts of the right inferior frontal gyrus (BA47); and right inferior frontal gyrus (BA11).
90-1	18020-18023	OMT	_	
90-2	18024-18032	patients	_	
90-3	18033-18039	showed	_	
90-4	18040-18053	significantly	_	
90-5	18054-18061	smaller	_	
90-6	18062-18064	GM	_	
90-7	18065-18071	volume	_	
90-8	18072-18074	in	_	
90-9	18075-18078	the	_	
90-10	18079-18083	left	_	
90-11	18084-18087	and	_	
90-12	18088-18093	right	_	
90-13	18094-18102	anterior	_	
90-14	18103-18109	insula	_	
90-15	18110-18111	(	_	
90-16	18111-18115	BA13	_	
90-17	18115-18116	)	_	
90-18	18116-18117	;	_	
90-19	18118-18121	the	_	
90-20	18122-18126	left	_	
90-21	18127-18135	inferior	_	
90-22	18136-18143	frontal	_	
90-23	18144-18149	gyrus	_	
90-24	18150-18151	(	_	
90-25	18151-18155	BA47	_	
90-26	18155-18156	)	_	
90-27	18157-18160	and	_	
90-28	18161-18166	right	_	
90-29	18167-18174	frontal	_	
90-30	18175-18179	lobe	_	
90-31	18179-18180	,	_	
90-32	18181-18190	including	_	
90-33	18191-18194	the	_	
90-34	18195-18208	orbitofrontal	_	
90-35	18209-18214	parts	_	
90-36	18215-18217	of	_	
90-37	18218-18221	the	_	
90-38	18222-18227	right	_	
90-39	18228-18236	inferior	_	
90-40	18237-18244	frontal	_	
90-41	18245-18250	gyrus	_	
90-42	18251-18252	(	_	
90-43	18252-18256	BA47	_	
90-44	18256-18257	)	_	
90-45	18257-18258	;	_	
90-46	18259-18262	and	_	
90-47	18263-18268	right	_	
90-48	18269-18277	inferior	_	
90-49	18278-18285	frontal	_	
90-50	18286-18291	gyrus	_	
90-51	18292-18293	(	_	
90-52	18293-18297	BA11	_	
90-53	18297-18298	)	_	
90-54	18298-18299	.	_	

#Text=Additional, atlas-based analyses using CAT12 ROI analysis options corroborated these findings, indicating significant differences in GM volume in the left (t(37) = 3.245, P = 0.002) and right insula ROIs (t(37) = 3.452, P = 0.001) (Figure 1b and c), as well as in the left (t(37) = 2.396, P = 0.022) and right inferior frontal gyrus (t(37) = 2.583, P = 0.014).
91-1	18300-18310	Additional	_	
91-2	18310-18311	,	_	
91-3	18312-18323	atlas-based	_	
91-4	18324-18332	analyses	_	
91-5	18333-18338	using	_	
91-6	18339-18344	CAT12	_	
91-7	18345-18348	ROI	_	
91-8	18349-18357	analysis	_	
91-9	18358-18365	options	_	
91-10	18366-18378	corroborated	_	
91-11	18379-18384	these	_	
91-12	18385-18393	findings	_	
91-13	18393-18394	,	_	
91-14	18395-18405	indicating	_	
91-15	18406-18417	significant	_	
91-16	18418-18429	differences	_	
91-17	18430-18432	in	_	
91-18	18433-18435	GM	_	
91-19	18436-18442	volume	_	
91-20	18443-18445	in	_	
91-21	18446-18449	the	_	
91-22	18450-18454	left	_	
91-23	18455-18456	(	_	
91-24	18456-18457	t	_	
91-25	18457-18458	(	_	
91-26	18458-18460	37	_	
91-27	18460-18461	)	_	
91-28	18462-18463	=	_	
91-29	18464-18469	3.245	_	
91-30	18469-18470	,	_	
91-31	18471-18472	P	_	
91-32	18473-18474	=	_	
91-33	18475-18480	0.002	_	
91-34	18480-18481	)	_	
91-35	18482-18485	and	_	
91-36	18486-18491	right	_	
91-37	18492-18498	insula	_	
91-38	18499-18503	ROIs	_	
91-39	18504-18505	(	_	
91-40	18505-18506	t	_	
91-41	18506-18507	(	_	
91-42	18507-18509	37	_	
91-43	18509-18510	)	_	
91-44	18511-18512	=	_	
91-45	18513-18518	3.452	_	
91-46	18518-18519	,	_	
91-47	18520-18521	P	_	
91-48	18522-18523	=	_	
91-49	18524-18529	0.001	_	
91-50	18529-18530	)	_	
91-51	18531-18532	(	_	
91-52	18532-18538	Figure	_	
91-53	18539-18541	1b	_	
91-54	18542-18545	and	_	
91-55	18546-18547	c	_	
91-56	18547-18548	)	_	
91-57	18548-18549	,	_	
91-58	18550-18552	as	_	
91-59	18553-18557	well	_	
91-60	18558-18560	as	_	
91-61	18561-18563	in	_	
91-62	18564-18567	the	_	
91-63	18568-18572	left	_	
91-64	18573-18574	(	_	
91-65	18574-18575	t	_	
91-66	18575-18576	(	_	
91-67	18576-18578	37	_	
91-68	18578-18579	)	_	
91-69	18580-18581	=	_	
91-70	18582-18587	2.396	_	
91-71	18587-18588	,	_	
91-72	18589-18590	P	_	
91-73	18591-18592	=	_	
91-74	18593-18598	0.022	_	
91-75	18598-18599	)	_	
91-76	18600-18603	and	_	
91-77	18604-18609	right	_	
91-78	18610-18618	inferior	_	
91-79	18619-18626	frontal	_	
91-80	18627-18632	gyrus	_	
91-81	18633-18634	(	_	
91-82	18634-18635	t	_	
91-83	18635-18636	(	_	
91-84	18636-18638	37	_	
91-85	18638-18639	)	_	
91-86	18640-18641	=	_	
91-87	18642-18647	2.583	_	
91-88	18647-18648	,	_	
91-89	18649-18650	P	_	
91-90	18651-18652	=	_	
91-91	18653-18658	0.014	_	
91-92	18658-18659	)	_	
91-93	18659-18660	.	_	

#Text=Significant whole-brain GM volume differences between opioid maintenance patients (n = 19) and controls (n = 20) (N = 39, combined voxel-wise (P < 0.001) and cluster-extent (cluster size >103 voxel) threshold, corresponding to pFWE < 0.05 whole brain corrected)
#Text=Side\tLobe\tBrain areas\tCluster size (voxel)\tMNI coordinates (x, y, z)\ttmax\t \ta) Controls > OMT patients\t \t R\tFrontal\tAnterior insula, lateral and posterior orbitofrontal cortex, inferior frontal gyrus\t1638\t44\t42\t−12\t5.92\t \t L\tFrontal, temporal\tAnterior insula, superior temporal pole, inferior frontal gyrus\t234\t−38\t14\t−14\t4.27\t \tb) Controls < OMT patients\t \t—\t—\t—\t—\t—\t—\t—\t—\t \t
#Text=Depiction of (a) smaller GM volume in patients on opioid maintenance treatment, compared to healthy controls [combined voxel-wise (P < 0.001) and cluster-extent (cluster size >103 voxel) threshold, corresponding to pFWE < 0.05 whole brain corrected] in the (b) left and (c) right insula (HC = healthy controls).
92-1	18661-18672	Significant	_	
92-2	18673-18684	whole-brain	_	
92-3	18685-18687	GM	_	
92-4	18688-18694	volume	_	
92-5	18695-18706	differences	_	
92-6	18707-18714	between	_	
92-7	18715-18721	opioid	_	
92-8	18722-18733	maintenance	_	
92-9	18734-18742	patients	_	
92-10	18743-18744	(	_	
92-11	18744-18745	n	_	
92-12	18746-18747	=	_	
92-13	18748-18750	19	_	
92-14	18750-18751	)	_	
92-15	18752-18755	and	_	
92-16	18756-18764	controls	_	
92-17	18765-18766	(	_	
92-18	18766-18767	n	_	
92-19	18767-18768	 	_	
92-20	18768-18769	=	_	
92-21	18770-18772	20	_	
92-22	18772-18773	)	_	
92-23	18774-18775	(	_	
92-24	18775-18776	N	_	
92-25	18777-18778	=	_	
92-26	18779-18781	39	_	
92-27	18781-18782	,	_	
92-28	18783-18791	combined	_	
92-29	18792-18802	voxel-wise	_	
92-30	18803-18804	(	_	
92-31	18804-18805	P	_	
92-32	18806-18807	<	_	
92-33	18808-18813	0.001	_	
92-34	18813-18814	)	_	
92-35	18815-18818	and	_	
92-36	18819-18833	cluster-extent	_	
92-37	18834-18835	(	_	
92-38	18835-18842	cluster	_	
92-39	18843-18847	size	_	
92-40	18848-18849	>	_	
92-41	18849-18852	103	_	
92-42	18853-18858	voxel	_	
92-43	18858-18859	)	_	
92-44	18860-18869	threshold	_	
92-45	18869-18870	,	_	
92-46	18871-18884	corresponding	_	
92-47	18885-18887	to	_	
92-48	18888-18892	pFWE	_	
92-49	18893-18894	<	_	
92-50	18895-18899	0.05	_	
92-51	18900-18905	whole	_	
92-52	18906-18911	brain	_	
92-53	18912-18921	corrected	_	
92-54	18921-18922	)	_	
92-55	18923-18927	Side	_	
92-56	18928-18932	Lobe	_	
92-57	18933-18938	Brain	_	
92-58	18939-18944	areas	_	
92-59	18945-18952	Cluster	_	
92-60	18953-18957	size	_	
92-61	18958-18959	(	_	
92-62	18959-18964	voxel	_	
92-63	18964-18965	)	_	
92-64	18966-18969	MNI	_	
92-65	18970-18981	coordinates	_	
92-66	18982-18983	(	_	
92-67	18983-18984	x	_	
92-68	18984-18985	,	_	
92-69	18986-18987	y	_	
92-70	18987-18988	,	_	
92-71	18989-18990	z	_	
92-72	18990-18991	)	_	
92-73	18992-18996	tmax	_	
92-74	18999-19000	a	_	
92-75	19000-19001	)	_	
92-76	19002-19010	Controls	_	
92-77	19011-19012	>	_	
92-78	19013-19016	OMT	_	
92-79	19017-19025	patients	_	
92-80	19029-19030	R	_	
92-81	19031-19038	Frontal	_	
92-82	19039-19047	Anterior	_	
92-83	19048-19054	insula	_	
92-84	19054-19055	,	_	
92-85	19056-19063	lateral	_	
92-86	19064-19067	and	_	
92-87	19068-19077	posterior	_	
92-88	19078-19091	orbitofrontal	_	
92-89	19092-19098	cortex	_	
92-90	19098-19099	,	_	
92-91	19100-19108	inferior	_	
92-92	19109-19116	frontal	_	
92-93	19117-19122	gyrus	_	
92-94	19123-19127	1638	_	
92-95	19128-19130	44	_	
92-96	19131-19133	42	_	
92-97	19134-19135	−	_	
92-98	19135-19137	12	_	
92-99	19138-19142	5.92	_	
92-100	19146-19147	L	_	
92-101	19148-19155	Frontal	_	
92-102	19155-19156	,	_	
92-103	19157-19165	temporal	_	
92-104	19166-19174	Anterior	_	
92-105	19175-19181	insula	_	
92-106	19181-19182	,	_	
92-107	19183-19191	superior	_	
92-108	19192-19200	temporal	_	
92-109	19201-19205	pole	_	
92-110	19205-19206	,	_	
92-111	19207-19215	inferior	_	
92-112	19216-19223	frontal	_	
92-113	19224-19229	gyrus	_	
92-114	19230-19233	234	_	
92-115	19234-19235	−	_	
92-116	19235-19237	38	_	
92-117	19238-19240	14	_	
92-118	19241-19242	−	_	
92-119	19242-19244	14	_	
92-120	19245-19249	4.27	_	
92-121	19252-19253	b	_	
92-122	19253-19254	)	_	
92-123	19255-19263	Controls	_	
92-124	19264-19265	<	_	
92-125	19266-19269	OMT	_	
92-126	19270-19278	patients	_	
92-127	19281-19282	—	_	
92-128	19283-19284	—	_	
92-129	19285-19286	—	_	
92-130	19287-19288	—	_	
92-131	19289-19290	—	_	
92-132	19291-19292	—	_	
92-133	19293-19294	—	_	
92-134	19295-19296	—	_	
92-135	19300-19309	Depiction	_	
92-136	19310-19312	of	_	
92-137	19313-19314	(	_	
92-138	19314-19315	a	_	
92-139	19315-19316	)	_	
92-140	19317-19324	smaller	_	
92-141	19325-19327	GM	_	
92-142	19328-19334	volume	_	
92-143	19335-19337	in	_	
92-144	19338-19346	patients	_	
92-145	19347-19349	on	_	
92-146	19350-19356	opioid	_	
92-147	19357-19368	maintenance	_	
92-148	19369-19378	treatment	_	
92-149	19378-19379	,	_	
92-150	19380-19388	compared	_	
92-151	19389-19391	to	_	
92-152	19392-19399	healthy	_	
92-153	19400-19408	controls	_	
92-154	19409-19410	[	_	
92-155	19410-19418	combined	_	
92-156	19419-19429	voxel-wise	_	
92-157	19430-19431	(	_	
92-158	19431-19432	P	_	
92-159	19433-19434	<	_	
92-160	19435-19440	0.001	_	
92-161	19440-19441	)	_	
92-162	19442-19445	and	_	
92-163	19446-19460	cluster-extent	_	
92-164	19461-19462	(	_	
92-165	19462-19469	cluster	_	
92-166	19470-19474	size	_	
92-167	19475-19476	>	_	
92-168	19476-19479	103	_	
92-169	19480-19485	voxel	_	
92-170	19485-19486	)	_	
92-171	19487-19496	threshold	_	
92-172	19496-19497	,	_	
92-173	19498-19511	corresponding	_	
92-174	19512-19514	to	_	
92-175	19515-19519	pFWE	_	
92-176	19520-19521	<	_	
92-177	19522-19526	0.05	_	
92-178	19527-19532	whole	_	
92-179	19533-19538	brain	_	
92-180	19539-19548	corrected	_	
92-181	19548-19549	]	_	
92-182	19550-19552	in	_	
92-183	19553-19556	the	_	
92-184	19557-19558	(	_	
92-185	19558-19559	b	_	
92-186	19559-19560	)	_	
92-187	19561-19565	left	_	
92-188	19566-19569	and	_	
92-189	19570-19571	(	_	
92-190	19571-19572	c	_	
92-191	19572-19573	)	_	
92-192	19574-19579	right	_	
92-193	19580-19586	insula	_	
92-194	19587-19588	(	_	
92-195	19588-19590	HC	_	
92-196	19591-19592	=	_	
92-197	19593-19600	healthy	_	
92-198	19601-19609	controls	_	
92-199	19609-19610	)	_	
92-200	19610-19611	.	_	

#Text=Illustration of the partial correlations between (d) the subjective feeling of inclusion and (e) the subjective feeling of exclusion during the social ostracism task with GM volume in the left insula in the patient group (rpartial(inclusion) = 0.448, P = 0.047, rpartial(exclusion) = −0.484, P = 0.034, partial correlations considered TIV and age as covariates, residual values are displayed).
93-1	19612-19624	Illustration	_	
93-2	19625-19627	of	_	
93-3	19628-19631	the	_	
93-4	19632-19639	partial	_	
93-5	19640-19652	correlations	_	
93-6	19653-19660	between	_	
93-7	19661-19662	(	_	
93-8	19662-19663	d	_	
93-9	19663-19664	)	_	
93-10	19665-19668	the	_	
93-11	19669-19679	subjective	_	
93-12	19680-19687	feeling	_	
93-13	19688-19690	of	_	
93-14	19691-19700	inclusion	_	
93-15	19701-19704	and	_	
93-16	19705-19706	(	_	
93-17	19706-19707	e	_	
93-18	19707-19708	)	_	
93-19	19709-19712	the	_	
93-20	19713-19723	subjective	_	
93-21	19724-19731	feeling	_	
93-22	19732-19734	of	_	
93-23	19735-19744	exclusion	_	
93-24	19745-19751	during	_	
93-25	19752-19755	the	_	
93-26	19756-19762	social	_	
93-27	19763-19772	ostracism	_	
93-28	19773-19777	task	_	
93-29	19778-19782	with	_	
93-30	19783-19785	GM	_	
93-31	19786-19792	volume	_	
93-32	19793-19795	in	_	
93-33	19796-19799	the	_	
93-34	19800-19804	left	_	
93-35	19805-19811	insula	_	
93-36	19812-19814	in	_	
93-37	19815-19818	the	_	
93-38	19819-19826	patient	_	
93-39	19827-19832	group	_	
93-40	19833-19834	(	_	
93-41	19834-19842	rpartial	_	
93-42	19842-19843	(	_	
93-43	19843-19852	inclusion	_	
93-44	19852-19853	)	_	
93-45	19854-19855	=	_	
93-46	19856-19861	0.448	_	
93-47	19861-19862	,	_	
93-48	19863-19864	P	_	
93-49	19865-19866	=	_	
93-50	19867-19872	0.047	_	
93-51	19872-19873	,	_	
93-52	19874-19882	rpartial	_	
93-53	19882-19883	(	_	
93-54	19883-19892	exclusion	_	
93-55	19892-19893	)	_	
93-56	19894-19895	=	_	
93-57	19896-19897	−	_	
93-58	19897-19902	0.484	_	
93-59	19902-19903	,	_	
93-60	19904-19905	P	_	
93-61	19906-19907	=	_	
93-62	19908-19913	0.034	_	
93-63	19913-19914	,	_	
93-64	19915-19922	partial	_	
93-65	19923-19935	correlations	_	
93-66	19936-19946	considered	_	
93-67	19947-19950	TIV	_	
93-68	19951-19954	and	_	
93-69	19955-19958	age	_	
93-70	19959-19961	as	_	
93-71	19962-19972	covariates	_	
93-72	19972-19973	,	_	
93-73	19974-19982	residual	_	
93-74	19983-19989	values	_	
93-75	19990-19993	are	_	
93-76	19994-20003	displayed	_	
93-77	20003-20004	)	_	
93-78	20004-20005	.	_	

#Text=Associations between GM volume and social anxiety and social rejection sensitivity
#Text=Partial Pearson correlation analyses conducted separately for OMT patients and controls, considering age and TIV as covariates, showed significant associations between smaller left insula GM volume in OMT patients and diminished subjective feelings of inclusion during the inclusion condition of the fMRI Cyberball task [rpartial = 0.448, P = 0.047, pFDR = 0.047, see Figure 1d; details on the Cyberball task main effects on subjective feelings of in- and exclusion are reported in ].
94-1	20006-20018	Associations	_	
94-2	20019-20026	between	_	
94-3	20027-20029	GM	_	
94-4	20030-20036	volume	_	
94-5	20037-20040	and	_	
94-6	20041-20047	social	_	
94-7	20048-20055	anxiety	_	
94-8	20056-20059	and	_	
94-9	20060-20066	social	_	
94-10	20067-20076	rejection	_	
94-11	20077-20088	sensitivity	_	
94-12	20089-20096	Partial	_	
94-13	20097-20104	Pearson	_	
94-14	20105-20116	correlation	_	
94-15	20117-20125	analyses	_	
94-16	20126-20135	conducted	_	
94-17	20136-20146	separately	_	
94-18	20147-20150	for	_	
94-19	20151-20154	OMT	_	
94-20	20155-20163	patients	_	
94-21	20164-20167	and	_	
94-22	20168-20176	controls	_	
94-23	20176-20177	,	_	
94-24	20178-20189	considering	_	
94-25	20190-20193	age	_	
94-26	20194-20197	and	_	
94-27	20198-20201	TIV	_	
94-28	20202-20204	as	_	
94-29	20205-20215	covariates	_	
94-30	20215-20216	,	_	
94-31	20217-20223	showed	_	
94-32	20224-20235	significant	_	
94-33	20236-20248	associations	_	
94-34	20249-20256	between	_	
94-35	20257-20264	smaller	_	
94-36	20265-20269	left	_	
94-37	20270-20276	insula	_	
94-38	20277-20279	GM	_	
94-39	20280-20286	volume	_	
94-40	20287-20289	in	_	
94-41	20290-20293	OMT	_	
94-42	20294-20302	patients	_	
94-43	20303-20306	and	_	
94-44	20307-20317	diminished	_	
94-45	20318-20328	subjective	_	
94-46	20329-20337	feelings	_	
94-47	20338-20340	of	_	
94-48	20341-20350	inclusion	_	
94-49	20351-20357	during	_	
94-50	20358-20361	the	_	
94-51	20362-20371	inclusion	_	
94-52	20372-20381	condition	_	
94-53	20382-20384	of	_	
94-54	20385-20388	the	_	
94-55	20389-20393	fMRI	_	
94-56	20394-20403	Cyberball	_	
94-57	20404-20408	task	_	
94-58	20409-20410	[	_	
94-59	20410-20418	rpartial	_	
94-60	20419-20420	=	_	
94-61	20421-20426	0.448	_	
94-62	20426-20427	,	_	
94-63	20428-20429	P	_	
94-64	20430-20431	=	_	
94-65	20432-20437	0.047	_	
94-66	20437-20438	,	_	
94-67	20439-20443	pFDR	_	
94-68	20444-20445	=	_	
94-69	20446-20451	0.047	_	
94-70	20451-20452	,	_	
94-71	20453-20456	see	_	
94-72	20457-20463	Figure	_	
94-73	20464-20466	1d	_	
94-74	20466-20467	;	_	
94-75	20468-20475	details	_	
94-76	20476-20478	on	_	
94-77	20479-20482	the	_	
94-78	20483-20492	Cyberball	_	
94-79	20493-20497	task	_	
94-80	20498-20502	main	_	
94-81	20503-20510	effects	_	
94-82	20511-20513	on	_	
94-83	20514-20524	subjective	_	
94-84	20525-20533	feelings	_	
94-85	20534-20536	of	_	
94-86	20537-20539	in	_	
94-87	20539-20540	-	_	
94-88	20541-20544	and	_	
94-89	20545-20554	exclusion	_	
94-90	20555-20558	are	_	
94-91	20559-20567	reported	_	
94-92	20568-20570	in	_	
94-93	20571-20572	]	_	
94-94	20572-20573	.	_	

#Text=In addition, analyses indicated a significant partial correlation between smaller left anterior insula GM volume in OMT patients and stronger subjective feelings of being excluded during the inclusion condition (rpartial = −0.484, P = 0.034, pFDR = 0.047, see Figure 1e).
95-1	20574-20576	In	_	
95-2	20577-20585	addition	_	
95-3	20585-20586	,	_	
95-4	20587-20595	analyses	_	
95-5	20596-20605	indicated	_	
95-6	20606-20607	a	_	
95-7	20608-20619	significant	_	
95-8	20620-20627	partial	_	
95-9	20628-20639	correlation	_	
95-10	20640-20647	between	_	
95-11	20648-20655	smaller	_	
95-12	20656-20660	left	_	
95-13	20661-20669	anterior	_	
95-14	20670-20676	insula	_	
95-15	20677-20679	GM	_	
95-16	20680-20686	volume	_	
95-17	20687-20689	in	_	
95-18	20690-20693	OMT	_	
95-19	20694-20702	patients	_	
95-20	20703-20706	and	_	
95-21	20707-20715	stronger	_	
95-22	20716-20726	subjective	_	
95-23	20727-20735	feelings	_	
95-24	20736-20738	of	_	
95-25	20739-20744	being	_	
95-26	20745-20753	excluded	_	
95-27	20754-20760	during	_	
95-28	20761-20764	the	_	
95-29	20765-20774	inclusion	_	
95-30	20775-20784	condition	_	
95-31	20785-20786	(	_	
95-32	20786-20794	rpartial	_	
95-33	20795-20796	=	_	
95-34	20797-20798	−	_	
95-35	20798-20803	0.484	_	
95-36	20803-20804	,	_	
95-37	20805-20806	P	_	
95-38	20807-20808	=	_	
95-39	20809-20814	0.034	_	
95-40	20814-20815	,	_	
95-41	20816-20820	pFDR	_	
95-42	20821-20822	=	_	
95-43	20823-20828	0.047	_	
95-44	20828-20829	,	_	
95-45	20830-20833	see	_	
95-46	20834-20840	Figure	_	
95-47	20841-20843	1e	_	
95-48	20843-20844	)	_	
95-49	20844-20845	.	_	

#Text=While associations for the right insula and left and right inferior frontal gyri GM volume in OMT patients pointed in the same direction, results did not yield statistical significance (rmin = −0.241, pmin = 0.103).
96-1	20846-20851	While	_	
96-2	20852-20864	associations	_	
96-3	20865-20868	for	_	
96-4	20869-20872	the	_	
96-5	20873-20878	right	_	
96-6	20879-20885	insula	_	
96-7	20886-20889	and	_	
96-8	20890-20894	left	_	
96-9	20895-20898	and	_	
96-10	20899-20904	right	_	
96-11	20905-20913	inferior	_	
96-12	20914-20921	frontal	_	
96-13	20922-20926	gyri	_	
96-14	20927-20929	GM	_	
96-15	20930-20936	volume	_	
96-16	20937-20939	in	_	
96-17	20940-20943	OMT	_	
96-18	20944-20952	patients	_	
96-19	20953-20960	pointed	_	
96-20	20961-20963	in	_	
96-21	20964-20967	the	_	
96-22	20968-20972	same	_	
96-23	20973-20982	direction	_	
96-24	20982-20983	,	_	
96-25	20984-20991	results	_	
96-26	20992-20995	did	_	
96-27	20996-20999	not	_	
96-28	21000-21005	yield	_	
96-29	21006-21017	statistical	_	
96-30	21018-21030	significance	_	
96-31	21031-21032	(	_	
96-32	21032-21036	rmin	_	
96-33	21037-21038	=	_	
96-34	21039-21040	−	_	
96-35	21040-21045	0.241	_	
96-36	21045-21046	,	_	
96-37	21047-21051	pmin	_	
96-38	21052-21053	=	_	
96-39	21054-21059	0.103	_	
96-40	21059-21060	)	_	
96-41	21060-21061	.	_	

#Text=Associations between GM volume in the insula and inferior frontal gyrus did not display significant associations between subjective feelings of exclusion or inclusion in the group of healthy participants (rmax = 0.155, pmin = 0.233).
97-1	21062-21074	Associations	_	
97-2	21075-21082	between	_	
97-3	21083-21085	GM	_	
97-4	21086-21092	volume	_	
97-5	21093-21095	in	_	
97-6	21096-21099	the	_	
97-7	21100-21106	insula	_	
97-8	21107-21110	and	_	
97-9	21111-21119	inferior	_	
97-10	21120-21127	frontal	_	
97-11	21128-21133	gyrus	_	
97-12	21134-21137	did	_	
97-13	21138-21141	not	_	
97-14	21142-21149	display	_	
97-15	21150-21161	significant	_	
97-16	21162-21174	associations	_	
97-17	21175-21182	between	_	
97-18	21183-21193	subjective	_	
97-19	21194-21202	feelings	_	
97-20	21203-21205	of	_	
97-21	21206-21215	exclusion	_	
97-22	21216-21218	or	_	
97-23	21219-21228	inclusion	_	
97-24	21229-21231	in	_	
97-25	21232-21235	the	_	
97-26	21236-21241	group	_	
97-27	21242-21244	of	_	
97-28	21245-21252	healthy	_	
97-29	21253-21265	participants	_	
97-30	21266-21267	(	_	
97-31	21267-21271	rmax	_	
97-32	21272-21273	=	_	
97-33	21274-21279	0.155	_	
97-34	21279-21280	,	_	
97-35	21281-21285	pmin	_	
97-36	21286-21287	=	_	
97-37	21288-21293	0.233	_	
97-38	21293-21294	)	_	
97-39	21294-21295	.	_	

#Text=Further analyses in the whole study sample (patients and controls combined) showed that left anterior insula GM volume negatively correlated with social interaction anxiety symptoms, measured by the SIAS (rpartial = −0.277, P = 0.004, pFDR = 0.048); with global psychological distress levels, measured using the BSI (rpartial = −0.484, P = 0.001, pFDR = 0.048); with symptoms of social phobia, measured using the SPS (rpartial = −0.296, P = 0.038, pFDR = 0.048); and with social rejection sensitivity, measured using the RSQ (rpartial = −0.325, P = 0.025, pFDR = 0.048).
98-1	21296-21303	Further	_	
98-2	21304-21312	analyses	_	
98-3	21313-21315	in	_	
98-4	21316-21319	the	_	
98-5	21320-21325	whole	_	
98-6	21326-21331	study	_	
98-7	21332-21338	sample	_	
98-8	21339-21340	(	_	
98-9	21340-21348	patients	_	
98-10	21349-21352	and	_	
98-11	21353-21361	controls	_	
98-12	21362-21370	combined	_	
98-13	21370-21371	)	_	
98-14	21372-21378	showed	_	
98-15	21379-21383	that	_	
98-16	21384-21388	left	_	
98-17	21389-21397	anterior	_	
98-18	21398-21404	insula	_	
98-19	21405-21407	GM	_	
98-20	21408-21414	volume	_	
98-21	21415-21425	negatively	_	
98-22	21426-21436	correlated	_	
98-23	21437-21441	with	_	
98-24	21442-21448	social	_	
98-25	21449-21460	interaction	_	
98-26	21461-21468	anxiety	_	
98-27	21469-21477	symptoms	_	
98-28	21477-21478	,	_	
98-29	21479-21487	measured	_	
98-30	21488-21490	by	_	
98-31	21491-21494	the	_	
98-32	21495-21499	SIAS	_	
98-33	21500-21501	(	_	
98-34	21501-21509	rpartial	_	
98-35	21510-21511	=	_	
98-36	21512-21513	−	_	
98-37	21513-21518	0.277	_	
98-38	21518-21519	,	_	
98-39	21520-21521	P	_	
98-40	21522-21523	=	_	
98-41	21524-21529	0.004	_	
98-42	21529-21530	,	_	
98-43	21531-21535	pFDR	_	
98-44	21536-21537	=	_	
98-45	21538-21543	0.048	_	
98-46	21543-21544	)	_	
98-47	21544-21545	;	_	
98-48	21546-21550	with	_	
98-49	21551-21557	global	_	
98-50	21558-21571	psychological	_	
98-51	21572-21580	distress	_	
98-52	21581-21587	levels	_	
98-53	21587-21588	,	_	
98-54	21589-21597	measured	_	
98-55	21598-21603	using	_	
98-56	21604-21607	the	_	
98-57	21608-21611	BSI	_	
98-58	21612-21613	(	_	
98-59	21613-21621	rpartial	_	
98-60	21622-21623	=	_	
98-61	21624-21625	−	_	
98-62	21625-21630	0.484	_	
98-63	21630-21631	,	_	
98-64	21632-21633	P	_	
98-65	21634-21635	=	_	
98-66	21636-21641	0.001	_	
98-67	21641-21642	,	_	
98-68	21643-21647	pFDR	_	
98-69	21648-21649	=	_	
98-70	21650-21655	0.048	_	
98-71	21655-21656	)	_	
98-72	21656-21657	;	_	
98-73	21658-21662	with	_	
98-74	21663-21671	symptoms	_	
98-75	21672-21674	of	_	
98-76	21675-21681	social	_	
98-77	21682-21688	phobia	_	
98-78	21688-21689	,	_	
98-79	21690-21698	measured	_	
98-80	21699-21704	using	_	
98-81	21705-21708	the	_	
98-82	21709-21712	SPS	_	
98-83	21713-21714	(	_	
98-84	21714-21722	rpartial	_	
98-85	21723-21724	=	_	
98-86	21725-21726	−	_	
98-87	21726-21731	0.296	_	
98-88	21731-21732	,	_	
98-89	21733-21734	P	_	
98-90	21735-21736	=	_	
98-91	21737-21742	0.038	_	
98-92	21742-21743	,	_	
98-93	21744-21748	pFDR	_	
98-94	21749-21750	=	_	
98-95	21751-21756	0.048	_	
98-96	21756-21757	)	_	
98-97	21757-21758	;	_	
98-98	21759-21762	and	_	
98-99	21763-21767	with	_	
98-100	21768-21774	social	_	
98-101	21775-21784	rejection	_	
98-102	21785-21796	sensitivity	_	
98-103	21796-21797	,	_	
98-104	21798-21806	measured	_	
98-105	21807-21812	using	_	
98-106	21813-21816	the	_	
98-107	21817-21820	RSQ	_	
98-108	21821-21822	(	_	
98-109	21822-21830	rpartial	_	
98-110	21831-21832	=	_	
98-111	21833-21834	−	_	
98-112	21834-21839	0.325	_	
98-113	21839-21840	,	_	
98-114	21841-21842	P	_	
98-115	21843-21844	=	_	
98-116	21845-21850	0.025	_	
98-117	21850-21851	,	_	
98-118	21852-21856	pFDR	_	
98-119	21857-21858	=	_	
98-120	21859-21864	0.048	_	
98-121	21864-21865	)	_	
98-122	21865-21866	.	_	

#Text=In other words, smaller insula GM volume in the whole study sample was associated with higher (i) social interaction anxiety, (ii) global psychological distress levels, (iii) social phobia and (iv) social rejection sensitivity.
99-1	21867-21869	In	_	
99-2	21870-21875	other	_	
99-3	21876-21881	words	_	
99-4	21881-21882	,	_	
99-5	21883-21890	smaller	_	
99-6	21891-21897	insula	_	
99-7	21898-21900	GM	_	
99-8	21901-21907	volume	_	
99-9	21908-21910	in	_	
99-10	21911-21914	the	_	
99-11	21915-21920	whole	_	
99-12	21921-21926	study	_	
99-13	21927-21933	sample	_	
99-14	21934-21937	was	_	
99-15	21938-21948	associated	_	
99-16	21949-21953	with	_	
99-17	21954-21960	higher	_	
99-18	21961-21962	(	_	
99-19	21962-21963	i	_	
99-20	21963-21964	)	_	
99-21	21965-21971	social	_	
99-22	21972-21983	interaction	_	
99-23	21984-21991	anxiety	_	
99-24	21991-21992	,	_	
99-25	21993-21994	(	_	
99-26	21994-21996	ii	_	
99-27	21996-21997	)	_	
99-28	21998-22004	global	_	
99-29	22005-22018	psychological	_	
99-30	22019-22027	distress	_	
99-31	22028-22034	levels	_	
99-32	22034-22035	,	_	
99-33	22036-22037	(	_	
99-34	22037-22040	iii	_	
99-35	22040-22041	)	_	
99-36	22042-22048	social	_	
99-37	22049-22055	phobia	_	
99-38	22056-22059	and	_	
99-39	22060-22061	(	_	
99-40	22061-22063	iv	_	
99-41	22063-22064	)	_	
99-42	22065-22071	social	_	
99-43	22072-22081	rejection	_	
99-44	22082-22093	sensitivity	_	
99-45	22093-22094	.	_	

#Text=Additional analyses without the patient who had extreme values on the variable encoding left insula GM volume showed that correlation coefficients (partial correlation) remained significant (rSIAS = −0.306 P = 0.035; rSPS = −0.319 P = 0.029; rBSI = −0.462 P = 0.002; and rRSQ = −0.299 P = 0.038).
100-1	22095-22105	Additional	_	
100-2	22106-22114	analyses	_	
100-3	22115-22122	without	_	
100-4	22123-22126	the	_	
100-5	22127-22134	patient	_	
100-6	22135-22138	who	_	
100-7	22139-22142	had	_	
100-8	22143-22150	extreme	_	
100-9	22151-22157	values	_	
100-10	22158-22160	on	_	
100-11	22161-22164	the	_	
100-12	22165-22173	variable	_	
100-13	22174-22182	encoding	_	
100-14	22183-22187	left	_	
100-15	22188-22194	insula	_	
100-16	22195-22197	GM	_	
100-17	22198-22204	volume	_	
100-18	22205-22211	showed	_	
100-19	22212-22216	that	_	
100-20	22217-22228	correlation	_	
100-21	22229-22241	coefficients	_	
100-22	22242-22243	(	_	
100-23	22243-22250	partial	_	
100-24	22251-22262	correlation	_	
100-25	22262-22263	)	_	
100-26	22264-22272	remained	_	
100-27	22273-22284	significant	_	
100-28	22285-22286	(	_	
100-29	22286-22291	rSIAS	_	
100-30	22292-22293	=	_	
100-31	22294-22295	−	_	
100-32	22295-22300	0.306	_	
100-33	22301-22302	P	_	
100-34	22303-22304	=	_	
100-35	22305-22310	0.035	_	
100-36	22310-22311	;	_	
100-37	22312-22316	rSPS	_	
100-38	22317-22318	=	_	
100-39	22319-22320	−	_	
100-40	22320-22325	0.319	_	
100-41	22326-22327	P	_	
100-42	22328-22329	=	_	
100-43	22330-22335	0.029	_	
100-44	22335-22336	;	_	
100-45	22337-22341	rBSI	_	
100-46	22342-22343	=	_	
100-47	22344-22345	−	_	
100-48	22345-22350	0.462	_	
100-49	22351-22352	P	_	
100-50	22353-22354	=	_	
100-51	22355-22360	0.002	_	
100-52	22360-22361	;	_	
100-53	22362-22365	and	_	
100-54	22366-22370	rRSQ	_	
100-55	22371-22372	=	_	
100-56	22373-22374	−	_	
100-57	22374-22379	0.299	_	
100-58	22380-22381	P	_	
100-59	22382-22383	=	_	
100-60	22384-22389	0.038	_	
100-61	22389-22390	)	_	
100-62	22390-22391	.	_	

#Text=In line with the results of previous studies, SIAS, SPS, RSQ and BSI scores showed significant intercorrelations (see Supplementary Table S1).
101-1	22392-22394	In	_	
101-2	22395-22399	line	_	
101-3	22400-22404	with	_	
101-4	22405-22408	the	_	
101-5	22409-22416	results	_	
101-6	22417-22419	of	_	
101-7	22420-22428	previous	_	
101-8	22429-22436	studies	_	
101-9	22436-22437	,	_	
101-10	22438-22442	SIAS	_	
101-11	22442-22443	,	_	
101-12	22444-22447	SPS	_	
101-13	22447-22448	,	_	
101-14	22449-22452	RSQ	_	
101-15	22453-22456	and	_	
101-16	22457-22460	BSI	_	
101-17	22461-22467	scores	_	
101-18	22468-22474	showed	_	
101-19	22475-22486	significant	_	
101-20	22487-22504	intercorrelations	_	
101-21	22505-22506	(	_	
101-22	22506-22509	see	_	
101-23	22510-22523	Supplementary	_	
101-24	22524-22529	Table	_	
101-25	22530-22532	S1	_	
101-26	22532-22533	)	_	
101-27	22533-22534	.	_	

#Text=In addition, all scales showed significant positive association with the extent of task-induced subjective feelings of exclusion and negative associations with task-induced subjective feelings of inclusion during the inclusion condition of the fMRI Cyberball task (see Supplementary Table S1).
102-1	22535-22537	In	_	
102-2	22538-22546	addition	_	
102-3	22546-22547	,	_	
102-4	22548-22551	all	_	
102-5	22552-22558	scales	_	
102-6	22559-22565	showed	_	
102-7	22566-22577	significant	_	
102-8	22578-22586	positive	_	
102-9	22587-22598	association	_	
102-10	22599-22603	with	_	
102-11	22604-22607	the	_	
102-12	22608-22614	extent	_	
102-13	22615-22617	of	_	
102-14	22618-22630	task-induced	_	
102-15	22631-22641	subjective	_	
102-16	22642-22650	feelings	_	
102-17	22651-22653	of	_	
102-18	22654-22663	exclusion	_	
102-19	22664-22667	and	_	
102-20	22668-22676	negative	_	
102-21	22677-22689	associations	_	
102-22	22690-22694	with	_	
102-23	22695-22707	task-induced	_	
102-24	22708-22718	subjective	_	
102-25	22719-22727	feelings	_	
102-26	22728-22730	of	_	
102-27	22731-22740	inclusion	_	
102-28	22741-22747	during	_	
102-29	22748-22751	the	_	
102-30	22752-22761	inclusion	_	
102-31	22762-22771	condition	_	
102-32	22772-22774	of	_	
102-33	22775-22778	the	_	
102-34	22779-22783	fMRI	_	
102-35	22784-22793	Cyberball	_	
102-36	22794-22798	task	_	
102-37	22799-22800	(	_	
102-38	22800-22803	see	_	
102-39	22804-22817	Supplementary	_	
102-40	22818-22823	Table	_	
102-41	22824-22826	S1	_	
102-42	22826-22827	)	_	
102-43	22827-22828	.	_	

#Text=Associations between GM volume and substance use patterns
#Text=Comparison between patients with and without concurrent substance use of either a single substance or a combination of alcohol, heroin, cocaine and benzodiazepines showed no significant differences with regard to total GM or local GM volume in the left and right anterior insula and bilateral inferior frontal gyri (tmax = 0.911, pmin = 0.375).
103-1	22829-22841	Associations	_	
103-2	22842-22849	between	_	
103-3	22850-22852	GM	_	
103-4	22853-22859	volume	_	
103-5	22860-22863	and	_	
103-6	22864-22873	substance	_	
103-7	22874-22877	use	_	
103-8	22878-22886	patterns	_	
103-9	22887-22897	Comparison	_	
103-10	22898-22905	between	_	
103-11	22906-22914	patients	_	
103-12	22915-22919	with	_	
103-13	22920-22923	and	_	
103-14	22924-22931	without	_	
103-15	22932-22942	concurrent	_	
103-16	22943-22952	substance	_	
103-17	22953-22956	use	_	
103-18	22957-22959	of	_	
103-19	22960-22966	either	_	
103-20	22967-22968	a	_	
103-21	22969-22975	single	_	
103-22	22976-22985	substance	_	
103-23	22986-22988	or	_	
103-24	22989-22990	a	_	
103-25	22991-23002	combination	_	
103-26	23003-23005	of	_	
103-27	23006-23013	alcohol	_	
103-28	23013-23014	,	_	
103-29	23015-23021	heroin	_	
103-30	23021-23022	,	_	
103-31	23023-23030	cocaine	_	
103-32	23031-23034	and	_	
103-33	23035-23050	benzodiazepines	_	
103-34	23051-23057	showed	_	
103-35	23058-23060	no	_	
103-36	23061-23072	significant	_	
103-37	23073-23084	differences	_	
103-38	23085-23089	with	_	
103-39	23090-23096	regard	_	
103-40	23097-23099	to	_	
103-41	23100-23105	total	_	
103-42	23106-23108	GM	_	
103-43	23109-23111	or	_	
103-44	23112-23117	local	_	
103-45	23118-23120	GM	_	
103-46	23121-23127	volume	_	
103-47	23128-23130	in	_	
103-48	23131-23134	the	_	
103-49	23135-23139	left	_	
103-50	23140-23143	and	_	
103-51	23144-23149	right	_	
103-52	23150-23158	anterior	_	
103-53	23159-23165	insula	_	
103-54	23166-23169	and	_	
103-55	23170-23179	bilateral	_	
103-56	23180-23188	inferior	_	
103-57	23189-23196	frontal	_	
103-58	23197-23201	gyri	_	
103-59	23202-23203	(	_	
103-60	23203-23207	tmax	_	
103-61	23208-23209	=	_	
103-62	23210-23215	0.911	_	
103-63	23215-23216	,	_	
103-64	23217-23221	pmin	_	
103-65	23222-23223	=	_	
103-66	23224-23229	0.375	_	
103-67	23229-23230	)	_	
103-68	23230-23231	.	_	

#Text=In addition, comparisons of values of psychometric scales between patient groups with (n = 9) and without (n = 10) comorbid consumption of other substances revealed no significant difference between groups on any variable (SIAS, BSI, RSQ, SPS; tmax = 2.172, pmin = 0.054).
104-1	23232-23234	In	_	
104-2	23235-23243	addition	_	
104-3	23243-23244	,	_	
104-4	23245-23256	comparisons	_	
104-5	23257-23259	of	_	
104-6	23260-23266	values	_	
104-7	23267-23269	of	_	
104-8	23270-23282	psychometric	_	
104-9	23283-23289	scales	_	
104-10	23290-23297	between	_	
104-11	23298-23305	patient	_	
104-12	23306-23312	groups	_	
104-13	23313-23317	with	_	
104-14	23318-23319	(	_	
104-15	23319-23320	n	_	
104-16	23321-23322	=	_	
104-17	23323-23324	9	_	
104-18	23324-23325	)	_	
104-19	23326-23329	and	_	
104-20	23330-23337	without	_	
104-21	23338-23339	(	_	
104-22	23339-23340	n	_	
104-23	23341-23342	=	_	
104-24	23343-23345	10	_	
104-25	23345-23346	)	_	
104-26	23347-23355	comorbid	_	
104-27	23356-23367	consumption	_	
104-28	23368-23370	of	_	
104-29	23371-23376	other	_	
104-30	23377-23387	substances	_	
104-31	23388-23396	revealed	_	
104-32	23397-23399	no	_	
104-33	23400-23411	significant	_	
104-34	23412-23422	difference	_	
104-35	23423-23430	between	_	
104-36	23431-23437	groups	_	
104-37	23438-23440	on	_	
104-38	23441-23444	any	_	
104-39	23445-23453	variable	_	
104-40	23454-23455	(	_	
104-41	23455-23459	SIAS	_	
104-42	23459-23460	,	_	
104-43	23461-23464	BSI	_	
104-44	23464-23465	,	_	
104-45	23466-23469	RSQ	_	
104-46	23469-23470	,	_	
104-47	23471-23474	SPS	_	
104-48	23474-23475	;	_	
104-49	23476-23480	tmax	_	
104-50	23481-23482	=	_	
104-51	23483-23488	2.172	_	
104-52	23488-23489	,	_	
104-53	23490-23494	pmin	_	
104-54	23495-23496	=	_	
104-55	23497-23502	0.054	_	
104-56	23502-23503	)	_	
104-57	23503-23504	.	_	

#Text=While concurrent substance use did not show a significant effect on social rejection sensitivity, anxiety symptoms or social phobia symptoms or GM volume, partial correlations, considering age and TIV as covariates, showed a significant association between lower GM volume in the left inferior frontal gyrus (BA47) and the number of years patients took heroin without being on OMT (rpartial = −0.737, P = 0.007, M = 11.50 years, s.d. = 6.7, see Supplementary Figure S1).
105-1	23505-23510	While	_	
105-2	23511-23521	concurrent	_	
105-3	23522-23531	substance	_	
105-4	23532-23535	use	_	
105-5	23536-23539	did	_	
105-6	23540-23543	not	_	
105-7	23544-23548	show	_	
105-8	23549-23550	a	_	
105-9	23551-23562	significant	_	
105-10	23563-23569	effect	_	
105-11	23570-23572	on	_	
105-12	23573-23579	social	_	
105-13	23580-23589	rejection	_	
105-14	23590-23601	sensitivity	_	
105-15	23601-23602	,	_	
105-16	23603-23610	anxiety	_	
105-17	23611-23619	symptoms	_	
105-18	23620-23622	or	_	
105-19	23623-23629	social	_	
105-20	23630-23636	phobia	_	
105-21	23637-23645	symptoms	_	
105-22	23646-23648	or	_	
105-23	23649-23651	GM	_	
105-24	23652-23658	volume	_	
105-25	23658-23659	,	_	
105-26	23660-23667	partial	_	
105-27	23668-23680	correlations	_	
105-28	23680-23681	,	_	
105-29	23682-23693	considering	_	
105-30	23694-23697	age	_	
105-31	23698-23701	and	_	
105-32	23702-23705	TIV	_	
105-33	23706-23708	as	_	
105-34	23709-23719	covariates	_	
105-35	23719-23720	,	_	
105-36	23721-23727	showed	_	
105-37	23728-23729	a	_	
105-38	23730-23741	significant	_	
105-39	23742-23753	association	_	
105-40	23754-23761	between	_	
105-41	23762-23767	lower	_	
105-42	23768-23770	GM	_	
105-43	23771-23777	volume	_	
105-44	23778-23780	in	_	
105-45	23781-23784	the	_	
105-46	23785-23789	left	_	
105-47	23790-23798	inferior	_	
105-48	23799-23806	frontal	_	
105-49	23807-23812	gyrus	_	
105-50	23813-23814	(	_	
105-51	23814-23818	BA47	_	
105-52	23818-23819	)	_	
105-53	23820-23823	and	_	
105-54	23824-23827	the	_	
105-55	23828-23834	number	_	
105-56	23835-23837	of	_	
105-57	23838-23843	years	_	
105-58	23844-23852	patients	_	
105-59	23853-23857	took	_	
105-60	23858-23864	heroin	_	
105-61	23865-23872	without	_	
105-62	23873-23878	being	_	
105-63	23879-23881	on	_	
105-64	23882-23885	OMT	_	
105-65	23886-23887	(	_	
105-66	23887-23895	rpartial	_	
105-67	23896-23897	=	_	
105-68	23898-23899	−	_	
105-69	23899-23904	0.737	_	
105-70	23904-23905	,	_	
105-71	23906-23907	P	_	
105-72	23908-23909	=	_	
105-73	23910-23915	0.007	_	
105-74	23915-23916	,	_	
105-75	23917-23918	M	_	
105-76	23919-23920	=	_	
105-77	23921-23926	11.50	_	
105-78	23926-23927	 	_	
105-79	23927-23932	years	_	
105-80	23932-23933	,	_	
105-81	23934-23937	s.d	_	
105-82	23937-23938	.	_	
105-83	23939-23940	=	_	
105-84	23941-23944	6.7	_	
105-85	23944-23945	,	_	
105-86	23946-23949	see	_	
105-87	23950-23963	Supplementary	_	
105-88	23964-23970	Figure	_	
105-89	23971-23973	S1	_	
105-90	23973-23974	)	_	
105-91	23974-23975	.	_	

#Text=Discussion
#Text=For the first time, we could show that smaller insula GM volume in OMT patients was associated with higher subjective feelings of exclusion and lower subjective inclusion during the social ostracism Cyberball task and smaller insula GM volume was associated with higher social anxiety scores.
106-1	23976-23986	Discussion	_	
106-2	23987-23990	For	_	
106-3	23991-23994	the	_	
106-4	23995-24000	first	_	
106-5	24001-24005	time	_	
106-6	24005-24006	,	_	
106-7	24007-24009	we	_	
106-8	24010-24015	could	_	
106-9	24016-24020	show	_	
106-10	24021-24025	that	_	
106-11	24026-24033	smaller	_	
106-12	24034-24040	insula	_	
106-13	24041-24043	GM	_	
106-14	24044-24050	volume	_	
106-15	24051-24053	in	_	
106-16	24054-24057	OMT	_	
106-17	24058-24066	patients	_	
106-18	24067-24070	was	_	
106-19	24071-24081	associated	_	
106-20	24082-24086	with	_	
106-21	24087-24093	higher	_	
106-22	24094-24104	subjective	_	
106-23	24105-24113	feelings	_	
106-24	24114-24116	of	_	
106-25	24117-24126	exclusion	_	
106-26	24127-24130	and	_	
106-27	24131-24136	lower	_	
106-28	24137-24147	subjective	_	
106-29	24148-24157	inclusion	_	
106-30	24158-24164	during	_	
106-31	24165-24168	the	_	
106-32	24169-24175	social	_	
106-33	24176-24185	ostracism	_	
106-34	24186-24195	Cyberball	_	
106-35	24196-24200	task	_	
106-36	24201-24204	and	_	
106-37	24205-24212	smaller	_	
106-38	24213-24219	insula	_	
106-39	24220-24222	GM	_	
106-40	24223-24229	volume	_	
106-41	24230-24233	was	_	
106-42	24234-24244	associated	_	
106-43	24245-24249	with	_	
106-44	24250-24256	higher	_	
106-45	24257-24263	social	_	
106-46	24264-24271	anxiety	_	
106-47	24272-24278	scores	_	
106-48	24278-24279	.	_	

#Text=Previous structural MRI studies that investigated more than 300 healthy participants found that GM volume in the region of the posterior cingulate cortex and precuneus was negatively associated with RSQ scores, while GM volume in the inferior temporal gyrus was positively correlated with RSQ scores.
107-1	24280-24288	Previous	_	
107-2	24289-24299	structural	_	
107-3	24300-24303	MRI	_	
107-4	24304-24311	studies	_	
107-5	24312-24316	that	_	
107-6	24317-24329	investigated	_	
107-7	24330-24334	more	_	
107-8	24335-24339	than	_	
107-9	24340-24343	300	_	
107-10	24344-24351	healthy	_	
107-11	24352-24364	participants	_	
107-12	24365-24370	found	_	
107-13	24371-24375	that	_	
107-14	24376-24378	GM	_	
107-15	24379-24385	volume	_	
107-16	24386-24388	in	_	
107-17	24389-24392	the	_	
107-18	24393-24399	region	_	
107-19	24400-24402	of	_	
107-20	24403-24406	the	_	
107-21	24407-24416	posterior	_	
107-22	24417-24426	cingulate	_	
107-23	24427-24433	cortex	_	
107-24	24434-24437	and	_	
107-25	24438-24447	precuneus	_	
107-26	24448-24451	was	_	
107-27	24452-24462	negatively	_	
107-28	24463-24473	associated	_	
107-29	24474-24478	with	_	
107-30	24479-24482	RSQ	_	
107-31	24483-24489	scores	_	
107-32	24489-24490	,	_	
107-33	24491-24496	while	_	
107-34	24497-24499	GM	_	
107-35	24500-24506	volume	_	
107-36	24507-24509	in	_	
107-37	24510-24513	the	_	
107-38	24514-24522	inferior	_	
107-39	24523-24531	temporal	_	
107-40	24532-24537	gyrus	_	
107-41	24538-24541	was	_	
107-42	24542-24552	positively	_	
107-43	24553-24563	correlated	_	
107-44	24564-24568	with	_	
107-45	24569-24572	RSQ	_	
107-46	24573-24579	scores	_	
107-47	24579-24580	.	_	

#Text=These large-scale data support the association between GM volume and social rejection sensitivity.
108-1	24581-24586	These	_	
108-2	24587-24598	large-scale	_	
108-3	24599-24603	data	_	
108-4	24604-24611	support	_	
108-5	24612-24615	the	_	
108-6	24616-24627	association	_	
108-7	24628-24635	between	_	
108-8	24636-24638	GM	_	
108-9	24639-24645	volume	_	
108-10	24646-24649	and	_	
108-11	24650-24656	social	_	
108-12	24657-24666	rejection	_	
108-13	24667-24678	sensitivity	_	
108-14	24678-24679	.	_	

#Text=In line with previous work, current data demonstrate smaller GM volume in bilateral anterior insula and inferior frontal gyri in OMT patients (for review, see).
109-1	24680-24682	In	_	
109-2	24683-24687	line	_	
109-3	24688-24692	with	_	
109-4	24693-24701	previous	_	
109-5	24702-24706	work	_	
109-6	24706-24707	,	_	
109-7	24708-24715	current	_	
109-8	24716-24720	data	_	
109-9	24721-24732	demonstrate	_	
109-10	24733-24740	smaller	_	
109-11	24741-24743	GM	_	
109-12	24744-24750	volume	_	
109-13	24751-24753	in	_	
109-14	24754-24763	bilateral	_	
109-15	24764-24772	anterior	_	
109-16	24773-24779	insula	_	
109-17	24780-24783	and	_	
109-18	24784-24792	inferior	_	
109-19	24793-24800	frontal	_	
109-20	24801-24805	gyri	_	
109-21	24806-24808	in	_	
109-22	24809-24812	OMT	_	
109-23	24813-24821	patients	_	
109-24	24822-24823	(	_	
109-25	24823-24826	for	_	
109-26	24827-24833	review	_	
109-27	24833-24834	,	_	
109-28	24835-24838	see	_	
109-29	24838-24839	)	_	
109-30	24839-24840	.	_	

#Text=A recent meta-analysis, investigating the role of different brain structures in interoception, emotion processing and social cognition, confirmed the role of the bilateral anterior insula (BA13) in emotion processing and interoception.
110-1	24841-24842	A	_	
110-2	24843-24849	recent	_	
110-3	24850-24863	meta-analysis	_	
110-4	24863-24864	,	_	
110-5	24865-24878	investigating	_	
110-6	24879-24882	the	_	
110-7	24883-24887	role	_	
110-8	24888-24890	of	_	
110-9	24891-24900	different	_	
110-10	24901-24906	brain	_	
110-11	24907-24917	structures	_	
110-12	24918-24920	in	_	
110-13	24921-24934	interoception	_	
110-14	24934-24935	,	_	
110-15	24936-24943	emotion	_	
110-16	24944-24954	processing	_	
110-17	24955-24958	and	_	
110-18	24959-24965	social	_	
110-19	24966-24975	cognition	_	
110-20	24975-24976	,	_	
110-21	24977-24986	confirmed	_	
110-22	24987-24990	the	_	
110-23	24991-24995	role	_	
110-24	24996-24998	of	_	
110-25	24999-25002	the	_	
110-26	25003-25012	bilateral	_	
110-27	25013-25021	anterior	_	
110-28	25022-25028	insula	_	
110-29	25029-25030	(	_	
110-30	25030-25034	BA13	_	
110-31	25034-25035	)	_	
110-32	25036-25038	in	_	
110-33	25039-25046	emotion	_	
110-34	25047-25057	processing	_	
110-35	25058-25061	and	_	
110-36	25062-25075	interoception	_	
110-37	25075-25076	.	_	

#Text=Further, specifically the left insula seems to be involved in social cognition.
111-1	25077-25084	Further	_	
111-2	25084-25085	,	_	
111-3	25086-25098	specifically	_	
111-4	25099-25102	the	_	
111-5	25103-25107	left	_	
111-6	25108-25114	insula	_	
111-7	25115-25120	seems	_	
111-8	25121-25123	to	_	
111-9	25124-25126	be	_	
111-10	25127-25135	involved	_	
111-11	25136-25138	in	_	
111-12	25139-25145	social	_	
111-13	25146-25155	cognition	_	
111-14	25155-25156	.	_	

#Text=The study by Adolfi and colleagues also indicated a contribution of the bilateral inferior frontal gyri (BA47) to social cognition and emotion processing, while no robust evidence was found for a role of this region in processing interoceptive information.
112-1	25157-25160	The	_	
112-2	25161-25166	study	_	
112-3	25167-25169	by	_	
112-4	25170-25176	Adolfi	_	
112-5	25177-25180	and	_	
112-6	25181-25191	colleagues	_	
112-7	25192-25196	also	_	
112-8	25197-25206	indicated	_	
112-9	25207-25208	a	_	
112-10	25209-25221	contribution	_	
112-11	25222-25224	of	_	
112-12	25225-25228	the	_	
112-13	25229-25238	bilateral	_	
112-14	25239-25247	inferior	_	
112-15	25248-25255	frontal	_	
112-16	25256-25260	gyri	_	
112-17	25261-25262	(	_	
112-18	25262-25266	BA47	_	
112-19	25266-25267	)	_	
112-20	25268-25270	to	_	
112-21	25271-25277	social	_	
112-22	25278-25287	cognition	_	
112-23	25288-25291	and	_	
112-24	25292-25299	emotion	_	
112-25	25300-25310	processing	_	
112-26	25310-25311	,	_	
112-27	25312-25317	while	_	
112-28	25318-25320	no	_	
112-29	25321-25327	robust	_	
112-30	25328-25336	evidence	_	
112-31	25337-25340	was	_	
112-32	25341-25346	found	_	
112-33	25347-25350	for	_	
112-34	25351-25352	a	_	
112-35	25353-25357	role	_	
112-36	25358-25360	of	_	
112-37	25361-25365	this	_	
112-38	25366-25372	region	_	
112-39	25373-25375	in	_	
112-40	25376-25386	processing	_	
112-41	25387-25400	interoceptive	_	
112-42	25401-25412	information	_	
112-43	25412-25413	.	_	

#Text=This suggests that specifically the left insula is a hub where social, interoceptive and emotional perceptive components are processed.
113-1	25414-25418	This	_	
113-2	25419-25427	suggests	_	
113-3	25428-25432	that	_	
113-4	25433-25445	specifically	_	
113-5	25446-25449	the	_	
113-6	25450-25454	left	_	
113-7	25455-25461	insula	_	
113-8	25462-25464	is	_	
113-9	25465-25466	a	_	
113-10	25467-25470	hub	_	
113-11	25471-25476	where	_	
113-12	25477-25483	social	_	
113-13	25483-25484	,	_	
113-14	25485-25498	interoceptive	_	
113-15	25499-25502	and	_	
113-16	25503-25512	emotional	_	
113-17	25513-25523	perceptive	_	
113-18	25524-25534	components	_	
113-19	25535-25538	are	_	
113-20	25539-25548	processed	_	
113-21	25548-25549	.	_	

#Text=Further meta-analyses of fMRI data on social rejection confirmed the insula as one of three regions that was reliably recruited during experimental induction of social exclusion, in addition to the inferior frontal cortex and the left anterior cingulate cortex.
114-1	25550-25557	Further	_	
114-2	25558-25571	meta-analyses	_	
114-3	25572-25574	of	_	
114-4	25575-25579	fMRI	_	
114-5	25580-25584	data	_	
114-6	25585-25587	on	_	
114-7	25588-25594	social	_	
114-8	25595-25604	rejection	_	
114-9	25605-25614	confirmed	_	
114-10	25615-25618	the	_	
114-11	25619-25625	insula	_	
114-12	25626-25628	as	_	
114-13	25629-25632	one	_	
114-14	25633-25635	of	_	
114-15	25636-25641	three	_	
114-16	25642-25649	regions	_	
114-17	25650-25654	that	_	
114-18	25655-25658	was	_	
114-19	25659-25667	reliably	_	
114-20	25668-25677	recruited	_	
114-21	25678-25684	during	_	
114-22	25685-25697	experimental	_	
114-23	25698-25707	induction	_	
114-24	25708-25710	of	_	
114-25	25711-25717	social	_	
114-26	25718-25727	exclusion	_	
114-27	25727-25728	,	_	
114-28	25729-25731	in	_	
114-29	25732-25740	addition	_	
114-30	25741-25743	to	_	
114-31	25744-25747	the	_	
114-32	25748-25756	inferior	_	
114-33	25757-25764	frontal	_	
114-34	25765-25771	cortex	_	
114-35	25772-25775	and	_	
114-36	25776-25779	the	_	
114-37	25780-25784	left	_	
114-38	25785-25793	anterior	_	
114-39	25794-25803	cingulate	_	
114-40	25804-25810	cortex	_	
114-41	25810-25811	.	_	

#Text=Further studies supported the involvement of the insula in the processing of social rejection.
115-1	25812-25819	Further	_	
115-2	25820-25827	studies	_	
115-3	25828-25837	supported	_	
115-4	25838-25841	the	_	
115-5	25842-25853	involvement	_	
115-6	25854-25856	of	_	
115-7	25857-25860	the	_	
115-8	25861-25867	insula	_	
115-9	25868-25870	in	_	
115-10	25871-25874	the	_	
115-11	25875-25885	processing	_	
115-12	25886-25888	of	_	
115-13	25889-25895	social	_	
115-14	25896-25905	rejection	_	
115-15	25905-25906	.	_	

#Text=The prominent role of the insula is further underlined by its extensive connections to other brain areas.
116-1	25907-25910	The	_	
116-2	25911-25920	prominent	_	
116-3	25921-25925	role	_	
116-4	25926-25928	of	_	
116-5	25929-25932	the	_	
116-6	25933-25939	insula	_	
116-7	25940-25942	is	_	
116-8	25943-25950	further	_	
116-9	25951-25961	underlined	_	
116-10	25962-25964	by	_	
116-11	25965-25968	its	_	
116-12	25969-25978	extensive	_	
116-13	25979-25990	connections	_	
116-14	25991-25993	to	_	
116-15	25994-25999	other	_	
116-16	26000-26005	brain	_	
116-17	26006-26011	areas	_	
116-18	26011-26012	.	_	

#Text=Specifically, the insula shows strong connections to ventral parts of the striatum.
117-1	26013-26025	Specifically	_	
117-2	26025-26026	,	_	
117-3	26027-26030	the	_	
117-4	26031-26037	insula	_	
117-5	26038-26043	shows	_	
117-6	26044-26050	strong	_	
117-7	26051-26062	connections	_	
117-8	26063-26065	to	_	
117-9	26066-26073	ventral	_	
117-10	26074-26079	parts	_	
117-11	26080-26082	of	_	
117-12	26083-26086	the	_	
117-13	26087-26095	striatum	_	
117-14	26095-26096	.	_	

#Text=Greater anatomical connection strength between both areas (measured using MRI-based tractography) was related to less-risky gambling choices, stressing the role of the insula and its connections to addictive behavior.
118-1	26097-26104	Greater	_	
118-2	26105-26115	anatomical	_	
118-3	26116-26126	connection	_	
118-4	26127-26135	strength	_	
118-5	26136-26143	between	_	
118-6	26144-26148	both	_	
118-7	26149-26154	areas	_	
118-8	26155-26156	(	_	
118-9	26156-26164	measured	_	
118-10	26165-26170	using	_	
118-11	26171-26180	MRI-based	_	
118-12	26181-26193	tractography	_	
118-13	26193-26194	)	_	
118-14	26195-26198	was	_	
118-15	26199-26206	related	_	
118-16	26207-26209	to	_	
118-17	26210-26220	less-risky	_	
118-18	26221-26229	gambling	_	
118-19	26230-26237	choices	_	
118-20	26237-26238	,	_	
118-21	26239-26248	stressing	_	
118-22	26249-26252	the	_	
118-23	26253-26257	role	_	
118-24	26258-26260	of	_	
118-25	26261-26264	the	_	
118-26	26265-26271	insula	_	
118-27	26272-26275	and	_	
118-28	26276-26279	its	_	
118-29	26280-26291	connections	_	
118-30	26292-26294	to	_	
118-31	26295-26304	addictive	_	
118-32	26305-26313	behavior	_	
118-33	26313-26314	.	_	

#Text=Further, the anterior insula is reciprocally connected with the amygdala, and it has been suggested that these connections might link social stress and drug seeking.) proposed that the insula and connected brain circuits might be neural substrates for a social ‘spiral of distress’.
119-1	26315-26322	Further	_	
119-2	26322-26323	,	_	
119-3	26324-26327	the	_	
119-4	26328-26336	anterior	_	
119-5	26337-26343	insula	_	
119-6	26344-26346	is	_	
119-7	26347-26359	reciprocally	_	
119-8	26360-26369	connected	_	
119-9	26370-26374	with	_	
119-10	26375-26378	the	_	
119-11	26379-26387	amygdala	_	
119-12	26387-26388	,	_	
119-13	26389-26392	and	_	
119-14	26393-26395	it	_	
119-15	26396-26399	has	_	
119-16	26400-26404	been	_	
119-17	26405-26414	suggested	_	
119-18	26415-26419	that	_	
119-19	26420-26425	these	_	
119-20	26426-26437	connections	_	
119-21	26438-26443	might	_	
119-22	26444-26448	link	_	
119-23	26449-26455	social	_	
119-24	26456-26462	stress	_	
119-25	26463-26466	and	_	
119-26	26467-26471	drug	_	
119-27	26472-26479	seeking	_	
119-28	26479-26480	.	_	
119-29	26480-26481	)	_	
119-30	26482-26490	proposed	_	
119-31	26491-26495	that	_	
119-32	26496-26499	the	_	
119-33	26500-26506	insula	_	
119-34	26507-26510	and	_	
119-35	26511-26520	connected	_	
119-36	26521-26526	brain	_	
119-37	26527-26535	circuits	_	
119-38	26536-26541	might	_	
119-39	26542-26544	be	_	
119-40	26545-26551	neural	_	
119-41	26552-26562	substrates	_	
119-42	26563-26566	for	_	
119-43	26567-26568	a	_	
119-44	26569-26575	social	_	
119-45	26576-26577	‘	_	
119-46	26577-26583	spiral	_	
119-47	26584-26586	of	_	
119-48	26587-26595	distress	_	
119-49	26595-26596	’	_	
119-50	26596-26597	.	_	

#Text=The correlations between insula GM volume and specifically the left insula GM volume with subjective feelings of exclusion during a social ostracism Cyberball task, as well as social interaction anxiety scores, social phobia symptoms and, importantly, social rejection sensitivity, support the role of the insula as part of the neural basis of social rejection sensitivity and processing of negative social feedback.
120-1	26598-26601	The	_	
120-2	26602-26614	correlations	_	
120-3	26615-26622	between	_	
120-4	26623-26629	insula	_	
120-5	26630-26632	GM	_	
120-6	26633-26639	volume	_	
120-7	26640-26643	and	_	
120-8	26644-26656	specifically	_	
120-9	26657-26660	the	_	
120-10	26661-26665	left	_	
120-11	26666-26672	insula	_	
120-12	26673-26675	GM	_	
120-13	26676-26682	volume	_	
120-14	26683-26687	with	_	
120-15	26688-26698	subjective	_	
120-16	26699-26707	feelings	_	
120-17	26708-26710	of	_	
120-18	26711-26720	exclusion	_	
120-19	26721-26727	during	_	
120-20	26728-26729	a	_	
120-21	26730-26736	social	_	
120-22	26737-26746	ostracism	_	
120-23	26747-26756	Cyberball	_	
120-24	26757-26761	task	_	
120-25	26761-26762	,	_	
120-26	26763-26765	as	_	
120-27	26766-26770	well	_	
120-28	26771-26773	as	_	
120-29	26774-26780	social	_	
120-30	26781-26792	interaction	_	
120-31	26793-26800	anxiety	_	
120-32	26801-26807	scores	_	
120-33	26807-26808	,	_	
120-34	26809-26815	social	_	
120-35	26816-26822	phobia	_	
120-36	26823-26831	symptoms	_	
120-37	26832-26835	and	_	
120-38	26835-26836	,	_	
120-39	26837-26848	importantly	_	
120-40	26848-26849	,	_	
120-41	26850-26856	social	_	
120-42	26857-26866	rejection	_	
120-43	26867-26878	sensitivity	_	
120-44	26878-26879	,	_	
120-45	26880-26887	support	_	
120-46	26888-26891	the	_	
120-47	26892-26896	role	_	
120-48	26897-26899	of	_	
120-49	26900-26903	the	_	
120-50	26904-26910	insula	_	
120-51	26911-26913	as	_	
120-52	26914-26918	part	_	
120-53	26919-26921	of	_	
120-54	26922-26925	the	_	
120-55	26926-26932	neural	_	
120-56	26933-26938	basis	_	
120-57	26939-26941	of	_	
120-58	26942-26948	social	_	
120-59	26949-26958	rejection	_	
120-60	26959-26970	sensitivity	_	
120-61	26971-26974	and	_	
120-62	26975-26985	processing	_	
120-63	26986-26988	of	_	
120-64	26989-26997	negative	_	
120-65	26998-27004	social	_	
120-66	27005-27013	feedback	_	
120-67	27013-27014	.	_	

#Text=Previous studies also reported reduced GM volume in patients with social anxiety, supporting the idea that a loss of insula GM volume might play a role in social anxiety.
121-1	27015-27023	Previous	_	
121-2	27024-27031	studies	_	
121-3	27032-27036	also	_	
121-4	27037-27045	reported	_	
121-5	27046-27053	reduced	_	
121-6	27054-27056	GM	_	
121-7	27057-27063	volume	_	
121-8	27064-27066	in	_	
121-9	27067-27075	patients	_	
121-10	27076-27080	with	_	
121-11	27081-27087	social	_	
121-12	27088-27095	anxiety	_	
121-13	27095-27096	,	_	
121-14	27097-27107	supporting	_	
121-15	27108-27111	the	_	
121-16	27112-27116	idea	_	
121-17	27117-27121	that	_	
121-18	27122-27123	a	_	
121-19	27124-27128	loss	_	
121-20	27129-27131	of	_	
121-21	27132-27138	insula	_	
121-22	27139-27141	GM	_	
121-23	27142-27148	volume	_	
121-24	27149-27154	might	_	
121-25	27155-27159	play	_	
121-26	27160-27161	a	_	
121-27	27162-27166	role	_	
121-28	27167-27169	in	_	
121-29	27170-27176	social	_	
121-30	27177-27184	anxiety	_	
121-31	27184-27185	.	_	

#Text=The relevance of structural changes in the insula in OMT patients is further supported by evidence that demonstrates an association between negative social interaction and relapse risk in heroin addiction.
122-1	27186-27189	The	_	
122-2	27190-27199	relevance	_	
122-3	27200-27202	of	_	
122-4	27203-27213	structural	_	
122-5	27214-27221	changes	_	
122-6	27222-27224	in	_	
122-7	27225-27228	the	_	
122-8	27229-27235	insula	_	
122-9	27236-27238	in	_	
122-10	27239-27242	OMT	_	
122-11	27243-27251	patients	_	
122-12	27252-27254	is	_	
122-13	27255-27262	further	_	
122-14	27263-27272	supported	_	
122-15	27273-27275	by	_	
122-16	27276-27284	evidence	_	
122-17	27285-27289	that	_	
122-18	27290-27302	demonstrates	_	
122-19	27303-27305	an	_	
122-20	27306-27317	association	_	
122-21	27318-27325	between	_	
122-22	27326-27334	negative	_	
122-23	27335-27341	social	_	
122-24	27342-27353	interaction	_	
122-25	27354-27357	and	_	
122-26	27358-27365	relapse	_	
122-27	27366-27370	risk	_	
122-28	27371-27373	in	_	
122-29	27374-27380	heroin	_	
122-30	27381-27390	addiction	_	
122-31	27390-27391	.	_	

#Text=The GM volume deficits in the insula and inferior frontal gyrus in the current patient sample might therefore influence social interaction and emotion processing and render OMT patients more vulnerable to psychosocial stressors and subsequent relapse.
123-1	27392-27395	The	_	
123-2	27396-27398	GM	_	
123-3	27399-27405	volume	_	
123-4	27406-27414	deficits	_	
123-5	27415-27417	in	_	
123-6	27418-27421	the	_	
123-7	27422-27428	insula	_	
123-8	27429-27432	and	_	
123-9	27433-27441	inferior	_	
123-10	27442-27449	frontal	_	
123-11	27450-27455	gyrus	_	
123-12	27456-27458	in	_	
123-13	27459-27462	the	_	
123-14	27463-27470	current	_	
123-15	27471-27478	patient	_	
123-16	27479-27485	sample	_	
123-17	27486-27491	might	_	
123-18	27492-27501	therefore	_	
123-19	27502-27511	influence	_	
123-20	27512-27518	social	_	
123-21	27519-27530	interaction	_	
123-22	27531-27534	and	_	
123-23	27535-27542	emotion	_	
123-24	27543-27553	processing	_	
123-25	27554-27557	and	_	
123-26	27558-27564	render	_	
123-27	27565-27568	OMT	_	
123-28	27569-27577	patients	_	
123-29	27578-27582	more	_	
123-30	27583-27593	vulnerable	_	
123-31	27594-27596	to	_	
123-32	27597-27609	psychosocial	_	
123-33	27610-27619	stressors	_	
123-34	27620-27623	and	_	
123-35	27624-27634	subsequent	_	
123-36	27635-27642	relapse	_	
123-37	27642-27643	.	_	

#Text=The observation of a significant intercorrelation between the psychometric scales and associations with the extent of task-induced subjective feelings of exclusion during social ostracism task indicate that the different psychometric scales (SPS, SIAS, RSQ, BSI) and the social ostracism task measure, at least in part, a common construct.
124-1	27644-27647	The	_	
124-2	27648-27659	observation	_	
124-3	27660-27662	of	_	
124-4	27663-27664	a	_	
124-5	27665-27676	significant	_	
124-6	27677-27693	intercorrelation	_	
124-7	27694-27701	between	_	
124-8	27702-27705	the	_	
124-9	27706-27718	psychometric	_	
124-10	27719-27725	scales	_	
124-11	27726-27729	and	_	
124-12	27730-27742	associations	_	
124-13	27743-27747	with	_	
124-14	27748-27751	the	_	
124-15	27752-27758	extent	_	
124-16	27759-27761	of	_	
124-17	27762-27774	task-induced	_	
124-18	27775-27785	subjective	_	
124-19	27786-27794	feelings	_	
124-20	27795-27797	of	_	
124-21	27798-27807	exclusion	_	
124-22	27808-27814	during	_	
124-23	27815-27821	social	_	
124-24	27822-27831	ostracism	_	
124-25	27832-27836	task	_	
124-26	27837-27845	indicate	_	
124-27	27846-27850	that	_	
124-28	27851-27854	the	_	
124-29	27855-27864	different	_	
124-30	27865-27877	psychometric	_	
124-31	27878-27884	scales	_	
124-32	27885-27886	(	_	
124-33	27886-27889	SPS	_	
124-34	27889-27890	,	_	
124-35	27891-27895	SIAS	_	
124-36	27895-27896	,	_	
124-37	27897-27900	RSQ	_	
124-38	27900-27901	,	_	
124-39	27902-27905	BSI	_	
124-40	27905-27906	)	_	
124-41	27907-27910	and	_	
124-42	27911-27914	the	_	
124-43	27915-27921	social	_	
124-44	27922-27931	ostracism	_	
124-45	27932-27936	task	_	
124-46	27937-27944	measure	_	
124-47	27944-27945	,	_	
124-48	27946-27948	at	_	
124-49	27949-27954	least	_	
124-50	27955-27957	in	_	
124-51	27958-27962	part	_	
124-52	27962-27963	,	_	
124-53	27964-27965	a	_	
124-54	27966-27972	common	_	
124-55	27973-27982	construct	_	
124-56	27982-27983	.	_	

#Text=Previous research investigated whether the intercorrelation between SPS and SIAS and other scales measuring anxiety and depressive symptoms reflect a measure of ‘general emotional distress’ or if high levels of ‘fear of negative evaluation’ mediate the associations (the latter was measured using the specific ‘Fear of Negative Evaluation Scale’ (FNES).
125-1	27984-27992	Previous	_	
125-2	27993-28001	research	_	
125-3	28002-28014	investigated	_	
125-4	28015-28022	whether	_	
125-5	28023-28026	the	_	
125-6	28027-28043	intercorrelation	_	
125-7	28044-28051	between	_	
125-8	28052-28055	SPS	_	
125-9	28056-28059	and	_	
125-10	28060-28064	SIAS	_	
125-11	28065-28068	and	_	
125-12	28069-28074	other	_	
125-13	28075-28081	scales	_	
125-14	28082-28091	measuring	_	
125-15	28092-28099	anxiety	_	
125-16	28100-28103	and	_	
125-17	28104-28114	depressive	_	
125-18	28115-28123	symptoms	_	
125-19	28124-28131	reflect	_	
125-20	28132-28133	a	_	
125-21	28134-28141	measure	_	
125-22	28142-28144	of	_	
125-23	28145-28146	‘	_	
125-24	28146-28153	general	_	
125-25	28154-28163	emotional	_	
125-26	28164-28172	distress	_	
125-27	28172-28173	’	_	
125-28	28174-28176	or	_	
125-29	28177-28179	if	_	
125-30	28180-28184	high	_	
125-31	28185-28191	levels	_	
125-32	28192-28194	of	_	
125-33	28195-28196	‘	_	
125-34	28196-28200	fear	_	
125-35	28201-28203	of	_	
125-36	28204-28212	negative	_	
125-37	28213-28223	evaluation	_	
125-38	28223-28224	’	_	
125-39	28225-28232	mediate	_	
125-40	28233-28236	the	_	
125-41	28237-28249	associations	_	
125-42	28250-28251	(	_	
125-43	28251-28254	the	_	
125-44	28255-28261	latter	_	
125-45	28262-28265	was	_	
125-46	28266-28274	measured	_	
125-47	28275-28280	using	_	
125-48	28281-28284	the	_	
125-49	28285-28293	specific	_	
125-50	28294-28295	‘	_	
125-51	28295-28299	Fear	_	
125-52	28300-28302	of	_	
125-53	28303-28311	Negative	_	
125-54	28312-28322	Evaluation	_	
125-55	28323-28328	Scale	_	
125-56	28328-28329	’	_	
125-57	28330-28331	(	_	
125-58	28331-28335	FNES	_	
125-59	28335-28336	)	_	
125-60	28336-28337	.	_	

#Text=The results indicated that when the effects of the general emotional distress measures were controlled, FNES remained a significant predictor of both SPS and SIAS scores.
126-1	28338-28341	The	_	
126-2	28342-28349	results	_	
126-3	28350-28359	indicated	_	
126-4	28360-28364	that	_	
126-5	28365-28369	when	_	
126-6	28370-28373	the	_	
126-7	28374-28381	effects	_	
126-8	28382-28384	of	_	
126-9	28385-28388	the	_	
126-10	28389-28396	general	_	
126-11	28397-28406	emotional	_	
126-12	28407-28415	distress	_	
126-13	28416-28424	measures	_	
126-14	28425-28429	were	_	
126-15	28430-28440	controlled	_	
126-16	28440-28441	,	_	
126-17	28442-28446	FNES	_	
126-18	28447-28455	remained	_	
126-19	28456-28457	a	_	
126-20	28458-28469	significant	_	
126-21	28470-28479	predictor	_	
126-22	28480-28482	of	_	
126-23	28483-28487	both	_	
126-24	28488-28491	SPS	_	
126-25	28492-28495	and	_	
126-26	28496-28500	SIAS	_	
126-27	28501-28507	scores	_	
126-28	28507-28508	.	_	

#Text=This suggests that fear of negative evaluation might be an underlying construct of the associations between anxiety symptoms and social rejection sensitivity.
127-1	28509-28513	This	_	
127-2	28514-28522	suggests	_	
127-3	28523-28527	that	_	
127-4	28528-28532	fear	_	
127-5	28533-28535	of	_	
127-6	28536-28544	negative	_	
127-7	28545-28555	evaluation	_	
127-8	28556-28561	might	_	
127-9	28562-28564	be	_	
127-10	28565-28567	an	_	
127-11	28568-28578	underlying	_	
127-12	28579-28588	construct	_	
127-13	28589-28591	of	_	
127-14	28592-28595	the	_	
127-15	28596-28608	associations	_	
127-16	28609-28616	between	_	
127-17	28617-28624	anxiety	_	
127-18	28625-28633	symptoms	_	
127-19	28634-28637	and	_	
127-20	28638-28644	social	_	
127-21	28645-28654	rejection	_	
127-22	28655-28666	sensitivity	_	
127-23	28666-28667	.	_	

#Text=Longitudinal studies also confirmed that social rejection sensitivity was associated with social anxiety and social withdrawal.
128-1	28668-28680	Longitudinal	_	
128-2	28681-28688	studies	_	
128-3	28689-28693	also	_	
128-4	28694-28703	confirmed	_	
128-5	28704-28708	that	_	
128-6	28709-28715	social	_	
128-7	28716-28725	rejection	_	
128-8	28726-28737	sensitivity	_	
128-9	28738-28741	was	_	
128-10	28742-28752	associated	_	
128-11	28753-28757	with	_	
128-12	28758-28764	social	_	
128-13	28765-28772	anxiety	_	
128-14	28773-28776	and	_	
128-15	28777-28783	social	_	
128-16	28784-28794	withdrawal	_	
128-17	28794-28795	.	_	

#Text=While social anxiety and social rejection seem to be interconnected and both contribute to subjective experience of loneliness and dysfunctional social interaction patterns, it has been suggested that social rejection sensitivity is qualitatively different from social anxiety.
129-1	28796-28801	While	_	
129-2	28802-28808	social	_	
129-3	28809-28816	anxiety	_	
129-4	28817-28820	and	_	
129-5	28821-28827	social	_	
129-6	28828-28837	rejection	_	
129-7	28838-28842	seem	_	
129-8	28843-28845	to	_	
129-9	28846-28848	be	_	
129-10	28849-28863	interconnected	_	
129-11	28864-28867	and	_	
129-12	28868-28872	both	_	
129-13	28873-28883	contribute	_	
129-14	28884-28886	to	_	
129-15	28887-28897	subjective	_	
129-16	28898-28908	experience	_	
129-17	28909-28911	of	_	
129-18	28912-28922	loneliness	_	
129-19	28923-28926	and	_	
129-20	28927-28940	dysfunctional	_	
129-21	28941-28947	social	_	
129-22	28948-28959	interaction	_	
129-23	28960-28968	patterns	_	
129-24	28968-28969	,	_	
129-25	28970-28972	it	_	
129-26	28973-28976	has	_	
129-27	28977-28981	been	_	
129-28	28982-28991	suggested	_	
129-29	28992-28996	that	_	
129-30	28997-29003	social	_	
129-31	29004-29013	rejection	_	
129-32	29014-29025	sensitivity	_	
129-33	29026-29028	is	_	
129-34	29029-29042	qualitatively	_	
129-35	29043-29052	different	_	
129-36	29053-29057	from	_	
129-37	29058-29064	social	_	
129-38	29065-29072	anxiety	_	
129-39	29072-29073	.	_	

#Text=The disentanglement of social rejection and social anxiety is beyond the scope of the current study, but future research seems warranted as both factors are likely to contribute to dysfunctional behavioral patterns that are observed in opioid-dependent patients.
130-1	29074-29077	The	_	
130-2	29078-29093	disentanglement	_	
130-3	29094-29096	of	_	
130-4	29097-29103	social	_	
130-5	29104-29113	rejection	_	
130-6	29114-29117	and	_	
130-7	29118-29124	social	_	
130-8	29125-29132	anxiety	_	
130-9	29133-29135	is	_	
130-10	29136-29142	beyond	_	
130-11	29143-29146	the	_	
130-12	29147-29152	scope	_	
130-13	29153-29155	of	_	
130-14	29156-29159	the	_	
130-15	29160-29167	current	_	
130-16	29168-29173	study	_	
130-17	29173-29174	,	_	
130-18	29175-29178	but	_	
130-19	29179-29185	future	_	
130-20	29186-29194	research	_	
130-21	29195-29200	seems	_	
130-22	29201-29210	warranted	_	
130-23	29211-29213	as	_	
130-24	29214-29218	both	_	
130-25	29219-29226	factors	_	
130-26	29227-29230	are	_	
130-27	29231-29237	likely	_	
130-28	29238-29240	to	_	
130-29	29241-29251	contribute	_	
130-30	29252-29254	to	_	
130-31	29255-29268	dysfunctional	_	
130-32	29269-29279	behavioral	_	
130-33	29280-29288	patterns	_	
130-34	29289-29293	that	_	
130-35	29294-29297	are	_	
130-36	29298-29306	observed	_	
130-37	29307-29309	in	_	
130-38	29310-29326	opioid-dependent	_	
130-39	29327-29335	patients	_	
130-40	29335-29336	.	_	

#Text=Previous studies have indicated that heroin-induced changes in cerebral blood flow and brain metabolism, especially in frontal lobe regions, might be the cause for neurobiological structural changes.
131-1	29337-29345	Previous	_	
131-2	29346-29353	studies	_	
131-3	29354-29358	have	_	
131-4	29359-29368	indicated	_	
131-5	29369-29373	that	_	
131-6	29374-29388	heroin-induced	_	
131-7	29389-29396	changes	_	
131-8	29397-29399	in	_	
131-9	29400-29408	cerebral	_	
131-10	29409-29414	blood	_	
131-11	29415-29419	flow	_	
131-12	29420-29423	and	_	
131-13	29424-29429	brain	_	
131-14	29430-29440	metabolism	_	
131-15	29440-29441	,	_	
131-16	29442-29452	especially	_	
131-17	29453-29455	in	_	
131-18	29456-29463	frontal	_	
131-19	29464-29468	lobe	_	
131-20	29469-29476	regions	_	
131-21	29476-29477	,	_	
131-22	29478-29483	might	_	
131-23	29484-29486	be	_	
131-24	29487-29490	the	_	
131-25	29491-29496	cause	_	
131-26	29497-29500	for	_	
131-27	29501-29516	neurobiological	_	
131-28	29517-29527	structural	_	
131-29	29528-29535	changes	_	
131-30	29535-29536	.	_	

#Text=Importantly, heroin, but not methadone, has been associated with such unfavorable changes in perfusion, measured using brain spectroscopy and transcranial sonography, and brain metabolism, suggesting that OMT might not contribute to the progress of impairments.
132-1	29537-29548	Importantly	_	
132-2	29548-29549	,	_	
132-3	29550-29556	heroin	_	
132-4	29556-29557	,	_	
132-5	29558-29561	but	_	
132-6	29562-29565	not	_	
132-7	29566-29575	methadone	_	
132-8	29575-29576	,	_	
132-9	29577-29580	has	_	
132-10	29581-29585	been	_	
132-11	29586-29596	associated	_	
132-12	29597-29601	with	_	
132-13	29602-29606	such	_	
132-14	29607-29618	unfavorable	_	
132-15	29619-29626	changes	_	
132-16	29627-29629	in	_	
132-17	29630-29639	perfusion	_	
132-18	29639-29640	,	_	
132-19	29641-29649	measured	_	
132-20	29650-29655	using	_	
132-21	29656-29661	brain	_	
132-22	29662-29674	spectroscopy	_	
132-23	29675-29678	and	_	
132-24	29679-29691	transcranial	_	
132-25	29692-29702	sonography	_	
132-26	29702-29703	,	_	
132-27	29704-29707	and	_	
132-28	29708-29713	brain	_	
132-29	29714-29724	metabolism	_	
132-30	29724-29725	,	_	
132-31	29726-29736	suggesting	_	
132-32	29737-29741	that	_	
132-33	29742-29745	OMT	_	
132-34	29746-29751	might	_	
132-35	29752-29755	not	_	
132-36	29756-29766	contribute	_	
132-37	29767-29769	to	_	
132-38	29770-29773	the	_	
132-39	29774-29782	progress	_	
132-40	29783-29785	of	_	
132-41	29786-29797	impairments	_	
132-42	29797-29798	.	_	

#Text=In contrast, studies suggested that patients that remained on stable OMT without relapse to heroin showed an amelioration of structural abnormalities in the superior frontal gyrus, while differences in the middle frontal gyrus, occipital gyrus and cingulate persisted.
133-1	29799-29801	In	_	
133-2	29802-29810	contrast	_	
133-3	29810-29811	,	_	
133-4	29812-29819	studies	_	
133-5	29820-29829	suggested	_	
133-6	29830-29834	that	_	
133-7	29835-29843	patients	_	
133-8	29844-29848	that	_	
133-9	29849-29857	remained	_	
133-10	29858-29860	on	_	
133-11	29861-29867	stable	_	
133-12	29868-29871	OMT	_	
133-13	29872-29879	without	_	
133-14	29880-29887	relapse	_	
133-15	29888-29890	to	_	
133-16	29891-29897	heroin	_	
133-17	29898-29904	showed	_	
133-18	29905-29907	an	_	
133-19	29908-29920	amelioration	_	
133-20	29921-29923	of	_	
133-21	29924-29934	structural	_	
133-22	29935-29948	abnormalities	_	
133-23	29949-29951	in	_	
133-24	29952-29955	the	_	
133-25	29956-29964	superior	_	
133-26	29965-29972	frontal	_	
133-27	29973-29978	gyrus	_	
133-28	29978-29979	,	_	
133-29	29980-29985	while	_	
133-30	29986-29997	differences	_	
133-31	29998-30000	in	_	
133-32	30001-30004	the	_	
133-33	30005-30011	middle	_	
133-34	30012-30019	frontal	_	
133-35	30020-30025	gyrus	_	
133-36	30025-30026	,	_	
133-37	30027-30036	occipital	_	
133-38	30037-30042	gyrus	_	
133-39	30043-30046	and	_	
133-40	30047-30056	cingulate	_	
133-41	30057-30066	persisted	_	
133-42	30066-30067	.	_	

#Text=However, it should be noted that a study in Asian population investigating former heroin-dependent individuals (mean heroin use 20.43 years) without OMT that were in drug rehabilitation and remained abstinent for 5 months from any drugs still showed GM volume deficits in the insula and inferior frontal gyrus.
134-1	30068-30075	However	_	
134-2	30075-30076	,	_	
134-3	30077-30079	it	_	
134-4	30080-30086	should	_	
134-5	30087-30089	be	_	
134-6	30090-30095	noted	_	
134-7	30096-30100	that	_	
134-8	30101-30102	a	_	
134-9	30103-30108	study	_	
134-10	30109-30111	in	_	
134-11	30112-30117	Asian	_	
134-12	30118-30128	population	_	
134-13	30129-30142	investigating	_	
134-14	30143-30149	former	_	
134-15	30150-30166	heroin-dependent	_	
134-16	30167-30178	individuals	_	
134-17	30179-30180	(	_	
134-18	30180-30184	mean	_	
134-19	30185-30191	heroin	_	
134-20	30192-30195	use	_	
134-21	30196-30201	20.43	_	
134-22	30201-30202	 	_	
134-23	30202-30207	years	_	
134-24	30207-30208	)	_	
134-25	30209-30216	without	_	
134-26	30217-30220	OMT	_	
134-27	30221-30225	that	_	
134-28	30226-30230	were	_	
134-29	30231-30233	in	_	
134-30	30234-30238	drug	_	
134-31	30239-30253	rehabilitation	_	
134-32	30254-30257	and	_	
134-33	30258-30266	remained	_	
134-34	30267-30276	abstinent	_	
134-35	30277-30280	for	_	
134-36	30281-30282	5	_	
134-37	30283-30289	months	_	
134-38	30290-30294	from	_	
134-39	30295-30298	any	_	
134-40	30299-30304	drugs	_	
134-41	30305-30310	still	_	
134-42	30311-30317	showed	_	
134-43	30318-30320	GM	_	
134-44	30321-30327	volume	_	
134-45	30328-30336	deficits	_	
134-46	30337-30339	in	_	
134-47	30340-30343	the	_	
134-48	30344-30350	insula	_	
134-49	30351-30354	and	_	
134-50	30355-30363	inferior	_	
134-51	30364-30371	frontal	_	
134-52	30372-30377	gyrus	_	
134-53	30377-30378	.	_	

#Text=Importantly, structural deficits were replicated in opioid-dependent patients with no concurrent use of other psychoactive substances.
135-1	30379-30390	Importantly	_	
135-2	30390-30391	,	_	
135-3	30392-30402	structural	_	
135-4	30403-30411	deficits	_	
135-5	30412-30416	were	_	
135-6	30417-30427	replicated	_	
135-7	30428-30430	in	_	
135-8	30431-30447	opioid-dependent	_	
135-9	30448-30456	patients	_	
135-10	30457-30461	with	_	
135-11	30462-30464	no	_	
135-12	30465-30475	concurrent	_	
135-13	30476-30479	use	_	
135-14	30480-30482	of	_	
135-15	30483-30488	other	_	
135-16	30489-30501	psychoactive	_	
135-17	30502-30512	substances	_	
135-18	30512-30513	.	_	

#Text=This suggests that current or past use of psychoactive substances other than heroine might not be the only relevant factor contributing to GM differences.
136-1	30514-30518	This	_	
136-2	30519-30527	suggests	_	
136-3	30528-30532	that	_	
136-4	30533-30540	current	_	
136-5	30541-30543	or	_	
136-6	30544-30548	past	_	
136-7	30549-30552	use	_	
136-8	30553-30555	of	_	
136-9	30556-30568	psychoactive	_	
136-10	30569-30579	substances	_	
136-11	30580-30585	other	_	
136-12	30586-30590	than	_	
136-13	30591-30598	heroine	_	
136-14	30599-30604	might	_	
136-15	30605-30608	not	_	
136-16	30609-30611	be	_	
136-17	30612-30615	the	_	
136-18	30616-30620	only	_	
136-19	30621-30629	relevant	_	
136-20	30630-30636	factor	_	
136-21	30637-30649	contributing	_	
136-22	30650-30652	to	_	
136-23	30653-30655	GM	_	
136-24	30656-30667	differences	_	
136-25	30667-30668	.	_	

#Text=This is corroborated by the data of our study that show no differences between groups with or without current use of psychoactive substances.
137-1	30669-30673	This	_	
137-2	30674-30676	is	_	
137-3	30677-30689	corroborated	_	
137-4	30690-30692	by	_	
137-5	30693-30696	the	_	
137-6	30697-30701	data	_	
137-7	30702-30704	of	_	
137-8	30705-30708	our	_	
137-9	30709-30714	study	_	
137-10	30715-30719	that	_	
137-11	30720-30724	show	_	
137-12	30725-30727	no	_	
137-13	30728-30739	differences	_	
137-14	30740-30747	between	_	
137-15	30748-30754	groups	_	
137-16	30755-30759	with	_	
137-17	30760-30762	or	_	
137-18	30763-30770	without	_	
137-19	30771-30778	current	_	
137-20	30779-30782	use	_	
137-21	30783-30785	of	_	
137-22	30786-30798	psychoactive	_	
137-23	30799-30809	substances	_	
137-24	30809-30810	.	_	

#Text=Furthermore, differences in social anxiety scores, higher social phobia scores and increased rejection sensitivity could not be explained by absence or presence of comorbid substance consumption.
138-1	30811-30822	Furthermore	_	
138-2	30822-30823	,	_	
138-3	30824-30835	differences	_	
138-4	30836-30838	in	_	
138-5	30839-30845	social	_	
138-6	30846-30853	anxiety	_	
138-7	30854-30860	scores	_	
138-8	30860-30861	,	_	
138-9	30862-30868	higher	_	
138-10	30869-30875	social	_	
138-11	30876-30882	phobia	_	
138-12	30883-30889	scores	_	
138-13	30890-30893	and	_	
138-14	30894-30903	increased	_	
138-15	30904-30913	rejection	_	
138-16	30914-30925	sensitivity	_	
138-17	30926-30931	could	_	
138-18	30932-30935	not	_	
138-19	30936-30938	be	_	
138-20	30939-30948	explained	_	
138-21	30949-30951	by	_	
138-22	30952-30959	absence	_	
138-23	30960-30962	or	_	
138-24	30963-30971	presence	_	
138-25	30972-30974	of	_	
138-26	30975-30983	comorbid	_	
138-27	30984-30993	substance	_	
138-28	30994-31005	consumption	_	
138-29	31005-31006	.	_	

#Text=Based on previous literature, we speculate that the frequent experience of stigmatization and social rejection in OMT patients might have fostered negative expectations and beliefs regarding social interactions and might have triggered social anxiety and social phobia.
139-1	31007-31012	Based	_	
139-2	31013-31015	on	_	
139-3	31016-31024	previous	_	
139-4	31025-31035	literature	_	
139-5	31035-31036	,	_	
139-6	31037-31039	we	_	
139-7	31040-31049	speculate	_	
139-8	31050-31054	that	_	
139-9	31055-31058	the	_	
139-10	31059-31067	frequent	_	
139-11	31068-31078	experience	_	
139-12	31079-31081	of	_	
139-13	31082-31096	stigmatization	_	
139-14	31097-31100	and	_	
139-15	31101-31107	social	_	
139-16	31108-31117	rejection	_	
139-17	31118-31120	in	_	
139-18	31121-31124	OMT	_	
139-19	31125-31133	patients	_	
139-20	31134-31139	might	_	
139-21	31140-31144	have	_	
139-22	31145-31153	fostered	_	
139-23	31154-31162	negative	_	
139-24	31163-31175	expectations	_	
139-25	31176-31179	and	_	
139-26	31180-31187	beliefs	_	
139-27	31188-31197	regarding	_	
139-28	31198-31204	social	_	
139-29	31205-31217	interactions	_	
139-30	31218-31221	and	_	
139-31	31222-31227	might	_	
139-32	31228-31232	have	_	
139-33	31233-31242	triggered	_	
139-34	31243-31249	social	_	
139-35	31250-31257	anxiety	_	
139-36	31258-31261	and	_	
139-37	31262-31268	social	_	
139-38	31269-31275	phobia	_	
139-39	31275-31276	.	_	

#Text=Additionally, current results may implicate that GM volume differences in limbic brain areas might also contribute to an increased social anxiety, social phobia and rejection sensitivity.
140-1	31277-31289	Additionally	_	
140-2	31289-31290	,	_	
140-3	31291-31298	current	_	
140-4	31299-31306	results	_	
140-5	31307-31310	may	_	
140-6	31311-31320	implicate	_	
140-7	31321-31325	that	_	
140-8	31326-31328	GM	_	
140-9	31329-31335	volume	_	
140-10	31336-31347	differences	_	
140-11	31348-31350	in	_	
140-12	31351-31357	limbic	_	
140-13	31358-31363	brain	_	
140-14	31364-31369	areas	_	
140-15	31370-31375	might	_	
140-16	31376-31380	also	_	
140-17	31381-31391	contribute	_	
140-18	31392-31394	to	_	
140-19	31395-31397	an	_	
140-20	31398-31407	increased	_	
140-21	31408-31414	social	_	
140-22	31415-31422	anxiety	_	
140-23	31422-31423	,	_	
140-24	31424-31430	social	_	
140-25	31431-31437	phobia	_	
140-26	31438-31441	and	_	
140-27	31442-31451	rejection	_	
140-28	31452-31463	sensitivity	_	
140-29	31463-31464	.	_	

#Text=Limitations
#Text=Current data do not allow statements about the chronology and causality of the development of opioid dependence and GM volume deficits.
141-1	31465-31476	Limitations	_	
141-2	31477-31484	Current	_	
141-3	31485-31489	data	_	
141-4	31490-31492	do	_	
141-5	31493-31496	not	_	
141-6	31497-31502	allow	_	
141-7	31503-31513	statements	_	
141-8	31514-31519	about	_	
141-9	31520-31523	the	_	
141-10	31524-31534	chronology	_	
141-11	31535-31538	and	_	
141-12	31539-31548	causality	_	
141-13	31549-31551	of	_	
141-14	31552-31555	the	_	
141-15	31556-31567	development	_	
141-16	31568-31570	of	_	
141-17	31571-31577	opioid	_	
141-18	31578-31588	dependence	_	
141-19	31589-31592	and	_	
141-20	31593-31595	GM	_	
141-21	31596-31602	volume	_	
141-22	31603-31611	deficits	_	
141-23	31611-31612	.	_	

#Text=However, based on previous studies that established a negative association between heroin intake and both brain perfusion and brain metabolism, and associations between duration of heroin abuse and extent of GM deficits, it seems likely that heroin consumption contributed to the deficits that were found in the current study.
142-1	31613-31620	However	_	
142-2	31620-31621	,	_	
142-3	31622-31627	based	_	
142-4	31628-31630	on	_	
142-5	31631-31639	previous	_	
142-6	31640-31647	studies	_	
142-7	31648-31652	that	_	
142-8	31653-31664	established	_	
142-9	31665-31666	a	_	
142-10	31667-31675	negative	_	
142-11	31676-31687	association	_	
142-12	31688-31695	between	_	
142-13	31696-31702	heroin	_	
142-14	31703-31709	intake	_	
142-15	31710-31713	and	_	
142-16	31714-31718	both	_	
142-17	31719-31724	brain	_	
142-18	31725-31734	perfusion	_	
142-19	31735-31738	and	_	
142-20	31739-31744	brain	_	
142-21	31745-31755	metabolism	_	
142-22	31755-31756	,	_	
142-23	31757-31760	and	_	
142-24	31761-31773	associations	_	
142-25	31774-31781	between	_	
142-26	31782-31790	duration	_	
142-27	31791-31793	of	_	
142-28	31794-31800	heroin	_	
142-29	31801-31806	abuse	_	
142-30	31807-31810	and	_	
142-31	31811-31817	extent	_	
142-32	31818-31820	of	_	
142-33	31821-31823	GM	_	
142-34	31824-31832	deficits	_	
142-35	31832-31833	,	_	
142-36	31834-31836	it	_	
142-37	31837-31842	seems	_	
142-38	31843-31849	likely	_	
142-39	31850-31854	that	_	
142-40	31855-31861	heroin	_	
142-41	31862-31873	consumption	_	
142-42	31874-31885	contributed	_	
142-43	31886-31888	to	_	
142-44	31889-31892	the	_	
142-45	31893-31901	deficits	_	
142-46	31902-31906	that	_	
142-47	31907-31911	were	_	
142-48	31912-31917	found	_	
142-49	31918-31920	in	_	
142-50	31921-31924	the	_	
142-51	31925-31932	current	_	
142-52	31933-31938	study	_	
142-53	31938-31939	.	_	

#Text=In addition, the temporal connection between social rejection sensitivity and social anxiety and opioid dependence could not be determined based on current data.
143-1	31940-31942	In	_	
143-2	31943-31951	addition	_	
143-3	31951-31952	,	_	
143-4	31953-31956	the	_	
143-5	31957-31965	temporal	_	
143-6	31966-31976	connection	_	
143-7	31977-31984	between	_	
143-8	31985-31991	social	_	
143-9	31992-32001	rejection	_	
143-10	32002-32013	sensitivity	_	
143-11	32014-32017	and	_	
143-12	32018-32024	social	_	
143-13	32025-32032	anxiety	_	
143-14	32033-32036	and	_	
143-15	32037-32043	opioid	_	
143-16	32044-32054	dependence	_	
143-17	32055-32060	could	_	
143-18	32061-32064	not	_	
143-19	32065-32067	be	_	
143-20	32068-32078	determined	_	
143-21	32079-32084	based	_	
143-22	32085-32087	on	_	
143-23	32088-32095	current	_	
143-24	32096-32100	data	_	
143-25	32100-32101	.	_	

#Text=We speculate that there is a bidirectional interdependency between learning history and structural deficits in OMT patients that cannot be disentangled, based on the correlational design of the current study.
144-1	32102-32104	We	_	
144-2	32105-32114	speculate	_	
144-3	32115-32119	that	_	
144-4	32120-32125	there	_	
144-5	32126-32128	is	_	
144-6	32129-32130	a	_	
144-7	32131-32144	bidirectional	_	
144-8	32145-32160	interdependency	_	
144-9	32161-32168	between	_	
144-10	32169-32177	learning	_	
144-11	32178-32185	history	_	
144-12	32186-32189	and	_	
144-13	32190-32200	structural	_	
144-14	32201-32209	deficits	_	
144-15	32210-32212	in	_	
144-16	32213-32216	OMT	_	
144-17	32217-32225	patients	_	
144-18	32226-32230	that	_	
144-19	32231-32237	cannot	_	
144-20	32238-32240	be	_	
144-21	32241-32253	disentangled	_	
144-22	32253-32254	,	_	
144-23	32255-32260	based	_	
144-24	32261-32263	on	_	
144-25	32264-32267	the	_	
144-26	32268-32281	correlational	_	
144-27	32282-32288	design	_	
144-28	32289-32291	of	_	
144-29	32292-32295	the	_	
144-30	32296-32303	current	_	
144-31	32304-32309	study	_	
144-32	32309-32310	.	_	

#Text=Further research is warranted, in order to determine the relative contribution and temporal alignment of both factors.
145-1	32311-32318	Further	_	
145-2	32319-32327	research	_	
145-3	32328-32330	is	_	
145-4	32331-32340	warranted	_	
145-5	32340-32341	,	_	
145-6	32342-32344	in	_	
145-7	32345-32350	order	_	
145-8	32351-32353	to	_	
145-9	32354-32363	determine	_	
145-10	32364-32367	the	_	
145-11	32368-32376	relative	_	
145-12	32377-32389	contribution	_	
145-13	32390-32393	and	_	
145-14	32394-32402	temporal	_	
145-15	32403-32412	alignment	_	
145-16	32413-32415	of	_	
145-17	32416-32420	both	_	
145-18	32421-32428	factors	_	
145-19	32428-32429	.	_	

#Text=However, even without this information, the association between the extent of social rejection sensitivity and GM volume reductions in brain regions that are prominently involved in social cognition and emotion processing seems relevant and should be considered in treatment.
146-1	32430-32437	However	_	
146-2	32437-32438	,	_	
146-3	32439-32443	even	_	
146-4	32444-32451	without	_	
146-5	32452-32456	this	_	
146-6	32457-32468	information	_	
146-7	32468-32469	,	_	
146-8	32470-32473	the	_	
146-9	32474-32485	association	_	
146-10	32486-32493	between	_	
146-11	32494-32497	the	_	
146-12	32498-32504	extent	_	
146-13	32505-32507	of	_	
146-14	32508-32514	social	_	
146-15	32515-32524	rejection	_	
146-16	32525-32536	sensitivity	_	
146-17	32537-32540	and	_	
146-18	32541-32543	GM	_	
146-19	32544-32550	volume	_	
146-20	32551-32561	reductions	_	
146-21	32562-32564	in	_	
146-22	32565-32570	brain	_	
146-23	32571-32578	regions	_	
146-24	32579-32583	that	_	
146-25	32584-32587	are	_	
146-26	32588-32599	prominently	_	
146-27	32600-32608	involved	_	
146-28	32609-32611	in	_	
146-29	32612-32618	social	_	
146-30	32619-32628	cognition	_	
146-31	32629-32632	and	_	
146-32	32633-32640	emotion	_	
146-33	32641-32651	processing	_	
146-34	32652-32657	seems	_	
146-35	32658-32666	relevant	_	
146-36	32667-32670	and	_	
146-37	32671-32677	should	_	
146-38	32678-32680	be	_	
146-39	32681-32691	considered	_	
146-40	32692-32694	in	_	
146-41	32695-32704	treatment	_	
146-42	32704-32705	.	_	

#Text=A limitation of the current study is the small sample size that might have limited the possibility to detect smaller effects (e.g. associations between right insula GM volume and social perception).
147-1	32706-32707	A	_	
147-2	32708-32718	limitation	_	
147-3	32719-32721	of	_	
147-4	32722-32725	the	_	
147-5	32726-32733	current	_	
147-6	32734-32739	study	_	
147-7	32740-32742	is	_	
147-8	32743-32746	the	_	
147-9	32747-32752	small	_	
147-10	32753-32759	sample	_	
147-11	32760-32764	size	_	
147-12	32765-32769	that	_	
147-13	32770-32775	might	_	
147-14	32776-32780	have	_	
147-15	32781-32788	limited	_	
147-16	32789-32792	the	_	
147-17	32793-32804	possibility	_	
147-18	32805-32807	to	_	
147-19	32808-32814	detect	_	
147-20	32815-32822	smaller	_	
147-21	32823-32830	effects	_	
147-22	32831-32832	(	_	
147-23	32832-32835	e.g	_	
147-24	32835-32836	.	_	
147-25	32837-32849	associations	_	
147-26	32850-32857	between	_	
147-27	32858-32863	right	_	
147-28	32864-32870	insula	_	
147-29	32871-32873	GM	_	
147-30	32874-32880	volume	_	
147-31	32881-32884	and	_	
147-32	32885-32891	social	_	
147-33	32892-32902	perception	_	
147-34	32902-32903	)	_	
147-35	32903-32904	.	_	

#Text=Additionally, the consideration of education level (which could be regarded as proxy for the socioeconomic status) as covariate in the group comparisons of psychometric data rendered some of the group differences on the SIAS, SPS, RSQ and BSI scales insignificant.
148-1	32905-32917	Additionally	_	
148-2	32917-32918	,	_	
148-3	32919-32922	the	_	
148-4	32923-32936	consideration	_	
148-5	32937-32939	of	_	
148-6	32940-32949	education	_	
148-7	32950-32955	level	_	
148-8	32956-32957	(	_	
148-9	32957-32962	which	_	
148-10	32963-32968	could	_	
148-11	32969-32971	be	_	
148-12	32972-32980	regarded	_	
148-13	32981-32983	as	_	
148-14	32984-32989	proxy	_	
148-15	32990-32993	for	_	
148-16	32994-32997	the	_	
148-17	32998-33011	socioeconomic	_	
148-18	33012-33018	status	_	
148-19	33018-33019	)	_	
148-20	33020-33022	as	_	
148-21	33023-33032	covariate	_	
148-22	33033-33035	in	_	
148-23	33036-33039	the	_	
148-24	33040-33045	group	_	
148-25	33046-33057	comparisons	_	
148-26	33058-33060	of	_	
148-27	33061-33073	psychometric	_	
148-28	33074-33078	data	_	
148-29	33079-33087	rendered	_	
148-30	33088-33092	some	_	
148-31	33093-33095	of	_	
148-32	33096-33099	the	_	
148-33	33100-33105	group	_	
148-34	33106-33117	differences	_	
148-35	33118-33120	on	_	
148-36	33121-33124	the	_	
148-37	33125-33129	SIAS	_	
148-38	33129-33130	,	_	
148-39	33131-33134	SPS	_	
148-40	33134-33135	,	_	
148-41	33136-33139	RSQ	_	
148-42	33140-33143	and	_	
148-43	33144-33147	BSI	_	
148-44	33148-33154	scales	_	
148-45	33155-33168	insignificant	_	
148-46	33168-33169	.	_	

#Text=This suggests that socioeconomic factors contribute significantly to the observed differences between patients and controls.
149-1	33170-33174	This	_	
149-2	33175-33183	suggests	_	
149-3	33184-33188	that	_	
149-4	33189-33202	socioeconomic	_	
149-5	33203-33210	factors	_	
149-6	33211-33221	contribute	_	
149-7	33222-33235	significantly	_	
149-8	33236-33238	to	_	
149-9	33239-33242	the	_	
149-10	33243-33251	observed	_	
149-11	33252-33263	differences	_	
149-12	33264-33271	between	_	
149-13	33272-33280	patients	_	
149-14	33281-33284	and	_	
149-15	33285-33293	controls	_	
149-16	33293-33294	.	_	

#Text=This suggests that not patient status per se determines the extent of social rejection sensitivity and anxiety but that socioeconomic status—independent of group—might account for a relevant proportion of the inter-individual differences.
150-1	33295-33299	This	_	
150-2	33300-33308	suggests	_	
150-3	33309-33313	that	_	
150-4	33314-33317	not	_	
150-5	33318-33325	patient	_	
150-6	33326-33332	status	_	
150-7	33333-33336	per	_	
150-8	33337-33339	se	_	
150-9	33340-33350	determines	_	
150-10	33351-33354	the	_	
150-11	33355-33361	extent	_	
150-12	33362-33364	of	_	
150-13	33365-33371	social	_	
150-14	33372-33381	rejection	_	
150-15	33382-33393	sensitivity	_	
150-16	33394-33397	and	_	
150-17	33398-33405	anxiety	_	
150-18	33406-33409	but	_	
150-19	33410-33414	that	_	
150-20	33415-33428	socioeconomic	_	
150-21	33429-33447	status—independent	_	
150-22	33448-33450	of	_	
150-23	33451-33462	group—might	_	
150-24	33463-33470	account	_	
150-25	33471-33474	for	_	
150-26	33475-33476	a	_	
150-27	33477-33485	relevant	_	
150-28	33486-33496	proportion	_	
150-29	33497-33499	of	_	
150-30	33500-33503	the	_	
150-31	33504-33520	inter-individual	_	
150-32	33521-33532	differences	_	
150-33	33532-33533	.	_	

#Text=While inferences should be drawn very carefully, the finding points toward the relevance of therapeutic strategies that aim at social rehabilitation of patients, which might contribute to an amelioration of social rejection sensitivity and social anxiety.
151-1	33534-33539	While	_	
151-2	33540-33550	inferences	_	
151-3	33551-33557	should	_	
151-4	33558-33560	be	_	
151-5	33561-33566	drawn	_	
151-6	33567-33571	very	_	
151-7	33572-33581	carefully	_	
151-8	33581-33582	,	_	
151-9	33583-33586	the	_	
151-10	33587-33594	finding	_	
151-11	33595-33601	points	_	
151-12	33602-33608	toward	_	
151-13	33609-33612	the	_	
151-14	33613-33622	relevance	_	
151-15	33623-33625	of	_	
151-16	33626-33637	therapeutic	_	
151-17	33638-33648	strategies	_	
151-18	33649-33653	that	_	
151-19	33654-33657	aim	_	
151-20	33658-33660	at	_	
151-21	33661-33667	social	_	
151-22	33668-33682	rehabilitation	_	
151-23	33683-33685	of	_	
151-24	33686-33694	patients	_	
151-25	33694-33695	,	_	
151-26	33696-33701	which	_	
151-27	33702-33707	might	_	
151-28	33708-33718	contribute	_	
151-29	33719-33721	to	_	
151-30	33722-33724	an	_	
151-31	33725-33737	amelioration	_	
151-32	33738-33740	of	_	
151-33	33741-33747	social	_	
151-34	33748-33757	rejection	_	
151-35	33758-33769	sensitivity	_	
151-36	33770-33773	and	_	
151-37	33774-33780	social	_	
151-38	33781-33788	anxiety	_	
151-39	33788-33789	.	_	

#Text=The control of current partnership status in the group comparisons did not change the significance of most results (RSQ, SPS, BSI) with the exception of the SIAS scale that did not show significant difference after controlling for partnership status.
152-1	33790-33793	The	_	
152-2	33794-33801	control	_	
152-3	33802-33804	of	_	
152-4	33805-33812	current	_	
152-5	33813-33824	partnership	_	
152-6	33825-33831	status	_	
152-7	33832-33834	in	_	
152-8	33835-33838	the	_	
152-9	33839-33844	group	_	
152-10	33845-33856	comparisons	_	
152-11	33857-33860	did	_	
152-12	33861-33864	not	_	
152-13	33865-33871	change	_	
152-14	33872-33875	the	_	
152-15	33876-33888	significance	_	
152-16	33889-33891	of	_	
152-17	33892-33896	most	_	
152-18	33897-33904	results	_	
152-19	33905-33906	(	_	
152-20	33906-33909	RSQ	_	
152-21	33909-33910	,	_	
152-22	33911-33914	SPS	_	
152-23	33914-33915	,	_	
152-24	33916-33919	BSI	_	
152-25	33919-33920	)	_	
152-26	33921-33925	with	_	
152-27	33926-33929	the	_	
152-28	33930-33939	exception	_	
152-29	33940-33942	of	_	
152-30	33943-33946	the	_	
152-31	33947-33951	SIAS	_	
152-32	33952-33957	scale	_	
152-33	33958-33962	that	_	
152-34	33963-33966	did	_	
152-35	33967-33970	not	_	
152-36	33971-33975	show	_	
152-37	33976-33987	significant	_	
152-38	33988-33998	difference	_	
152-39	33999-34004	after	_	
152-40	34005-34016	controlling	_	
152-41	34017-34020	for	_	
152-42	34021-34032	partnership	_	
152-43	34033-34039	status	_	
152-44	34039-34040	.	_	

#Text=While the current sample showed a relevant consumption of substances other than methadone and buprenorphine (e.g. benzodiazepines), the replication of GM volume deficits in brain areas that were implicated by recent meta-analyses (e.g. insula and inferior frontal gyrus) and the fact that statistical correction of concurrent substance use did not change significance of these results support the notion that the current sample might still reflect a representative sample of OMT patients.
153-1	34041-34046	While	_	
153-2	34047-34050	the	_	
153-3	34051-34058	current	_	
153-4	34059-34065	sample	_	
153-5	34066-34072	showed	_	
153-6	34073-34074	a	_	
153-7	34075-34083	relevant	_	
153-8	34084-34095	consumption	_	
153-9	34096-34098	of	_	
153-10	34099-34109	substances	_	
153-11	34110-34115	other	_	
153-12	34116-34120	than	_	
153-13	34121-34130	methadone	_	
153-14	34131-34134	and	_	
153-15	34135-34148	buprenorphine	_	
153-16	34149-34150	(	_	
153-17	34150-34153	e.g	_	
153-18	34153-34154	.	_	
153-19	34155-34170	benzodiazepines	_	
153-20	34170-34171	)	_	
153-21	34171-34172	,	_	
153-22	34173-34176	the	_	
153-23	34177-34188	replication	_	
153-24	34189-34191	of	_	
153-25	34192-34194	GM	_	
153-26	34195-34201	volume	_	
153-27	34202-34210	deficits	_	
153-28	34211-34213	in	_	
153-29	34214-34219	brain	_	
153-30	34220-34225	areas	_	
153-31	34226-34230	that	_	
153-32	34231-34235	were	_	
153-33	34236-34246	implicated	_	
153-34	34247-34249	by	_	
153-35	34250-34256	recent	_	
153-36	34257-34270	meta-analyses	_	
153-37	34271-34272	(	_	
153-38	34272-34275	e.g	_	
153-39	34275-34276	.	_	
153-40	34277-34283	insula	_	
153-41	34284-34287	and	_	
153-42	34288-34296	inferior	_	
153-43	34297-34304	frontal	_	
153-44	34305-34310	gyrus	_	
153-45	34310-34311	)	_	
153-46	34312-34315	and	_	
153-47	34316-34319	the	_	
153-48	34320-34324	fact	_	
153-49	34325-34329	that	_	
153-50	34330-34341	statistical	_	
153-51	34342-34352	correction	_	
153-52	34353-34355	of	_	
153-53	34356-34366	concurrent	_	
153-54	34367-34376	substance	_	
153-55	34377-34380	use	_	
153-56	34381-34384	did	_	
153-57	34385-34388	not	_	
153-58	34389-34395	change	_	
153-59	34396-34408	significance	_	
153-60	34409-34411	of	_	
153-61	34412-34417	these	_	
153-62	34418-34425	results	_	
153-63	34426-34433	support	_	
153-64	34434-34437	the	_	
153-65	34438-34444	notion	_	
153-66	34445-34449	that	_	
153-67	34450-34453	the	_	
153-68	34454-34461	current	_	
153-69	34462-34468	sample	_	
153-70	34469-34474	might	_	
153-71	34475-34480	still	_	
153-72	34481-34488	reflect	_	
153-73	34489-34490	a	_	
153-74	34491-34505	representative	_	
153-75	34506-34512	sample	_	
153-76	34513-34515	of	_	
153-77	34516-34519	OMT	_	
153-78	34520-34528	patients	_	
153-79	34528-34529	.	_	

#Text=Some patients presented with positive HCV antibodies.
154-1	34530-34534	Some	_	
154-2	34535-34543	patients	_	
154-3	34544-34553	presented	_	
154-4	34554-34558	with	_	
154-5	34559-34567	positive	_	
154-6	34568-34571	HCV	_	
154-7	34572-34582	antibodies	_	
154-8	34582-34583	.	_	

#Text=Previous studies showed that HCV-infected patients displayed GM atrophy in the bilateral insula and thalamus and increasing atrophy over a 7-year follow-up in the left amygdala and left parahippocampal regions.
155-1	34584-34592	Previous	_	
155-2	34593-34600	studies	_	
155-3	34601-34607	showed	_	
155-4	34608-34612	that	_	
155-5	34613-34625	HCV-infected	_	
155-6	34626-34634	patients	_	
155-7	34635-34644	displayed	_	
155-8	34645-34647	GM	_	
155-9	34648-34655	atrophy	_	
155-10	34656-34658	in	_	
155-11	34659-34662	the	_	
155-12	34663-34672	bilateral	_	
155-13	34673-34679	insula	_	
155-14	34680-34683	and	_	
155-15	34684-34692	thalamus	_	
155-16	34693-34696	and	_	
155-17	34697-34707	increasing	_	
155-18	34708-34715	atrophy	_	
155-19	34716-34720	over	_	
155-20	34721-34722	a	_	
155-21	34723-34724	7	_	
155-22	34724-34725	-	_	
155-23	34725-34729	year	_	
155-24	34730-34739	follow-up	_	
155-25	34740-34742	in	_	
155-26	34743-34746	the	_	
155-27	34747-34751	left	_	
155-28	34752-34760	amygdala	_	
155-29	34761-34764	and	_	
155-30	34765-34769	left	_	
155-31	34770-34785	parahippocampal	_	
155-32	34786-34793	regions	_	
155-33	34793-34794	.	_	

#Text=While we cannot rule out the possibility that HCV infection might have contributed to smaller GM volume in the OMT patient sample, exploratory two-sample t-test did not show a significant effect of HCV antibody status on any GM volume measure.
156-1	34795-34800	While	_	
156-2	34801-34803	we	_	
156-3	34804-34810	cannot	_	
156-4	34811-34815	rule	_	
156-5	34816-34819	out	_	
156-6	34820-34823	the	_	
156-7	34824-34835	possibility	_	
156-8	34836-34840	that	_	
156-9	34841-34844	HCV	_	
156-10	34845-34854	infection	_	
156-11	34855-34860	might	_	
156-12	34861-34865	have	_	
156-13	34866-34877	contributed	_	
156-14	34878-34880	to	_	
156-15	34881-34888	smaller	_	
156-16	34889-34891	GM	_	
156-17	34892-34898	volume	_	
156-18	34899-34901	in	_	
156-19	34902-34905	the	_	
156-20	34906-34909	OMT	_	
156-21	34910-34917	patient	_	
156-22	34918-34924	sample	_	
156-23	34924-34925	,	_	
156-24	34926-34937	exploratory	_	
156-25	34938-34948	two-sample	_	
156-26	34949-34955	t-test	_	
156-27	34956-34959	did	_	
156-28	34960-34963	not	_	
156-29	34964-34968	show	_	
156-30	34969-34970	a	_	
156-31	34971-34982	significant	_	
156-32	34983-34989	effect	_	
156-33	34990-34992	of	_	
156-34	34993-34996	HCV	_	
156-35	34997-35005	antibody	_	
156-36	35006-35012	status	_	
156-37	35013-35015	on	_	
156-38	35016-35019	any	_	
156-39	35020-35022	GM	_	
156-40	35023-35029	volume	_	
156-41	35030-35037	measure	_	
156-42	35037-35038	.	_	

#Text=Additionally, all patients that were included in the current analyses did not present with suprathreshold HCV load at the time of the experiment.
157-1	35039-35051	Additionally	_	
157-2	35051-35052	,	_	
157-3	35053-35056	all	_	
157-4	35057-35065	patients	_	
157-5	35066-35070	that	_	
157-6	35071-35075	were	_	
157-7	35076-35084	included	_	
157-8	35085-35087	in	_	
157-9	35088-35091	the	_	
157-10	35092-35099	current	_	
157-11	35100-35108	analyses	_	
157-12	35109-35112	did	_	
157-13	35113-35116	not	_	
157-14	35117-35124	present	_	
157-15	35125-35129	with	_	
157-16	35130-35144	suprathreshold	_	
157-17	35145-35148	HCV	_	
157-18	35149-35153	load	_	
157-19	35154-35156	at	_	
157-20	35157-35160	the	_	
157-21	35161-35165	time	_	
157-22	35166-35168	of	_	
157-23	35169-35172	the	_	
157-24	35173-35183	experiment	_	
157-25	35183-35184	.	_	

#Text=Conclusion
#Text=In summary, current data show GM volume reductions in the bilateral insulae and bilateral inferior frontal gyri in OMT patients.
158-1	35185-35195	Conclusion	_	
158-2	35196-35198	In	_	
158-3	35199-35206	summary	_	
158-4	35206-35207	,	_	
158-5	35208-35215	current	_	
158-6	35216-35220	data	_	
158-7	35221-35225	show	_	
158-8	35226-35228	GM	_	
158-9	35229-35235	volume	_	
158-10	35236-35246	reductions	_	
158-11	35247-35249	in	_	
158-12	35250-35253	the	_	
158-13	35254-35263	bilateral	_	
158-14	35264-35271	insulae	_	
158-15	35272-35275	and	_	
158-16	35276-35285	bilateral	_	
158-17	35286-35294	inferior	_	
158-18	35295-35302	frontal	_	
158-19	35303-35307	gyri	_	
158-20	35308-35310	in	_	
158-21	35311-35314	OMT	_	
158-22	35315-35323	patients	_	
158-23	35323-35324	.	_	

#Text=Especially the GM volume in the left insula was related to lower subjective feelings of inclusion during a social ostracism ‘Cyberball’ task and in addition associated with increased social rejection sensitivity, social anxiety and social phobia.
159-1	35325-35335	Especially	_	
159-2	35336-35339	the	_	
159-3	35340-35342	GM	_	
159-4	35343-35349	volume	_	
159-5	35350-35352	in	_	
159-6	35353-35356	the	_	
159-7	35357-35361	left	_	
159-8	35362-35368	insula	_	
159-9	35369-35372	was	_	
159-10	35373-35380	related	_	
159-11	35381-35383	to	_	
159-12	35384-35389	lower	_	
159-13	35390-35400	subjective	_	
159-14	35401-35409	feelings	_	
159-15	35410-35412	of	_	
159-16	35413-35422	inclusion	_	
159-17	35423-35429	during	_	
159-18	35430-35431	a	_	
159-19	35432-35438	social	_	
159-20	35439-35448	ostracism	_	
159-21	35449-35450	‘	_	
159-22	35450-35459	Cyberball	_	
159-23	35459-35460	’	_	
159-24	35461-35465	task	_	
159-25	35466-35469	and	_	
159-26	35470-35472	in	_	
159-27	35473-35481	addition	_	
159-28	35482-35492	associated	_	
159-29	35493-35497	with	_	
159-30	35498-35507	increased	_	
159-31	35508-35514	social	_	
159-32	35515-35524	rejection	_	
159-33	35525-35536	sensitivity	_	
159-34	35536-35537	,	_	
159-35	35538-35544	social	_	
159-36	35545-35552	anxiety	_	
159-37	35553-35556	and	_	
159-38	35557-35563	social	_	
159-39	35564-35570	phobia	_	
159-40	35570-35571	.	_	

#Text=As negative social interaction is a potential trigger for relapse, this is a relevant finding, and patients might benefit from therapeutic strategies that aim at enhancing social coping skills by means of how to cope with negative social feedback.
160-1	35572-35574	As	_	
160-2	35575-35583	negative	_	
160-3	35584-35590	social	_	
160-4	35591-35602	interaction	_	
160-5	35603-35605	is	_	
160-6	35606-35607	a	_	
160-7	35608-35617	potential	_	
160-8	35618-35625	trigger	_	
160-9	35626-35629	for	_	
160-10	35630-35637	relapse	_	
160-11	35637-35638	,	_	
160-12	35639-35643	this	_	
160-13	35644-35646	is	_	
160-14	35647-35648	a	_	
160-15	35649-35657	relevant	_	
160-16	35658-35665	finding	_	
160-17	35665-35666	,	_	
160-18	35667-35670	and	_	
160-19	35671-35679	patients	_	
160-20	35680-35685	might	_	
160-21	35686-35693	benefit	_	
160-22	35694-35698	from	_	
160-23	35699-35710	therapeutic	_	
160-24	35711-35721	strategies	_	
160-25	35722-35726	that	_	
160-26	35727-35730	aim	_	
160-27	35731-35733	at	_	
160-28	35734-35743	enhancing	_	
160-29	35744-35750	social	_	
160-30	35751-35757	coping	_	
160-31	35758-35764	skills	_	
160-32	35765-35767	by	_	
160-33	35768-35773	means	_	
160-34	35774-35776	of	_	
160-35	35777-35780	how	_	
160-36	35781-35783	to	_	
160-37	35784-35788	cope	_	
160-38	35789-35793	with	_	
160-39	35794-35802	negative	_	
160-40	35803-35809	social	_	
160-41	35810-35818	feedback	_	
160-42	35818-35819	.	_	

#Text=Although conclusions on causality cannot be drawn from our findings, they underline the need for additional support of OMT patients.
161-1	35820-35828	Although	_	
161-2	35829-35840	conclusions	_	
161-3	35841-35843	on	_	
161-4	35844-35853	causality	_	
161-5	35854-35860	cannot	_	
161-6	35861-35863	be	_	
161-7	35864-35869	drawn	_	
161-8	35870-35874	from	_	
161-9	35875-35878	our	_	
161-10	35879-35887	findings	_	
161-11	35887-35888	,	_	
161-12	35889-35893	they	_	
161-13	35894-35903	underline	_	
161-14	35904-35907	the	_	
161-15	35908-35912	need	_	
161-16	35913-35916	for	_	
161-17	35917-35927	additional	_	
161-18	35928-35935	support	_	
161-19	35936-35938	of	_	
161-20	35939-35942	OMT	_	
161-21	35943-35951	patients	_	
161-22	35951-35952	.	_	

#Text=Funding
#Text=This work was supported by a grant from the Deutsche Forschungsgemeinschaft (DFG Cooperative Research Center TRR 265/1 2019).
162-1	35953-35960	Funding	_	
162-2	35961-35965	This	_	
162-3	35966-35970	work	_	
162-4	35971-35974	was	_	
162-5	35975-35984	supported	_	
162-6	35985-35987	by	_	
162-7	35988-35989	a	_	
162-8	35990-35995	grant	_	
162-9	35996-36000	from	_	
162-10	36001-36004	the	_	
162-11	36005-36013	Deutsche	_	
162-12	36014-36036	Forschungsgemeinschaft	_	
162-13	36037-36038	(	_	
162-14	36038-36041	DFG	_	
162-15	36042-36053	Cooperative	_	
162-16	36054-36062	Research	_	
162-17	36063-36069	Center	_	
162-18	36070-36073	TRR	_	
162-19	36074-36077	265	_	
162-20	36077-36078	/	_	
162-21	36078-36079	1	_	
162-22	36080-36084	2019	_	
162-23	36084-36085	)	_	
162-24	36085-36086	.	_	

#Text=C.V. was a consultant to and received honoraria from Indivior and Mundipharma.
163-1	36087-36090	C.V	_	
163-2	36090-36091	.	_	
163-3	36092-36095	was	_	
163-4	36096-36097	a	_	
163-5	36098-36108	consultant	_	
163-6	36109-36111	to	_	
163-7	36112-36115	and	_	
163-8	36116-36124	received	_	
163-9	36125-36134	honoraria	_	
163-10	36135-36139	from	_	
163-11	36140-36148	Indivior	_	
163-12	36149-36152	and	_	
163-13	36153-36164	Mundipharma	_	
163-14	36164-36165	.	_	

#Text=Outside the submitted work, D.H. received honoraria for participating in advisory boards of the pharmaceutical companies Indivior, Camurus and Servier.
164-1	36166-36173	Outside	_	
164-2	36174-36177	the	_	
164-3	36178-36187	submitted	_	
164-4	36188-36192	work	_	
164-5	36192-36193	,	_	
164-6	36194-36197	D.H	_	
164-7	36197-36198	.	_	
164-8	36199-36207	received	_	
164-9	36208-36217	honoraria	_	
164-10	36218-36221	for	_	
164-11	36222-36235	participating	_	
164-12	36236-36238	in	_	
164-13	36239-36247	advisory	_	
164-14	36248-36254	boards	_	
164-15	36255-36257	of	_	
164-16	36258-36261	the	_	
164-17	36262-36276	pharmaceutical	_	
164-18	36277-36286	companies	_	
164-19	36287-36295	Indivior	_	
164-20	36295-36296	,	_	
164-21	36297-36304	Camurus	_	
164-22	36305-36308	and	_	
164-23	36309-36316	Servier	_	
164-24	36316-36317	.	_	

#Text=Conflict of interest
#Text=None declared.
165-1	36318-36326	Conflict	_	
165-2	36327-36329	of	_	
165-3	36330-36338	interest	_	
165-4	36339-36343	None	_	
165-5	36344-36352	declared	_	
165-6	36352-36353	.	_	

#Text=Authors contribution
#Text=D.H., F.K., S.L. and S.V.K. were responsible for study design.
166-1	36354-36361	Authors	_	
166-2	36362-36374	contribution	_	
166-3	36375-36378	D.H	_	
166-4	36378-36379	.	_	
166-5	36379-36380	,	_	
166-6	36381-36384	F.K	_	
166-7	36384-36385	.	_	
166-8	36385-36386	,	_	
166-9	36387-36390	S.L	_	
166-10	36390-36391	.	_	
166-11	36392-36395	and	_	
166-12	36396-36401	S.V.K	_	
166-13	36401-36402	.	_	
166-14	36403-36407	were	_	
166-15	36408-36419	responsible	_	
166-16	36420-36423	for	_	
166-17	36424-36429	study	_	
166-18	36430-36436	design	_	
166-19	36436-36437	.	_	

#Text=All authors contributed to the revision of the study concept.
167-1	36438-36441	All	_	
167-2	36442-36449	authors	_	
167-3	36450-36461	contributed	_	
167-4	36462-36464	to	_	
167-5	36465-36468	the	_	
167-6	36469-36477	revision	_	
167-7	36478-36480	of	_	
167-8	36481-36484	the	_	
167-9	36485-36490	study	_	
167-10	36491-36498	concept	_	
167-11	36498-36499	.	_	

#Text=C.V., P.B. and D.K. performed clinical experiments.
168-1	36500-36503	C.V	_	
168-2	36503-36504	.	_	
168-3	36504-36505	,	_	
168-4	36506-36509	P.B	_	
168-5	36509-36510	.	_	
168-6	36511-36514	and	_	
168-7	36515-36518	D.K	_	
168-8	36518-36519	.	_	
168-9	36520-36529	performed	_	
168-10	36530-36538	clinical	_	
168-11	36539-36550	experiments	_	
168-12	36550-36551	.	_	

#Text=P.B., M.B., D.K., D.H., S.K. and S.V.K. analyzed the data.
169-1	36552-36555	P.B	_	
169-2	36555-36556	.	_	
169-3	36556-36557	,	_	
169-4	36558-36561	M.B	_	
169-5	36561-36562	.	_	
169-6	36562-36563	,	_	
169-7	36564-36567	D.K	_	
169-8	36567-36568	.	_	
169-9	36568-36569	,	_	
169-10	36570-36573	D.H	_	
169-11	36573-36574	.	_	
169-12	36574-36575	,	_	
169-13	36576-36579	S.K	_	
169-14	36579-36580	.	_	
169-15	36581-36584	and	_	
169-16	36585-36590	S.V.K	_	
169-17	36590-36591	.	_	
169-18	36592-36600	analyzed	_	
169-19	36601-36604	the	_	
169-20	36605-36609	data	_	
169-21	36609-36610	.	_	

#Text=P.B., U.F., D.H., M.B., F.K., S.V.K., S.K., S.L. and M.B. drafted the manuscript.
170-1	36611-36614	P.B	_	
170-2	36614-36615	.	_	
170-3	36615-36616	,	_	
170-4	36617-36620	U.F	_	
170-5	36620-36621	.	_	
170-6	36621-36622	,	_	
170-7	36623-36626	D.H	_	
170-8	36626-36627	.	_	
170-9	36627-36628	,	_	
170-10	36629-36632	M.B	_	
170-11	36632-36633	.	_	
170-12	36633-36634	,	_	
170-13	36635-36638	F.K	_	
170-14	36638-36639	.	_	
170-15	36639-36640	,	_	
170-16	36641-36646	S.V.K	_	
170-17	36646-36647	.	_	
170-18	36647-36648	,	_	
170-19	36649-36652	S.K	_	
170-20	36652-36653	.	_	
170-21	36653-36654	,	_	
170-22	36655-36658	S.L	_	
170-23	36658-36659	.	_	
170-24	36660-36663	and	_	
170-25	36664-36667	M.B	_	
170-26	36667-36668	.	_	
170-27	36669-36676	drafted	_	
170-28	36677-36680	the	_	
170-29	36681-36691	manuscript	_	
170-30	36691-36692	.	_	

#Text=All authors revised the manuscript critically for important intellectual content and approved the final version.
171-1	36693-36696	All	_	
171-2	36697-36704	authors	_	
171-3	36705-36712	revised	_	
171-4	36713-36716	the	_	
171-5	36717-36727	manuscript	_	
171-6	36728-36738	critically	_	
171-7	36739-36742	for	_	
171-8	36743-36752	important	_	
171-9	36753-36765	intellectual	_	
171-10	36766-36773	content	_	
171-11	36774-36777	and	_	
171-12	36778-36786	approved	_	
171-13	36787-36790	the	_	
171-14	36791-36796	final	_	
171-15	36797-36804	version	_	
171-16	36804-36805	.	_	

#Text=References
#Text=Convergence of interoception, emotion, and social cognition: a twofold fMRI meta-analysis and lesion approach
#Text=Unified segmentation
#Text=Effects of social exclusion and physical pain in chronic opioid maintenance treatment: fMRI correlates
#Text=Controlling the false discovery rate: a practical and powerful approach to multiple testing
#Text=Rejection sensitivity and disruption of attention by social threat cues
#Text=Brain blood flow SPET imaging in heroin abusers
#Text=A quantitative meta-analysis of functional imaging studies of social rejection
#Text=Cortico-amygdala-striatal circuits are organized as hierarchical subsystems through the primate amygdala
#Text=Pathological regional cerebral blood flow in opiate-dependent patients during withdrawal: a HMPAO-SPECT study
#Text=Reduction in cerebral perfusion after heroin administration: a resting state arterial spin labeling study
#Text=Association of frontal gray matter volume and cerebral perfusion in heroin addiction: a multimodal neuroimaging study
#Text=The brief symptom inventory: an introductory report
#Text=A medical treatment for diacetylmorphine (heroin) addiction: a clinical trial with methadone hydrochloride
#Text=Cerebral processing of social rejection in patients with borderline personality disorder
#Text=Implications of rejection sensitivity for intimate relationships
#Text=Comparing CAT12 and VBM8 for detecting brain morphological abnormalities in temporal lobe epilepsy
#Text=Methadone treatment of heroin addiction
#Text=The vicious circle of perceived stigmatization, depressiveness, anxiety, and low quality of life in substituted heroin addicts
#Text=CAT-a computational anatomy toolbox for the analysis of structural MRI data
#Text=Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe
#Text=Time to connect: bringing social context into addiction neuroscience
#Text=Methadone treatment induces attenuation of cerebrovascular deficits associated with the prolonged abuse of cocaine and heroin
#Text=Insular volume reduction in patients with social anxiety disorder
#Text=Neural dynamics of rejection sensitivity
#Text=A brief version of the fear of negative evaluation scale
#Text=White-matter tract connecting anterior insula to nucleus Accumbens correlates with reduced preference for positively skewed gambles
#Text=Structural deficits in the emotion circuit and cerebellum are associated with depression, anxiety and cognitive dysfunction in methadone maintenance patients: a voxel-based morphometric study
#Text=Frontal and cingulate gray matter volume reduction in heroin dependence: optimized voxel-based morphometry
#Text=Social causes and consequences of rejection sensitivity
#Text=Prefrontal and temporal gray matter density decreases in opiate dependence
#Text=The interpersonally sensitive disposition and health: an integrative review
#Text=Development and validation of measures of social phobia scrutiny fear and social interaction anxiety
#Text=Interactions between rejection sensitivity and supportive relationships in the prediction of adolescents' internalizing difficulties
#Text=The insular cortex: a review
#Text=Cerebral patterns of neuropsychological disturbances in hepatitis C patients
#Text=Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers
#Text=Regional gray matter volume is associated with rejection sensitivity: a voxel-based morphometry study
#Text=Grey matter abnormalities in social anxiety disorder: a pilot study
#Text=Prediction of relapse to frequent heroin use and the role of methadone prescription: an analysis of the Amsterdam cohort study among drug users
#Text=Changes in brain gray matter in abstinent heroin addicts
#Text=Role of maintenance treatment in opioid dependence
#Text=Gray matter abnormalities in opioid-dependent patients: a neuroimaging meta-analysis
#Text=A quantitative evaluation of cross-participant registration techniques for MRI studies of the medial temporal lobe
#Text=Gray matter density negatively correlates with duration of heroin use in young lifetime heroin-dependent individuals
172-1	36806-36816	References	_	
172-2	36817-36828	Convergence	_	
172-3	36829-36831	of	_	
172-4	36832-36845	interoception	_	
172-5	36845-36846	,	_	
172-6	36847-36854	emotion	_	
172-7	36854-36855	,	_	
172-8	36856-36859	and	_	
172-9	36860-36866	social	_	
172-10	36867-36876	cognition	_	
172-11	36876-36877	:	_	
172-12	36878-36879	a	_	
172-13	36880-36887	twofold	_	
172-14	36888-36892	fMRI	_	
172-15	36893-36906	meta-analysis	_	
172-16	36907-36910	and	_	
172-17	36911-36917	lesion	_	
172-18	36918-36926	approach	_	
172-19	36927-36934	Unified	_	
172-20	36935-36947	segmentation	_	
172-21	36948-36955	Effects	_	
172-22	36956-36958	of	_	
172-23	36959-36965	social	_	
172-24	36966-36975	exclusion	_	
172-25	36976-36979	and	_	
172-26	36980-36988	physical	_	
172-27	36989-36993	pain	_	
172-28	36994-36996	in	_	
172-29	36997-37004	chronic	_	
172-30	37005-37011	opioid	_	
172-31	37012-37023	maintenance	_	
172-32	37024-37033	treatment	_	
172-33	37033-37034	:	_	
172-34	37035-37039	fMRI	_	
172-35	37040-37050	correlates	_	
172-36	37051-37062	Controlling	_	
172-37	37063-37066	the	_	
172-38	37067-37072	false	_	
172-39	37073-37082	discovery	_	
172-40	37083-37087	rate	_	
172-41	37087-37088	:	_	
172-42	37089-37090	a	_	
172-43	37091-37100	practical	_	
172-44	37101-37104	and	_	
172-45	37105-37113	powerful	_	
172-46	37114-37122	approach	_	
172-47	37123-37125	to	_	
172-48	37126-37134	multiple	_	
172-49	37135-37142	testing	_	
172-50	37143-37152	Rejection	_	
172-51	37153-37164	sensitivity	_	
172-52	37165-37168	and	_	
172-53	37169-37179	disruption	_	
172-54	37180-37182	of	_	
172-55	37183-37192	attention	_	
172-56	37193-37195	by	_	
172-57	37196-37202	social	_	
172-58	37203-37209	threat	_	
172-59	37210-37214	cues	_	
172-60	37215-37220	Brain	_	
172-61	37221-37226	blood	_	
172-62	37227-37231	flow	_	
172-63	37232-37236	SPET	_	
172-64	37237-37244	imaging	_	
172-65	37245-37247	in	_	
172-66	37248-37254	heroin	_	
172-67	37255-37262	abusers	_	
172-68	37263-37264	A	_	
172-69	37265-37277	quantitative	_	
172-70	37278-37291	meta-analysis	_	
172-71	37292-37294	of	_	
172-72	37295-37305	functional	_	
172-73	37306-37313	imaging	_	
172-74	37314-37321	studies	_	
172-75	37322-37324	of	_	
172-76	37325-37331	social	_	
172-77	37332-37341	rejection	_	
172-78	37342-37367	Cortico-amygdala-striatal	_	
172-79	37368-37376	circuits	_	
172-80	37377-37380	are	_	
172-81	37381-37390	organized	_	
172-82	37391-37393	as	_	
172-83	37394-37406	hierarchical	_	
172-84	37407-37417	subsystems	_	
172-85	37418-37425	through	_	
172-86	37426-37429	the	_	
172-87	37430-37437	primate	_	
172-88	37438-37446	amygdala	_	
172-89	37447-37459	Pathological	_	
172-90	37460-37468	regional	_	
172-91	37469-37477	cerebral	_	
172-92	37478-37483	blood	_	
172-93	37484-37488	flow	_	
172-94	37489-37491	in	_	
172-95	37492-37508	opiate-dependent	_	
172-96	37509-37517	patients	_	
172-97	37518-37524	during	_	
172-98	37525-37535	withdrawal	_	
172-99	37535-37536	:	_	
172-100	37537-37538	a	_	
172-101	37539-37550	HMPAO-SPECT	_	
172-102	37551-37556	study	_	
172-103	37557-37566	Reduction	_	
172-104	37567-37569	in	_	
172-105	37570-37578	cerebral	_	
172-106	37579-37588	perfusion	_	
172-107	37589-37594	after	_	
172-108	37595-37601	heroin	_	
172-109	37602-37616	administration	_	
172-110	37616-37617	:	_	
172-111	37618-37619	a	_	
172-112	37620-37627	resting	_	
172-113	37628-37633	state	_	
172-114	37634-37642	arterial	_	
172-115	37643-37647	spin	_	
172-116	37648-37656	labeling	_	
172-117	37657-37662	study	_	
172-118	37663-37674	Association	_	
172-119	37675-37677	of	_	
172-120	37678-37685	frontal	_	
172-121	37686-37690	gray	_	
172-122	37691-37697	matter	_	
172-123	37698-37704	volume	_	
172-124	37705-37708	and	_	
172-125	37709-37717	cerebral	_	
172-126	37718-37727	perfusion	_	
172-127	37728-37730	in	_	
172-128	37731-37737	heroin	_	
172-129	37738-37747	addiction	_	
172-130	37747-37748	:	_	
172-131	37749-37750	a	_	
172-132	37751-37761	multimodal	_	
172-133	37762-37774	neuroimaging	_	
172-134	37775-37780	study	_	
172-135	37781-37784	The	_	
172-136	37785-37790	brief	_	
172-137	37791-37798	symptom	_	
172-138	37799-37808	inventory	_	
172-139	37808-37809	:	_	
172-140	37810-37812	an	_	
172-141	37813-37825	introductory	_	
172-142	37826-37832	report	_	
172-143	37833-37834	A	_	
172-144	37835-37842	medical	_	
172-145	37843-37852	treatment	_	
172-146	37853-37856	for	_	
172-147	37857-37873	diacetylmorphine	_	
172-148	37874-37875	(	_	
172-149	37875-37881	heroin	_	
172-150	37881-37882	)	_	
172-151	37883-37892	addiction	_	
172-152	37892-37893	:	_	
172-153	37894-37895	a	_	
172-154	37896-37904	clinical	_	
172-155	37905-37910	trial	_	
172-156	37911-37915	with	_	
172-157	37916-37925	methadone	_	
172-158	37926-37939	hydrochloride	_	
172-159	37940-37948	Cerebral	_	
172-160	37949-37959	processing	_	
172-161	37960-37962	of	_	
172-162	37963-37969	social	_	
172-163	37970-37979	rejection	_	
172-164	37980-37982	in	_	
172-165	37983-37991	patients	_	
172-166	37992-37996	with	_	
172-167	37997-38007	borderline	_	
172-168	38008-38019	personality	_	
172-169	38020-38028	disorder	_	
172-170	38029-38041	Implications	_	
172-171	38042-38044	of	_	
172-172	38045-38054	rejection	_	
172-173	38055-38066	sensitivity	_	
172-174	38067-38070	for	_	
172-175	38071-38079	intimate	_	
172-176	38080-38093	relationships	_	
172-177	38094-38103	Comparing	_	
172-178	38104-38109	CAT12	_	
172-179	38110-38113	and	_	
172-180	38114-38118	VBM8	_	
172-181	38119-38122	for	_	
172-182	38123-38132	detecting	_	
172-183	38133-38138	brain	_	
172-184	38139-38152	morphological	_	
172-185	38153-38166	abnormalities	_	
172-186	38167-38169	in	_	
172-187	38170-38178	temporal	_	
172-188	38179-38183	lobe	_	
172-189	38184-38192	epilepsy	_	
172-190	38193-38202	Methadone	_	
172-191	38203-38212	treatment	_	
172-192	38213-38215	of	_	
172-193	38216-38222	heroin	_	
172-194	38223-38232	addiction	_	
172-195	38233-38236	The	_	
172-196	38237-38244	vicious	_	
172-197	38245-38251	circle	_	
172-198	38252-38254	of	_	
172-199	38255-38264	perceived	_	
172-200	38265-38279	stigmatization	_	
172-201	38279-38280	,	_	
172-202	38281-38295	depressiveness	_	
172-203	38295-38296	,	_	
172-204	38297-38304	anxiety	_	
172-205	38304-38305	,	_	
172-206	38306-38309	and	_	
172-207	38310-38313	low	_	
172-208	38314-38321	quality	_	
172-209	38322-38324	of	_	
172-210	38325-38329	life	_	
172-211	38330-38332	in	_	
172-212	38333-38344	substituted	_	
172-213	38345-38351	heroin	_	
172-214	38352-38359	addicts	_	
172-215	38360-38365	CAT-a	_	
172-216	38366-38379	computational	_	
172-217	38380-38387	anatomy	_	
172-218	38388-38395	toolbox	_	
172-219	38396-38399	for	_	
172-220	38400-38403	the	_	
172-221	38404-38412	analysis	_	
172-222	38413-38415	of	_	
172-223	38416-38426	structural	_	
172-224	38427-38430	MRI	_	
172-225	38431-38435	data	_	
172-226	38436-38453	Three-dimensional	_	
172-227	38454-38461	maximum	_	
172-228	38462-38473	probability	_	
172-229	38474-38479	atlas	_	
172-230	38480-38482	of	_	
172-231	38483-38486	the	_	
172-232	38487-38492	human	_	
172-233	38493-38498	brain	_	
172-234	38498-38499	,	_	
172-235	38500-38504	with	_	
172-236	38505-38515	particular	_	
172-237	38516-38525	reference	_	
172-238	38526-38528	to	_	
172-239	38529-38532	the	_	
172-240	38533-38541	temporal	_	
172-241	38542-38546	lobe	_	
172-242	38547-38551	Time	_	
172-243	38552-38554	to	_	
172-244	38555-38562	connect	_	
172-245	38562-38563	:	_	
172-246	38564-38572	bringing	_	
172-247	38573-38579	social	_	
172-248	38580-38587	context	_	
172-249	38588-38592	into	_	
172-250	38593-38602	addiction	_	
172-251	38603-38615	neuroscience	_	
172-252	38616-38625	Methadone	_	
172-253	38626-38635	treatment	_	
172-254	38636-38643	induces	_	
172-255	38644-38655	attenuation	_	
172-256	38656-38658	of	_	
172-257	38659-38674	cerebrovascular	_	
172-258	38675-38683	deficits	_	
172-259	38684-38694	associated	_	
172-260	38695-38699	with	_	
172-261	38700-38703	the	_	
172-262	38704-38713	prolonged	_	
172-263	38714-38719	abuse	_	
172-264	38720-38722	of	_	
172-265	38723-38730	cocaine	_	
172-266	38731-38734	and	_	
172-267	38735-38741	heroin	_	
172-268	38742-38749	Insular	_	
172-269	38750-38756	volume	_	
172-270	38757-38766	reduction	_	
172-271	38767-38769	in	_	
172-272	38770-38778	patients	_	
172-273	38779-38783	with	_	
172-274	38784-38790	social	_	
172-275	38791-38798	anxiety	_	
172-276	38799-38807	disorder	_	
172-277	38808-38814	Neural	_	
172-278	38815-38823	dynamics	_	
172-279	38824-38826	of	_	
172-280	38827-38836	rejection	_	
172-281	38837-38848	sensitivity	_	
172-282	38849-38850	A	_	
172-283	38851-38856	brief	_	
172-284	38857-38864	version	_	
172-285	38865-38867	of	_	
172-286	38868-38871	the	_	
172-287	38872-38876	fear	_	
172-288	38877-38879	of	_	
172-289	38880-38888	negative	_	
172-290	38889-38899	evaluation	_	
172-291	38900-38905	scale	_	
172-292	38906-38918	White-matter	_	
172-293	38919-38924	tract	_	
172-294	38925-38935	connecting	_	
172-295	38936-38944	anterior	_	
172-296	38945-38951	insula	_	
172-297	38952-38954	to	_	
172-298	38955-38962	nucleus	_	
172-299	38963-38972	Accumbens	_	
172-300	38973-38983	correlates	_	
172-301	38984-38988	with	_	
172-302	38989-38996	reduced	_	
172-303	38997-39007	preference	_	
172-304	39008-39011	for	_	
172-305	39012-39022	positively	_	
172-306	39023-39029	skewed	_	
172-307	39030-39037	gambles	_	
172-308	39038-39048	Structural	_	
172-309	39049-39057	deficits	_	
172-310	39058-39060	in	_	
172-311	39061-39064	the	_	
172-312	39065-39072	emotion	_	
172-313	39073-39080	circuit	_	
172-314	39081-39084	and	_	
172-315	39085-39095	cerebellum	_	
172-316	39096-39099	are	_	
172-317	39100-39110	associated	_	
172-318	39111-39115	with	_	
172-319	39116-39126	depression	_	
172-320	39126-39127	,	_	
172-321	39128-39135	anxiety	_	
172-322	39136-39139	and	_	
172-323	39140-39149	cognitive	_	
172-324	39150-39161	dysfunction	_	
172-325	39162-39164	in	_	
172-326	39165-39174	methadone	_	
172-327	39175-39186	maintenance	_	
172-328	39187-39195	patients	_	
172-329	39195-39196	:	_	
172-330	39197-39198	a	_	
172-331	39199-39210	voxel-based	_	
172-332	39211-39223	morphometric	_	
172-333	39224-39229	study	_	
172-334	39230-39237	Frontal	_	
172-335	39238-39241	and	_	
172-336	39242-39251	cingulate	_	
172-337	39252-39256	gray	_	
172-338	39257-39263	matter	_	
172-339	39264-39270	volume	_	
172-340	39271-39280	reduction	_	
172-341	39281-39283	in	_	
172-342	39284-39290	heroin	_	
172-343	39291-39301	dependence	_	
172-344	39301-39302	:	_	
172-345	39303-39312	optimized	_	
172-346	39313-39324	voxel-based	_	
172-347	39325-39336	morphometry	_	
172-348	39337-39343	Social	_	
172-349	39344-39350	causes	_	
172-350	39351-39354	and	_	
172-351	39355-39367	consequences	_	
172-352	39368-39370	of	_	
172-353	39371-39380	rejection	_	
172-354	39381-39392	sensitivity	_	
172-355	39393-39403	Prefrontal	_	
172-356	39404-39407	and	_	
172-357	39408-39416	temporal	_	
172-358	39417-39421	gray	_	
172-359	39422-39428	matter	_	
172-360	39429-39436	density	_	
172-361	39437-39446	decreases	_	
172-362	39447-39449	in	_	
172-363	39450-39456	opiate	_	
172-364	39457-39467	dependence	_	
172-365	39468-39471	The	_	
172-366	39472-39487	interpersonally	_	
172-367	39488-39497	sensitive	_	
172-368	39498-39509	disposition	_	
172-369	39510-39513	and	_	
172-370	39514-39520	health	_	
172-371	39520-39521	:	_	
172-372	39522-39524	an	_	
172-373	39525-39536	integrative	_	
172-374	39537-39543	review	_	
172-375	39544-39555	Development	_	
172-376	39556-39559	and	_	
172-377	39560-39570	validation	_	
172-378	39571-39573	of	_	
172-379	39574-39582	measures	_	
172-380	39583-39585	of	_	
172-381	39586-39592	social	_	
172-382	39593-39599	phobia	_	
172-383	39600-39608	scrutiny	_	
172-384	39609-39613	fear	_	
172-385	39614-39617	and	_	
172-386	39618-39624	social	_	
172-387	39625-39636	interaction	_	
172-388	39637-39644	anxiety	_	
172-389	39645-39657	Interactions	_	
172-390	39658-39665	between	_	
172-391	39666-39675	rejection	_	
172-392	39676-39687	sensitivity	_	
172-393	39688-39691	and	_	
172-394	39692-39702	supportive	_	
172-395	39703-39716	relationships	_	
172-396	39717-39719	in	_	
172-397	39720-39723	the	_	
172-398	39724-39734	prediction	_	
172-399	39735-39737	of	_	
172-400	39738-39749	adolescents	_	
172-401	39749-39750	'	_	
172-402	39751-39764	internalizing	_	
172-403	39765-39777	difficulties	_	
172-404	39778-39781	The	_	
172-405	39782-39789	insular	_	
172-406	39790-39796	cortex	_	
172-407	39796-39797	:	_	
172-408	39798-39799	a	_	
172-409	39800-39806	review	_	
172-410	39807-39815	Cerebral	_	
172-411	39816-39824	patterns	_	
172-412	39825-39827	of	_	
172-413	39828-39846	neuropsychological	_	
172-414	39847-39859	disturbances	_	
172-415	39860-39862	in	_	
172-416	39863-39872	hepatitis	_	
172-417	39873-39874	C	_	
172-418	39875-39883	patients	_	
172-419	39884-39891	Effects	_	
172-420	39892-39894	of	_	
172-421	39895-39908	buprenorphine	_	
172-422	39909-39915	versus	_	
172-423	39916-39929	buprenorphine	_	
172-424	39929-39930	/	_	
172-425	39930-39938	naloxone	_	
172-426	39939-39946	tablets	_	
172-427	39947-39949	in	_	
172-428	39950-39963	non-dependent	_	
172-429	39964-39970	opioid	_	
172-430	39971-39978	abusers	_	
172-431	39979-39987	Regional	_	
172-432	39988-39992	gray	_	
172-433	39993-39999	matter	_	
172-434	40000-40006	volume	_	
172-435	40007-40009	is	_	
172-436	40010-40020	associated	_	
172-437	40021-40025	with	_	
172-438	40026-40035	rejection	_	
172-439	40036-40047	sensitivity	_	
172-440	40047-40048	:	_	
172-441	40049-40050	a	_	
172-442	40051-40062	voxel-based	_	
172-443	40063-40074	morphometry	_	
172-444	40075-40080	study	_	
172-445	40081-40085	Grey	_	
172-446	40086-40092	matter	_	
172-447	40093-40106	abnormalities	_	
172-448	40107-40109	in	_	
172-449	40110-40116	social	_	
172-450	40117-40124	anxiety	_	
172-451	40125-40133	disorder	_	
172-452	40133-40134	:	_	
172-453	40135-40136	a	_	
172-454	40137-40142	pilot	_	
172-455	40143-40148	study	_	
172-456	40149-40159	Prediction	_	
172-457	40160-40162	of	_	
172-458	40163-40170	relapse	_	
172-459	40171-40173	to	_	
172-460	40174-40182	frequent	_	
172-461	40183-40189	heroin	_	
172-462	40190-40193	use	_	
172-463	40194-40197	and	_	
172-464	40198-40201	the	_	
172-465	40202-40206	role	_	
172-466	40207-40209	of	_	
172-467	40210-40219	methadone	_	
172-468	40220-40232	prescription	_	
172-469	40232-40233	:	_	
172-470	40234-40236	an	_	
172-471	40237-40245	analysis	_	
172-472	40246-40248	of	_	
172-473	40249-40252	the	_	
172-474	40253-40262	Amsterdam	_	
172-475	40263-40269	cohort	_	
172-476	40270-40275	study	_	
172-477	40276-40281	among	_	
172-478	40282-40286	drug	_	
172-479	40287-40292	users	_	
172-480	40293-40300	Changes	_	
172-481	40301-40303	in	_	
172-482	40304-40309	brain	_	
172-483	40310-40314	gray	_	
172-484	40315-40321	matter	_	
172-485	40322-40324	in	_	
172-486	40325-40334	abstinent	_	
172-487	40335-40341	heroin	_	
172-488	40342-40349	addicts	_	
172-489	40350-40354	Role	_	
172-490	40355-40357	of	_	
172-491	40358-40369	maintenance	_	
172-492	40370-40379	treatment	_	
172-493	40380-40382	in	_	
172-494	40383-40389	opioid	_	
172-495	40390-40400	dependence	_	
172-496	40401-40405	Gray	_	
172-497	40406-40412	matter	_	
172-498	40413-40426	abnormalities	_	
172-499	40427-40429	in	_	
172-500	40430-40446	opioid-dependent	_	
172-501	40447-40455	patients	_	
172-502	40455-40456	:	_	
172-503	40457-40458	a	_	
172-504	40459-40471	neuroimaging	_	
172-505	40472-40485	meta-analysis	_	
172-506	40486-40487	A	_	
172-507	40488-40500	quantitative	_	
172-508	40501-40511	evaluation	_	
172-509	40512-40514	of	_	
172-510	40515-40532	cross-participant	_	
172-511	40533-40545	registration	_	
172-512	40546-40556	techniques	_	
172-513	40557-40560	for	_	
172-514	40561-40564	MRI	_	
172-515	40565-40572	studies	_	
172-516	40573-40575	of	_	
172-517	40576-40579	the	_	
172-518	40580-40586	medial	_	
172-519	40587-40595	temporal	_	
172-520	40596-40600	lobe	_	
172-521	40601-40605	Gray	_	
172-522	40606-40612	matter	_	
172-523	40613-40620	density	_	
172-524	40621-40631	negatively	_	
172-525	40632-40642	correlates	_	
172-526	40643-40647	with	_	
172-527	40648-40656	duration	_	
172-528	40657-40659	of	_	
172-529	40660-40666	heroin	_	
172-530	40667-40670	use	_	
172-531	40671-40673	in	_	
172-532	40674-40679	young	_	
172-533	40680-40688	lifetime	_	
172-534	40689-40705	heroin-dependent	_	
172-535	40706-40717	individuals	_	
